CA3137125C - Camptothecin derivatives - Google Patents

Camptothecin derivatives

Info

Publication number
CA3137125C
CA3137125C CA3137125A CA3137125A CA3137125C CA 3137125 C CA3137125 C CA 3137125C CA 3137125 A CA3137125 A CA 3137125A CA 3137125 A CA3137125 A CA 3137125A CA 3137125 C CA3137125 C CA 3137125C
Authority
CA
Canada
Prior art keywords
ala
gly
alkylene
val
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3137125A
Other languages
French (fr)
Other versions
CA3137125A1 (en
Inventor
Ravi Chari
Wayne C. Widdison
Wei Li
David P. Pleynet
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority claimed from PCT/US2020/027831 external-priority patent/WO2020219287A1/en
Publication of CA3137125A1 publication Critical patent/CA3137125A1/en
Application granted granted Critical
Publication of CA3137125C publication Critical patent/CA3137125C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).

Description

.
CAMPTOTHECIN DERIVATIVES
[0001] This application claims the benefit of and priority from U.S.
Provisional Patent Applications 62/839,440, filed April 26, 2019, 62/875,169, filed July 17, 2019, and 62/978,159, filed February 18, 2020.
SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format Said ASCII copy, created on March 27, 2020, is named 000219-0002-WOl - 10 Sequence Listing.txt and is 61,926 bytes in size.
FIELD OF THE APPLICATION
[0003] Disclosed herein are novel compounds, and conjugates thereof More specifically, this disclosure relates to novel camptothecin derivatives, intermediates, metabolites and conjugates thereof~ and pharmaceutically acceptable salts thereof~ which are useful as 15 medicaments, in particular as anti-proliferative agents (anticancer agents).
BACKGROUND
[0004] Cell binding agent-drug conjugates, including antibody-drug conjugates (ADC) are emerging as a powerful class of agents with efficacy across a range of abnormal cell growth or proliferative diseases (e.g., cancers).
Cell binding agent-drug conjugates (such as ADCs) 20 are commonly composed of three distinct elements: a cell-binding agent (e.g., an antibody); a linker; and a cytotoxic moiety.
[0005] Camptothecin (CPT) is a pentacyclic alkaloid isolated from the bark and stem of Camptotheca acuminata (Camptotheca, Happy tree), a tree native to China.
Camptothecin inhibits topoisomerase I, which leads to cell death.
Because of its cytotoxic mechanism and 25 broad-spectrum antitumor activity, there have been substantial efforts towards developing clinical analogues of camptothecin.
Poor solubility and inactivity at physiological conditions, however, have limited the clinical development of suitable camptothecin analogues. 1 WO 2020/219287 PCT /0S2020/027831 Camptothecin and most of its derivatives are not soluble in aqueous buffers.
Further, camptothecin is in equilibrium in an active lactone form and inactive hydrolyzed carboxylate form, thereby limiting its therapeutic efficacy.
[0006] There exists a need for therapeutically effective camptothecin derivatives that have 5 increased solubility, potency, lactone stability, and bioavailability.
SUMMARY
[0007] In one aspect, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt, thereof: Z-Li-D (Formula I) 10 wherein: D is represented by the following structural formula: ,NV\ 0 Riis -F, -CH3, or -CF 3; R2 is -H, -F, -0R3 , -SR3 , -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri 15 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, -xi'-(Ci-C6 20 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 25 heteroaryl, or benzyl; Z is -Hor -X2• ' 2 WO 2020/219287 PCT /0S2020/027831 each R6 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 5 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; with the proviso that ifR1 is F, then L1 is -(C1-C6 alkylene)-, -(C1-C6 alkylene)-X1- (C1-C6 alkylene)-, -X1'-(C1-C6 alkylene)-*, or -(C1-C6 alkylene)-X1-L2-*; where* is the 10 site covalently attached to Z; and Z is -X2 ; and with the proviso that if R1 is F and R2 is -OMe, then -L 1-Z cannot be -NH2.
[0008] In some embodiments, the compound of Formula I has the further proviso that ifR1 is F and R2 is -Me, then -L1-Z cannot be-CH2OH.
[0009] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some 15 embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In some embodiments, R1 is -F and R2 is -methyl. 20
[0010] In some embodiments, -L1-Z is -H.
In some embodiments, -L1-Z is -(C1-C6 alkylene)-H, or -(C1-C6 alkylene)-X2.
In some embodiments, -L1-Z is -(C1-C6 alkylene)-H.
In some embodiments, -L1-Z is -(C1-C6 alkylene)-X2.
In some embodiments, -L1-Z is -(C1-C6 alkylene )-X2 .
In some embodiments, -L 1-Z is methyl, ethyl, propyl, or butyl.
[0011] In some embodiments, -L1-Z is -(C1-C4 alkylene)-OR6, -(C1-C4 alkylene)-SR6, 25 or -(C1-C4 alkylene)-N(R6)2.
In some embodiments, -L1-Z is -(C1-C4 alkylene)-OR6.
In some embodiments, -L1-Z is -(C1-C4 alkylene)-SR6.
In some embodiments, -L1-Z is -(C1-C4 alkylene)-N(R6)2. 3 WO 2020/219287 PCT /0S2020/027831
[0012] In some embodiments, -L1-Z is -CH2OH, -(CH2)2OH, -(CH2)3QH, -(CH2)4QH, - CH2OMe, -(CH2)2OMe, -(CH2)3QMe, -(CH2)4QMe, -CH2SH, -(CH2)2SH, -(CH2)3SH, - (CH2)4SH, -CH2SMe, -(CH2)2SMe, -(CH2)3SMe, -(CH2)4SMe, -CH2NH2, -(CH2)2NH2, - (CH2)3NH2, or-(CH2)4NH2. 5
[0013] In some embodiments, -L1-Z is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-OR6 , - (C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-SR6 , -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SR6 , or -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SSR6 .
In some embodiments, -L1-Z is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-OR6 .
In some embodiments, -L1-Z is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-SR6 .
In some embodiments, -L1-Z is-(C1-Cs 10 alkylene)-S-(C1-Cs alkylene)-SR6.
In some embodiments, -L1-Z is -(C1-Cs alkylene)-S-(C1- Cs alkylene)-SSR6 .
[0014] In some embodiments, -L1-Z is -CH2NHC(=O)CH2OH, -CH2NHC(=O)(CH2)2OH, - CH2NHC(=O)(CH2)3QH, -CH2NHC(=O)(CH2)4QH, -CH2NHC(=O)(CH2)sOH, - CH2NHC(=O)CH2OMe, -CH2NHC(=O)(CH2)2OMe, -CH2NHC(=O)(CH2)3QMe, - 15 CH2NHC(=O)(CH2)4QMe, -CH2NHC(=O)(CH2)sOMe, -CH2NHC(=O)CH2SH, - CH2NHC(=O)(CH2)2SH, -CH2NHC(=O)(CH2)3SH, -CH2NHC(=O)(CH2)4SH, - CH2NHC(=O)(CH2)sSH, -CH2NHC(=O)CH2SMe, -CH2NHC(=O)(CH2)2SMe, - CH2NHC(=O)(CH2)3SMe, -CH2NHC(=O)(CH2)4SMe, -CH2NHC(=O)(CH2)sSMe, - CH2SCH2OH, -CH2S(CH2)2OH, -CH2S(CH2)3QH, -CH2S(CH2)4QH, -CH2S(CH2)sOH, - 20 CH2SCH2OMe,-CH2S(CH2)2OMe, -CH2S(CH2)3QMe, -CH2S(CH2)4QMe, - CH2S(CH2)sOMe,-CH2SCH2SH, -CH2S(CH2)2SH, -CH2S(CH2)3SH, -CH2S(CH2)4SH, - CH2S(CH2)sSH, -CH2SCH2SMe, -CH2S(CH2)2SMe, -CH2S(CH2)3SMe, -CH2S(CH2)4SMe, or -CH2S(CH2)sSMe.
[0015] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some 25 embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
[0016] In some embodiments, each R6 is independently -H, methyl, or benzyl.
In some embodiments, each R6 is independently -H.
In some embodiments, each R6 is methyl.
In some embodiments, each R6 is benzyl. 4 WO 2020/219287 PCT /0S2020/027831
[0017] In some embodiments, -L1-Z is -X1'-(C1-C4 alkylene)-X2.
In some embodiments, - L 1-Z is -OCH2OH, -O(CH2)2OH, -O(CH2)3QH, -O(CH2)4QH, -SCH2OH, -S(CH2)2OH, - S(CH2)3QH, -S(CH2)4QH, -S(O)CH2OH, -S(O)(CH2)2OH, -S(O)(CH2)3QH, -S(O)(CH2)4QH, -S(O)2CH2OH, -S(O)2(CH2)2OH, -S(O)2(CH2)3QH, -S(O)2(CH2)4QH, -OCH2SMe, - s O(CH2)2SMe, - O(CH2)3SMe, -O(CH2)4SMe, -SCH2SMe, - S(CH2)2SMe, -S(CH2)3SMe, - S(CH2)4SMe, -S(O)CH2SMe, -S(O)(CH2)2SMe, -S(O)(CH2)3SMe, -S(O)(CH2)4SMe, - S(O)2CH2SMe, -S(O)2(CH2)2SMe, -S(O)2(CH2)3SMe, or -S(O)2(CH2)4SMe.
[0018] In some embodiments, -L1-Z is -(C1-C6 alkylene)-X1-L2-X2.
In some embodiments, - I .f'~N P NH2 .f'~Su H ~ L 1-Z is NH2 or O In some embodiments, -L 1-Z is I .f'~N P NH2 .f'~Su H ~ 10 NH2.
In some embodiments, -L1-Z is O
[0019] In some embodiments, the compound is any one of the compounds selected from the following: HO WO 2020/219287 PCT /0S2020/027831 ...,..s F
[0020] In some embodiments, the compound is any one of the compounds selected from the following: ...,..s F Ho--y NH p NH
[0021] In some embodiments, the compound is any one of the compounds selected from Table IB.
[0022] In another aspect, the invention provides a compound of Formula II, or a 10 pharmaceutically acceptable salt thereof: E-A-Z'-L 1-D (Formula II) wherein: 6 WO 2020/219287 PCT /0S2020/027831 D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri 5 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-* or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 20 heteroaryl, or benzyl; Li and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, Ci-C6 alkyl, Ci-C6 fluoroalkyl, Ci-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 25 heteroaryl, or benzyl; A is a peptide comprising 2 to IO amino acids; wherein A is optionally substituted with one or more polyol; and Eis -C(=O)-L3-X3; 7 WO 2020/219287 PCT /0S2020/027831 L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to X3; Y1 is absent, -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)- or -C(=O)NR9 -; 5 Y2 is absent, -(CReRdO)o-, or -(CR~dcRe'Rd'O)p-; n, m, o, and p are each independently 1-1 O; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, 10 -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; or -SR10• ' 11 ~-s~ 11 each W' is independently -H, -N(Rgg)2, C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, C3-C6 cycloalkyl, aryl, heteroaryl, or -(CH2CH2O)q-Rff; 20 q is 1 to 24; each Raa, Rb\ Rec, Ree, and Rff are independently-Hor optionally substituted C1-C6 alkyl; each RYY and Rxx are independently-Hor C1-C6 alkyl; 8 WO 2020/219287 PCT /0S2020/027831 Rgg are each independently-Hor C1-C6 alkyl; and R9 and R10 are each independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl.
[0023] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some s embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In some embodiments, R1 is -F and R2 is -methyl. 10
[0024] In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-O-CH2-NR8-*, -(C1-C4 alkylene)-S-CH2-NR8-*, or-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - (C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-NR8-*.
[0025] In some embodiments, -L 1-Z' -* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH-*, -(CH2)3Q- 1s CH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, -(CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or -(CH2)4NH-*.
[0026] In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-OCH2- NR8-*, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)S-( C1-Cs alkylene)-S-CH2-NR8-*, or-(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*. 20 In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-O-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SCH2- NR8-*.
In some embodiments, -L1-Z'-* is-(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2- NRs-*_ 2s
[0027] In some embodiments, -L1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3S- 9 WO 2020/219287 PCT /0S2020/027831 CH2-NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)sS-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3Q-CH2-NH-*, - CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - s CH2S(CH2)sS-CH2-NH-*.
[0028] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
In some embodiments, each R8 is independently -H, methyl, or benzyl.
In some embodiments, each R8 is independently -H.
In some 10 embodiments, each R8 is methyl.
In some embodiments, each R8 is benzyl.
[0029] In some embodiments, -L1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or-X1'-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - x1'-(C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -X1'-(C1-C4 alkylene)-S-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -X1'-(C1-C4 alkylene)-NR8-*. 1s
[0030] In some embodiments, -L1-Z'-* is -OCH2O-CH2-NH-*, - O(CH2)2O-CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH2O-CH2-NH-*, - S(CH2)2O-CH2-NH-*, - S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH2O-CH2-NH-*, -S(O)(CH2)2O-CH2- NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, -S(O)2CH2O-CH2-NH-*, - S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3Q-CH2-NH-*, -S(O)2(CH2)4Q-CH2-NH-*, -OCH2S- 20 CH2-NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH-*, -O(CH2)4S-CH2-NH-*, -SCH2SCH2- NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, - S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4SCH2- NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, -S(O)2(CH2)3S-CH2-NH-*, - S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, - O(CH2)3-NH-*, -O(CH2)4S-NH- 2s *, -SCH2-NH-*, - S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, - S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, -S(O)2CH2-NH-*, -S(O)2(CH2)2- NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*.
[0031] In some embodiments, -L 1-Z' -* is -(C1-C6 alkylene )-X1-L 2-Z' -*.
In some H rr(N'* sS''--,/~~ embodiments, -L 1-Z' -* is or 0 In some .f''---../So I ,,,_,,,,,, N,,,* embodiments, -L 1-Z' -* is H In some embodiments, -L 1-Z' -* is s
[0032] In the various embodiments disclosing -L 1-Z' -* herein, * is the site covalently attached to A
[0033] In some embodiments, A is a peptide comprising 2 to 8 amino acids.
In some embodiments, A is a peptide comprising 2 to 4 amino acids.
In some embodiments, at least one amino acid in said peptide is a L amino acid.
In some embodiments, each amino acid in 10 said peptide is a L amino acid.
In some embodiments, at least one amino acid in said peptide is a D amino acid.
[0034] In some embodiments, A is -(AA1)-(AA2)a1-*, where* is the site covalently attached to E; AA1 and AA2 are each independently an amino acid residue; and al is an integer from 1-9. 1s
[0035] In some embodiments, -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val-Ala-*, - Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -Ala-Lys-*, -LysAla-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* -Ile-Cit-*, -Phe-Ala-*,-Ala-Phe-*, -PheN9- tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-Arg-Phe *, -Phe-PheLys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, -Ile-Ala-Leu-*, - 20 Leu-Ala-Ile-* -Val-Ala-Val-* -Ala-Leu-Ala-Leu-* -Leu-Ala-Leu-Ala-* -~-Ala-Leu-Ala- ' ' ' ' JJ Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, -AlaAla-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -Ala-Leu- 11 WO 2020/219287 PCT /0S2020/027831 *, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, -AlaSer-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -Arg-Tyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*.
[0036] In some embodiments, -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cits *, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-D-Lys-*, -L-ValD- Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, -Val-D-Cit-*, -LAla- L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*.
[0037] In some embodiments, -AA1-(AA2)a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-*, -GlnLeu-*, -Leu-Gln-*, -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala- 10 Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly- *
[0038] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-AlaL- Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-*, -L-Gln-L-Leu-*, -L-Gln-D-Leu*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala- 1s L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-AlaD- Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly*, -Gly-D-Ala-Gly-Gly-*, Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, Gly-Gly-L-ValGly-*, -Gly-D-Val-Gly-Gly-*, Gly-Gly-D-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or Gly-Gly-LPhe- Gly-*. 20
[0039] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-LAla-*, - L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*.
[0040] In the various embodiments disclosing -AA1-(AA2)a1-* herein, * is the site covalently attached to E.
[0041] In some embodiments, A is substituted with one or more polyol.
In some 2s embodiments, E is substituted with one or more polyol.
In some embodiments, polyol is - (C1-C6 alkylene)-X5-Y3; wherein: X5 is -NR12C(=O)- or -C(=O)NR12-; Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 12 WO 2020/219287 PCT /0S2020/027831 0 OH OH \~~~OH
[0042] In some embodiments, wherein polyol is R12 OH OH ; wherein R12 is Hor methyl.
[0043] In some embodiments, Eis -C(=O)-(C1-C10 alkylene)-X3 .
In some embodiments, E IS '?.A/'-.. o ~ ~ V \_~SH 0 , or . 13 WO 2020/219287 PCT /0S2020/027831
[0044] In some embodiments, Eis -C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X3 ; Y1 is -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)-; and 11 ~ ~-s~ \..Jt .. ~ II N 0 ' ' or -SR10. 10 X4 is -NHC(=O)-; n is 2; m is 2 to 6; 11 ~-s~ 11 14 /2N ?' WO 2020/219287 PCT /0S2020/027831 or -SR10 .
[0046] In some embodiments, the compound is any one of the compounds selected from Table 2. s
[0047] In another aspect, the invention provides a compound of Formula III, or a pharmaceutically acceptable salt thereof: CBA-E'-A-Z'-L i_D (Formula III) wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 1s cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; WO 2020/219287 PCT /0S2020/027831 each R5 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and 10 each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more polyol; E' is -C(=O)-L3-X6-*; where* is the site covalently linked to CBA; 15 L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to x6; Y1 is absent, -(CRaRbO)n- or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)- or -C(=O)NR9 -; Y2 is absent, -(CRcRdO)o-, or -(CR~dcRc'Rd'O)p-; n, m, o, and p are each independently 1-1 O; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 25 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 16 WO 2020/219287 o oy* o o~~:xN ~ ~_11 I \ ~ S~* ~~ O \_..:z h * II 'z. 0 N 0 d CN * -0' ~ PCT /0S2020/027831 11 ~-NRaa_~~* CRbbRcc_*; where* is the site covalently attached to CBA; each Raa, Rb\ Rec, and Ree are independently-Hor optionally substituted C1-C6 alkyl; each RYY and Rxx are independently-Hor C1-C6 alkyl; R9 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; and CBA is a cell binding agent. 10
[0048] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In 1s some embodiments, R1 is -F and R2 is -methyl.
[0049] In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-O-CH2-NR8-*, -(C1-C4 alkylene)-S-CH2-NR8-*, or-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - (C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-NR8-*. 17 WO 2020/219287 PCT /0S2020/027831
[0050] In some embodiments, -L 1-Z' -* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH-*, -(CH2)3QCH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, -(CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or -(CH2)4NH-.
[0051] In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-O- 5 CH2-NR8-*, -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)S-( C1-Cs alkylene)-S-CH2-NR8-*, or-(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-O-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NRsC(=O)-(C1-Cs alkylene)-SCH2- NR8-*.
In some embodiments, -L1-Z'-* is-(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2- 10 NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2- NRs-*_
[0052] In some embodiments, -L1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - 15 CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3SCH2- NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)sS-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3Q-CH2-NH-*, - CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - 20 CH2S(CH2)sS-CH2-NH-*.
[0053] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
In some embodiments, each R8 is independently -H, methyl, or benzyl.
In some embodiments, each R8 is independently -H.
In some 25 embodiments, each R8 is methyl.
In some embodiments, each R8 is benzyl.
[0054] In some embodiments -L 1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or-X1'-(C1-C4 alkylene)-NR8-*.
In some embodiments -L1-Z'-* is - x1'-(C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments -L1-Z'-* is -X1'-(C1-C4 alkylene)S- CH2-NR8-*.
In some embodiments -L1-Z'-* is -X1'-(C1-C4 alkylene)-NR8-*. 18 WO 2020/219287 PCT /0S2020/027831
[0055] In some embodiments -L 1-Z'-* is -OCH2O-CH2-NH-*, - O(CH2)2O-CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH2O-CH2-NH-*, -S(CH2)2O-CH2-NH-*, - S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH2O-CH2-NH-*, -S(O)(CH2)2O-CH2- NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, -S(O)2CH2O-CH2-NH-*, - s S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3Q-CH2-NH-*, -S(O)2(CH2)4Q-CH2-NH-*, -OCH2SCH2- NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH-*, -O(CH2)4S-CH2-NH-*, -SCH2SCH2- NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, - S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4SCH2- NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, -S(O)2(CH2)3S-CH2-NH-*, - 10 S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, -O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, -S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, - S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, -S(O)2CH2-NH-*, -S(O)2(CH2)2- NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*.
[0056] In some embodiments, -L1-Z'-* is -(C1-C6 alkylene)-X1-L2-Z'-*.
In some H embodiments, -L 1-Z' -* is .f'.......__,,,So I ,,_,,,,,, N,,,* H ('yN'* s>'-......_,,,-N~ 0 In some embodiments, -L 1-Z' -* is H In some embodiments, -L 1-Z' -* is
[0057] In the various embodiments disclosing -L 1-Z' -* herein, * is the site covalently attached to A 20
[0058] In some embodiments, A is a peptide comprising 2 to 8 amino acids.
In some embodiments, A is a peptide comprising 2 to 4 amino acids.
In some embodiments, at least one amino acid in said peptide is a L amino acid.
In some embodiments, each amino acid in 19 WO 2020/219287 PCT /0S2020/027831 said peptide is a L amino acid.
In some embodiments, at least one amino acid in said peptide is a D amino acid.
[0059] In some embodiments, A is -(AA1)-(AA2)a1-*, where* is the point of attachment to E', AA1 and AA2 are each independently an amino acid residue; and al is an integer from 1- 5 9.
[0060] In some embodiments, -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val-Ala-*, - Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -Ala-Lys-*, -LysAla-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-*, -Phe-Ala-*,-Ala-Phe-*, - Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-Arg-Phe *, -Phe- 10 Phe-Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, -Ile-Ala-Leu* -Leu-Ala-Ile-* -Val-Ala-Val-* -Ala-Leu-Ala-Leu-* -Leu-Ala-Leu-Ala-* -~-Ala-Leu- ' ' ' ' ' JJ Ala-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, - Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -AlaLeu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, - 15 Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -ArgTyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*.
[0061] In some embodiments, -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cit*, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-D-Lys-*, -L-ValD- Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, -Val-D-Cit-*, -L- 20 Ala-L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*.
[0062] In some embodiments, -AA1-(AA2)a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-* -GlnLeu-*, -Leu-Gln-*, -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-AlaGly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly- * 25
[0063] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-AlaL- Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-*, -L-Gln-L-Leu-*, -L-Gln-D-Leu*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-AlaL- Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-Ala- WO 2020/219287 PCT /0S2020/027831 D-Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly- * ,-Gly-D-Ala-Gly-Gly-*, Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, Gly-Gly-L-Val-Gly*, -Gly-D-Val-Gly-Gly-*, Gly-Gly-D-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or Gly-Gly-L-PheGly-*. s
[0064] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, - L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*.
[0065] In the various embodiments disclosing -AA1-(AA2)a1-* herein, * is the site covalently attached to E'.
[0066] In some embodiments, A is substituted with one or more polyol.
In some 10 embodiments, E' is substituted with one or more polyol.
In some embodiments, polyol is - (C1-C6 alkylene)-X5-Y3; wherein: X5 is -NR12C(=O)- or -C(=O)NR12-; Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 0 OH OH \~~~OH
[0067] In some embodiments, polyol is R12 OH OH ; wherein R12 is H 1s or methyl.
[0068] In some embodiments, E' is -C(=O)-(C1-C10 alkylene)-X6-*.
In some embodiments, E' is 21 WO 2020/219287 PCT /0S2020/027831 l_;y 0 , -C(=O)CH2CH2-C(=O)-CRbbRcc_*, or -C(=O)CH2CH2-NRee_C(=O)- CRbbRcc_*; where* is the site covalently attached to CBA. s
[0069] In some embodiments, E' is -C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X6 - Y1 is -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)-; and d CN * ,0 \: 11 ~-NRaa_~~* CRbbRcc_*; where* is the site covalently attached to CBA. 22 WO 2020/219287
[0070] In some embodiments, E' is -C(=O)-Y1-(CH2)2-X4-(CH2)2-X6-*; Y 1 is -(CH2O)n-, or -(CH2CH2O)m-; X4 is -NHC(=O)-; n is 2; m is 2 to 6; PCT /0S2020/027831 11 ~-NRaa_fi~* d CN * -0' ~ CRbbRcc_*; where* is the site covalently attached to the CBA.
[0071] In some embodiments, the CBA comprises a -SH group that covalently links with E' /-N~S-CBA \-J) ~i~J-,,s-CBA }-1 0s-CBA 'r 10 to provide O O 0 O ~MS-CBA o)~YN'( \~o o d CN O S-CBA j-NUS-CBA H ~ ' ' 23 WO 2020/219287 /'(ii N, ~N o--fZ S-CBA ' PCT /0S2020/027831 HO S-CBA ✓
[0072] In some embodiments, the CBA is an antibody and -E'-A-Z'-L 1 - Dis a druglinker structure, the average number of drug-linker structures conjugated per antibody is in 5 the range of from 2 to IO.
[0073] In some embodiments, the average number of drug-linker structures conjugated per antibody is in the range of from 2 to 10.
In some embodiments, the average number of druglinker structures conjugated per antibody is in the range of from 6 to 8.
In some embodiments, the average number of drug-linker structures conjugated per antibody is 8. 10
[0074] In some embodiments, the CBA is an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, a domain antibody fragment that specifically binds to the target cell, 15 a probody, a nanobody, a hexabody, a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, or a nutrient-transport molecule.
[0075] In some embodiments, the CBA binds to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing any 20 one or more of 5T4, ADAM-9, ALK, AMHRII, ASCT2, Axl, B7-H3, BCMA, C4.4a, CA6, CA9, CanAg, CD123, CD138, CD142, CD166, CD184, CD19, CD20, CD205, CD22, CD248, CD25, CD3, CD30, CD33, CD352, CD37, CD38, CD40L, CD44v6, CD45, CD46, CD48, CD51, CD56, CD7, CD70, CD71, CD74, CD79b, CDH6, CEACAM5, CEACAM6, cKIT, CLDN18.2, CLDN6, CLL-1, c-MET, Cripto, CSP-I, CXCR5, DLK-1, DLL3, DPEP3, 25 Dysadherin, EFNA4, EGFR, EGFRviii, ENPP3, EpCAM, EphA2, EphA3, ETBR, FGFR2, FGFR3, FLT3, FOLR-alpha, FSH, GCC, GD2, GD3, Globo H, GPC-1, GPC3, gpNMB, 24 WO 2020/219287 PCT /0S2020/027831 HER-2, HER-3, HLA-DR, HSP90, IGF-IR, IL-13R, ILIRAP, IL7R, Interleukin-4 Receptor (IL4R), KAAG-I, LAMP-I, Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, LIV-I, LRP-I, LRRCI5, Ly6E, MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MTI-MMP, MTX3, MTX5, MUCI, MUCI6, NaPi2b, 5 Nectin-4, NOTCH3, OAcGD2, OX00IL, p-Cadherin, PD-LI, Phosphatidylserine (PS), Polymorphic epithelial mucin (PEM), Prolactin Receptor (PRLR), PSMA, PTK7, RNF43, RORI, ROR2, SAIL, SLAMF7, SLC44A4, SLITRK6, SSTR2, STEAP-I, STING, STn, TIM-I, TM4SFI, TNF- alpha, TRA, TROP-2, Tumor-associated glycoprotein 72 (TAG-72), tumor-specific epitope ofmucin-I (TA-MUCI), CDS, TIM-3, UPK2, orUPKib antigen. 10
[0076] In some embodiments, the cell-binding agent is an anti-folate receptor antibody or an antibody fragment thereof, an anti-EGFR antibody or an antibody fragment thereof, an antiCD33 antibody or an antibody fragment thereof, an anti-EpCAM antibody or an antibody fragment thereof, an anti-CDI9 antibody or an antibody fragment thereof, an anti-Mucl antibody or an antibody fragment thereof, or an anti-CD37 antibody or an antibody fragment 15 thereof.
[0077] The present invention also includes a composition (e.g., a pharmaceutical composition) comprising a cytotoxic compound or a conjugate of the present invention described herein, and a carrier (a pharmaceutically acceptable carrier).
The present compounds, conjugates or compositions are useful for inhibiting abnormal cell growth or 20 treating a proliferative disorder (e.g., cancer), an autoimmune disorder, destructive bone disorder, infectious disease, viral disease, fibrotic disease, neurodegenerative disorder, pancreatitis or kidney disease in a mammal (e.g., human).
[0078] The present compounds, conjugates or compositions are useful for treating cancer in a subject in need thereof.
In some embodiments, the cancer is a lymphoma or a leukemia.
In 25 some embodiments, the cancer is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), acute B lymphoblastic leukemia or B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL ), hairy cell leukemia (HCL ), acute promyelocytic leukemia (APL), B-cell chronic lymphoproliferative disease (B-CLPD), atypical chronic lymphocytic WO 2020/219287 PCT /0S2020/027831 leukemia, diffuse large B-cell lymphoma (DLBCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), mantel cell leukemia (MCL), small lymphocytic lymphoma (SLL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma.
In some embodiments, the cancer is endometrial cancer, lung cancer, colorectal 5 cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular cancer, myeloid cancer, melanoma, and lymphoid cancer.
In some embodiments, the lung cancer is non-small cell lung cancer or small-cell lung cancer. 10
[0079] Also included in the present invention is the use of a cytotoxic compound, a conjugate, or a composition of the present invention for the manufacture of a medicament for inhibiting abnormal cell growth or treating a proliferative disorder (e.g., cancer), an autoimmune disorder, destructive bone disorder, infectious disease, viral disease, fibrotic disease, neurodegenerative disorder, pancreatitis or kidney disease in a mammal (e.g., 15 human).
[0080] The present compounds, conjugates or compositions are useful for the manufacture of a medicament for treating cancer in a subject in need thereof.
In some embodiments, the cancer is a lymphoma or a leukemia.
In some embodiments, the cancer is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), 20 acute lymphoblastic leukemia (ALL), acute B lymphoblastic leukemia or B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL ), acute promyelocytic leukemia (APL), B-cell chronic lymphoproliferative disease (BCLPD), atypical chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), 25 mantel cell leukemia (MCL), small lymphocytic lymphoma (SLL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma.
In some embodiments, the cancer is endometrial cancer, lung cancer, colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular 26 WO 2020/219287 PCT /0S2020/027831 cancer, myeloid cancer, melanoma, and lymphoid cancer.
In some embodiments, the lung cancer is non-small cell lung cancer or small-cell lung cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0081] FIG. I depicts the first part of the synthesis of camptothecin building blocks. s
[0082] FIG. 2 depicts the second part of the synthesis of camptothecin building blocks.
[0083] FIG. 3 depicts the first part of the synthesis of the side chains.
[0084] FIG. 4 depicts the second part of the synthesis of the side chains.
[0085] FIG. 5 depicts the first part of coupling the camptothecin building blocks to the side chains. 10
[0086] FIG. 6 depicts the second part of coupling the camptothecin building blocks to the side chains.
[0087] FIG. 7 depicts the third part of coupling the camptothecin building blocks to of the side chains.
[0088] FIG. 8 depicts the synthesis of additional camptothecin metabolites. 1s
[0089] FIG. 9 depicts the coupling of camptothecin building blocks to side chains.
[0090] FIG. IO depicts the synthesis of additional camptothecin compounds.
[0091] FIG. 11 depicts compounds used for comparison, which include a generic Ab-999 structure of an ADC bearing the 999 moiety linked through reduced inter-chain di sulfides of an antibody. 20
[0092] FIG. 12 depicts the cytotoxicity of the sulfide-bearing compound Sc and its sulfoxide 34a and sulfone 34b.
[0093] FIG. 13 depicts the pharmacokinetics of ML66-999 in mice.
Top panel depicts plots of concentration (μg/mL) vs time of the mAb component (average), and payload component, 27 WO 2020/219287 PCT /0S2020/027831 at 2 min, I day and 3 day time points post administration in mice.
Bottom panel depicts plots of concentration (μg/mL) vs time of the mAb component (average), and retained Bioactivity (pooled samples), of ADCs at 2 min, I day and 3 day time points post administration in mice.
[0094] FIG. 14 depicts the pharmacokinetics ofML66-22a in mice.
Top panel depicts plots 5 of concentration (μg/mL) vs time of the mAb component (average), and payload component, at 2 min, I day and 3 day time points post administration in mice.
Bottom panel depicts plots of concentration (μg/mL) vs time of the mAb component (average), and retained Bioactivity (pooled samples), of ADCs at 2 min, I day and 3 day time points post administration in mice.
[0095] FIG. 15 depicts the in vitro cytotoxicities of ADCs against Ag+ and Ag- cells. ADC 10 standard in formulation (Standard) or blood serum (pooled) containing ADC taken at 2 min, I day or 3 days post administration into mice for ML66-999.
[0096] FIG. 16 depicts the in vitro cytotoxicities of ADCs against Ag+ and Ag- cells. ADC standard in formulation (Standard) or blood serum (pooled) containing ADC taken at 2 min, I day or 3 days post administration into mice for ML66-22a. 15
[0097] FIG. 17 depicts the efficacy of ADCs in a HSC-2 xenograft model.
Dosing is based on payload (75 μg/kg and 250 μg/kg are - 3 mg/kg and -10 mg/kg based on antibody).
[0098] FIG. 18 depicts the efficacy of ADCs in a FaDu xenograft models.
Dosing is based on payload (75 μg/kg and 250 μg/kg are - 3 mg/kg and -10 mg/kg based on antibody).
[0099] FIG. 19 depicts the mouse tolerability to ML66-999, ML66-22a and ML66-28a 20 ADCs.
[00100] FIG. 20 depicts the anti-tumor activity of ADCs in a HI 703 mouse xenograft model.
Dosing is based on payload (75 μg/kg and 250 μg/kg are - 3 mg/kg and-10 mg/kg based on antibody).
[00101] FIG. 21 depicts the mouse tolerability of non-cross-reactive ADCs at 5000 μg/kg 25 payload dose (-200 mg/kg based on the Ab component).
AbF = humanized anti-folate receptor antibody. 28 DETAILED DESCRIPTION
[00102] In order that the invention described herein may be fully understood, the following detailed description is set forth.
While the invention will be described in conjunction with the enumerated embodiments, it will be understood that they are not intended to limit the 5 invention to those embodiments.
On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents that can be included within the scope of the present invention as defined by the claims.
One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. 10
[00103] The term "herein" means the entire application.
[00104] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this invention belongs.
Generally, nomenclature used in connection with the compounds, composition and methods described herein, are those well-known and 15 commonly used in the art.
[00105] It should be understood that any of the embodiments described herein, including those described under different aspects of the invention and different parts of the specification (including embodiments described only in the Examples) can be combined with one or more other embodiments of the invention, unless explicitly disclaimed or improper. 20 Combination of embodiments are not limited to those specific combinations claimed via the multiple dependent claims. [00 I 06] Chemistry terms used herein are used according to conventional usage in the art, as exemplified by "The McGraw-Hill Dictionary of Chemical Terms", Parker S., Ed., McGrawHill, San Francisco, C.A. (1985). 25 [00107] 29 5
[00108] Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer (or components) or group of integers ( or components), but not the exclusion of any other integer (or components) or group of integers (or components). [00 I 09] Throughout the specification, where compositions are described as having, including, 10 or comprising (or variations thereof), specific components, it is contemplated that compositions also may consist essentially of, or consist of, the recited components.
Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also may consist essentially of, or consist of, the recited processing steps.
Further, it should be understood that the order of steps or order for 15 performing certain actions is immaterial so long as the compositions and methods described herein remains operable.
Moreover, two or more steps or actions can be conducted simultaneously.
[00110] The term "including" is used to mean "including but not limited to." "Including" and "including but not limited to" are used interchangeably. 20
[00111] As used herein, "about" or "approximately" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system.
[00112] The use of the terms "a" and "an" and "the" and similar referents in the context of 25 describing the elements ( especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
[00113] The term "or" as used herein should be understood to mean "and/or," unless the context clearly indicates otherwise.
[00114] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless s otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the 10 scope of the claims unless otherwise stated.
No language in the specification should be construed as indicating any non-claimed element as essential.
Definitions
[00115] The term "alkyl' or "linear or branched alkyl" as used herein refers to a saturated linear or branched monovalent hydrocarbon radical.
In preferred embodiments, a straight 1s chain or branched chain alkyl has thirty or fewer carbon atoms (e.g., C1-C30 for straight chain alkyl group and C3-C30 for branched alkyl), and more preferably twenty or fewer carbon atoms.
Even more preferably, the straight chain or branched chain alkyl has ten or fewer carbon atoms (i.e., C1-C10 for straight chain alkyl group and C3-C10 for branched alkyl).
In other embodiments, the straight chain or branched chain alkyl has six or fewer carbon atoms 20 (i.e., C1-C6 for straight chain alkyl group or C3-C6 for branched chain alkyl).
Examples of alkyl include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, I-butyl, 2-methyl-1- propyl, -CH2CH(CH3)2), 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl 3-pentyl, 2-methyl-2- butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl), 2-hexyl, 3-hexyl, 2- methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3- 25 pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, and the like.
Moreover, the term "alkyl" as used throughout the specification, examples, and claims is intended to include both "unsubstituted alkyls" and "substituted alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon 31 WO 2020/219287 PCT /0S2020/027831 backbone.
As used herein, (Cx-Cxx)alkyl or Cx-xxalkyl means a linear or branched alkyl having x-xx number of carbon atoms.
[00116] The term "alkylene" as used herein refers to a saturated linear or branched divalent hydrocarbon radical.
In preferred embodiments, a straight chain or branched chain alkylene 5 has thirty or fewer carbon atoms (e.g., C1-C30 for straight chain alkylene group and C3-C30 for branched alkylene ), and more preferably twenty or fewer carbon atoms.
Even more preferably, the straight chain or branched chain alkylene has ten or fewer carbon atoms (i.e., C1-C10 for straight chain alkylene group and C3-C10 for branched alkylene).
In other embodiments, the straight chain or branched chain alkylene has six or fewer carbon atoms 10 (i.e., C1-C6 for straight chain alkylene group or C3-C6 for branched chain alkylene).
As used herein, (Cx-Cxx)alkylene or Cx-xxalkylene means a linear or branched alkylene having x-xx number of carbon atoms.
[00117] The term "alkenyl" or "linear or branched alkenyl" refers to linear or branched-chain monovalent hydrocarbon radical of two to twenty carbon atoms with at least one site of 15 unsaturation, i.e., a carbon-carbon double bond, wherein the alkenyl radical includes radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations.
Examples include, but are not limited to, ethylenyl or vinyl (-CH=CH2), allyl (-CH2CH=CH2), and the like.
Preferably, the alkenyl has two to ten carbon atoms.
More preferably, the alkyl has two to four carbon atoms. 20
[00118] The term "alkynyl" or "linear or branched alkynyl" refers to a linear or branched monovalent hydrocarbon radical of two to twenty carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, triple bond.
Examples include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, hexynyl, and the like.
Preferably, the alkynyl has two to ten carbon atoms.
More preferably, the alkynyl has 25 two to four carbon atoms.
[00119] The terms "cyclic alkyl" and "cycloalkyl" can be used interchangeably.
As used herein, the term refers to the radical of a saturated carbocyclic ring.
In preferred embodiments, cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably from 5 to 7 carbon atoms in the ring structure.
In some embodiments, the two cyclic rings can have two or 32 WO 2020/219287 PCT /0S2020/027831 more atoms in common, e.g., the rings are "fused rings." Suitable cycloalkyls include, but are not limited to cycloheptyl, cyclohexyl, cyclopentyl, cyclobutyl and cyclopropyl.
In some embodiments, the cycloalkyl is a monocyclic group.
In some embodiments, the cycloalkyl is a bicyclic group.
In some embodiments, the cycloalkyl is a tricyclic group. 5
[00120] The term "cycloalklalkyl" refers to an alkyl group described above that is substituted with a cycloalkyl group.
[00121] The term "cyclic alkenyl" refers to a carbocyclic ring radical having at least one double bond in the ring structure.
[00122] The term "cyclic alkynyl" refers to a carbocyclic ring radical having at least one 10 triple bond in the ring structure.
[00123] The term "aryl" or "aromatic ring" as used herein, include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon.
Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring.
Aryl groups include, but are not limited to, phenyl, phenol, aniline, and the like.
The terms "aryl" 15 also includes "polycyclyl", "polycycle", and "polycyclic" ring systems having two or more rings in which two or more atoms are common to two adjoining rings, e.g., the rings are "fused rings," wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, or aromatic rings.
In some preferred embodiments, polycycles have 2-3 rings.
In certain preferred embodiments, polycyclic ring systems have 20 two cyclic rings in which both of the rings are aromatic.
Each of the rings of the polycycle can be substituted or unsubstituted.
In certain embodiments, each ring of the polycycle contains from 3 to 10 carbon atoms in the ring, preferably from 5 to 7.
For example, aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6, 7,8-tetrahydronaphthyl, 25 and the like.
In some embodiments, the aryl is a single-ring aromatic group.
In some embodiments, the aryl is a two-ring aromatic group.
In some embodiments, the aryl is a threering aromatic group. 33 WO 2020/219287 PCT /0S2020/027831
[00124] The term "heteroalkyl" refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., 0, S, N (e.g., -NH, -N(alkyl)-), or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalky 1.
In one aspect, a heteroalky 1 is a C 1 -C 3oheteroalky 1. A C 1 - 5 C3oheteroalkyl refers to an alkyl group having 1 to 30 carbon atoms and 1 to 15 heteroatoms.
Examples of C1-C3oheteroalkyl groups include, but are not limited to, ethers ( e.g., -CH2-OCH3, -(CH2)2-O-CH3, -(CH2)3-O-(CH2)2-O-CH3, -(CH2)2-O-(CH2)3CH3, CH2-O-CH2-O-CH3, - CH2-O-(CH2)3-O-CH3), polyethylene glycol (PEG) derivatives (e.g., -[(CH2)2O]ioCH2CH3), thiothers (e.g., -CH2-S-CH3, -(CH2)2-S-CH3, -(CH2)3-S-(CH2)2CH3, -((CH2)2S)10CH2CH3), - 10 CH2-S-S-CH2, -(CH2)2-S-(CH2)3CH3, CH2-S-CH2-S-CH3, -CH2-S-(CH2)3-S-CH3), amines (e.g., -CH2-NH-CH3, -(CH2)2-N(alkyl)-CH3, -(CH2)3-NH-(CH2)2CH3, -(CH2)2-N(alkyl)( CH2)3CH3, CH2-NH-CH2-NH-CH3, -CH2-NH-(CH2)3-NH-CH3), or combinations thereof.
This disclosure also contemplates C1-C3oheteroalkyl groups wherein one of the 1 to 15 heteroatoms occupies the terminal position of the alkyl group, resulting in, for example, an 15 alcohol (i.e., OH), thiol (i.e., SH), or amine (e.g., -NH2) in the terminal position of the moiety.
[00125] The term "heteroalkenyl" refers to an alkenyl group as defined herein, in which one or more of the carbon atoms have been replaced by a heteroatom, e.g., 0, S, N (e.g., -NH, - N(alkyl)-). A heteroalkenyl is attached to the rest of the molecule at a carbon atom of the 20 heteroalkenyl.
In one aspect, a heteroalkenyl is a C1-C3oheteroalkenyl. A C1-C3oheteroalkenyl refers to an alkenyl group having 1 to 30 carbon atoms and 1 to 15 heteroatoms, for example, 1 to 10 heteroatoms or 1 to 5 heteroatoms.
This disclosure also contemplates C1- C3oheteroalkenyl groups wherein one of the 1 to 15 heteroatoms occupies the terminal position of the alkenyl group, resulting in, for example, an alcohol (i.e., OH), thiol (i.e., SH), 25 amine (e.g., -NH2), or imine (-C=N) in the terminal position of the moiety.
[00126] The term "heteroalkynyl" refers to an alkenyl group as defined herein, in which one or more of the carbon atoms have been replaced by a heteroatom, e.g., 0, S, N (e.g., -NH, - N(alkyl)-). A heteroalkynyl is attached to the rest of the molecule at a carbon atom of the heteroalkynyl.
In one aspect, a heteroalkynyl is a C1-C3oheteroalkynyl. A C1-C3oheteroalkenyl 30 refers to an alkynyl group having 1 to 30 carbon atoms and 1 to 15 heteroatoms, for example, 34 WO 2020/219287 PCT /0S2020/027831 I to 10 heteroatoms or I to 5 heteroatoms.
This disclosure also contemplates C1- C3oheteroalkynyl groups wherein one of the I to 15 heteroatoms occupies the terminal position of the alkynyl group, resulting in, for example, an alcohol (i.e., OH), thiol (i.e., SH), amine (e.g., -NH2), or nitrile (-C=N) in the terminal position of the moiety. 5
[00127] The terms "heterocycle," "heterocyclyl," and "heterocyclic ring" as used herein, refers to substituted or unsubstituted non-aromatic ring structures of 3- to 18-membered rings, preferably 3- to IO-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms.
In certain embodiments, the ring structure can have two 10 cyclic rings.
In some embodiments, the two cyclic rings can have two or more atoms in common, e.g., the rings are "fused rings." Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
Heterocycles are described in Paquette, Leo A; "Principles of Modem Heterocyclic Chemistry" (W. A Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of 15 Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J.
Am.
Chem.
Soc. (1960) 82:5566.
Examples of heterocyclic rings include, but are not limited to, tetrahydrofurane, dihydrofuran, tetrahydrothiene, tetrahydropyran, dihydropyran, tetrahydrothiopyran, thiomorpholine, thioxane, homopiperazine, azetidine, oxetane, thietane, homopiperidine, 20 piperidine, piperazine, pyrrolidine, morpholine, oxepane, thiepane, oxazepine, diazepine, thiazepine, 2-pyrroline, 3-pyrroline, indoline, 2H-pyrane, 4H-pyrane, dioxane, 1,3-dioxolane, pyrazoline, dithiane, dithiolane, dihydropyrane, dihydrothiene, dihydrofurane, pyrazoli diny limi dazoline, imi dazoli dine, 3-azabi cyco[3. 1. 0 ]hexane, 3- azabi cycl o[ 4. 1.0]heptane, and azabicyclo[2.2.2]hexane.
Spiro moieties are also included 25 within the scope of this definition.
Examples of a heterocyclic group wherein ring atoms are substituted with oxo (=O) moieties are pyrimidinone and 1,1-dioxo-thiomorpholine.
[00128] The term "heteroaryl" or "heteroaromatic ring" as used herein, refers to substituted or unsubstituted aromatic single ring structures, preferably 6- to 18-member rings, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures 30 include at least one heteroatom (e.g., 0, N, or S), preferably one to four or one to three WO 2020/219287 PCT /0S2020/027831 heteroatoms, more preferably one or two heteroatoms.
When two or more heteroatoms are present in a heteroaryl ring, they may be the same or different.
The term "heteroaryl" also includes "polycyclyl", "polycycle", and "polycyclic" ring systems having two or more cyclic rings in which two or more ring atoms are common to two adjoining rings, e.g., the rings are 5 "fused rings," wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaromatics, and/or heterocyclyls.
In some preferred embodiments, polycyclic heteroaryls have 2-3 rings.
In certain embodiments, preferred polycyclic heteroaryls have two cyclic rings in which both of the rings are aromatic.
In certain embodiments, each ring of the polycycle contains from 3 to 10 10 atoms in the ring, preferably from 5 to 7 atoms in the ring.
For examples, heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, quinoline, pyrimidine, indolizine, indole, indazole, benzimidazole, benzothiazole, benzofuran, benzothiophene, cinnoline, phthalazine, quinazoline, carbazole, phenoxazine, quinoline, purine and the like.
In some embodiments, 15 the heteroaryl is a single-ring aromatic group.
In some embodiments, the heteroaryl is a tworing aromatic group.
In some embodiments, the heteroaryl is a three-ring aromatic group.
[00129] The heterocycle or heteroaryl groups can be carbon (carbon-linked) or nitrogen (nitrogen-linked) attached where such is possible.
By way of example and not limitation, carbon bonded heterocycles or heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, 20 position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of 25 an isoquinoline.
[00130] By way of example and not limitation, nitrogen bonded heterocycles or heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3- pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2- pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, lH-indazole, position 2 of a 36 WO 2020/219287 PCT /0S2020/027831 isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or 0- carboline.
[00131] The heteroatoms present in heteroaryl or heterocyclyl include the oxidized forms such as NO, SO, and SO2. 5
[00132] In some embodiments, the heteroaromatic ring is a 5- to 18-membered ring.
[00133] The term "halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
In some embodiments, the halogen is fluorine.
In some embodiments, the halogen is chlorine.
In some embodiments, the halogen is bromine.
In some embodiments, the halogen is iodine.
As used herein, the term "haloalkyl" refers to an alkyl, as defined herein, 10 that is substituted by one or more halo groups as defined herein.
The haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl. A monohaloalkyl can have one fluoro, chloro, bromo, or iodo substituent.
Dihaloalkyl or polyhaloalkyl can be substituted with two or more of the same halo atoms or a combination of different halo groups.
Examples of haloalkyl include, but are not limited to, flouromethyl, difluoromethyl, trifluoromethyl, chloroamethyl, 15 dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, diflurochloromethyl, dichlorofluoromethyl, difluoroehthyl, diflosoropropyl, dichloroethyl and dichloropropyl.
[00134] The term "alkoxy" used herein refers to alkyl-O-, wherein alkyl is defined herein above.
Examples of alkoxy include, not are not limited to, methoxy, ethoxy, propoxy, 2- propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like. 20
[00135] The alkyl, haloalkyl, alkoxy, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl described above can be optionally substituted with one or more (e.g., 2, 3, 4, 5, 6 or more) substituents.
[00136] Unless specifically stated as "unsubstituted," references to chemical moieties herein are understood to also include substituted variants.
For example, reference to an "alkyl" 25 group or moiety implicitly includes both substituted and unsubstituted variants.
Examples of substituents on chemical moieties includes but is not limited to, halogen, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioformate), alkoxyl, alkylthio, acyloxy, phosphoryl, phosphate, phosphonate, 37 WO 2020/219287 PCT /0S2020/027831 amino, amido, amidine, imine, cyano, nitro, azido, sulfuydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, or aryl or heteroaryl moiety. [00137] "Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the application includes instances where the circumstance occurs 5 and instances where it does not.
For example, the phrase "optionally substituted" means that a nonhydrogen substituent may or may not be present on a given atom, and, thus, the application includes structures wherein a non-hydrogen substituent is present and structures wherein a nonhydrogen substituent is not present.
[00138] The term "substituted" refers to moieties having substituents replacing a hydrogen on 10 one or more carbons, nitrogens, oxygens or sulfurs atoms.
It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
As used herein, the 15 term "substituted" is contemplated to include all permissible substituents of organic compounds.
In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
The permissible substituents can be one or more and the same or different for appropriate organic compounds.
For purposes of the invention, the 20 heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms.
Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, an alkylthio, 25 an acyloxy, a phosphoryl, a phosphate, a phosphonate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfuydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety.
To illustrate, monofluoroalkyl is alkyl substituted with a fluoro substituent, and difluoroalkyl is alkyl substituted with two fluoro substituents.
It should be recognized that if 38 WO 2020/219287 PCT /0S2020/027831 there is more than one substitution on a substituent, each non-hydrogen substituent may be identical or different (unless otherwise stated).
[00139] If a carbon of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the carbon (to the extent there 5 are any) can separately and/or together be replaced with an independently selected optional substituent.
If a nitrogen of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the nitrogen (to the extent there are any) can each be replaced with an independently selected optional substituent.
One exemplary substituent can be depicted as -NR'R' ', wherein R' and R'' together with the 10 nitrogen atom to which they are attached, can form a heterocyclic ring.
The heterocyclic ring formed from R' and R'' together with the nitrogen atom to which they are attached can be partially or fully saturated.
In some embodiments, the heterocyclic ring consists of 3 to 7 atoms.
In other embodiments, the heterocyclic ring is selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, pyridyl and thiazolyl. 15
[00140] This specification uses the terms "substituent," "radical," and "group" interchangeably.
[00141] If a group of substituents are collectively described as being optionally substituted by one or more of a list of substituents, the group can include: (1) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) 20 substitutable substituents that are substituted by one or more of the optional substituents.
[00142] If a substituent is described as being optionally substituted with up to a particular number of non-hydrogen substituents, that substituent can be either (1) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less.
Thus, for 25 example, if a substituent is described as a heteroaryl optionally substituted with up to 3 nonhydrogen substituents, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the heteroaryl has substitutable positions.
Such substituents, in non-limiting examples, can be selected from a linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, aryl, 39 WO 2020/219287 PCT /0S2020/027831 heteroaryl, heterocyclyl, halogen, guanidinium [-NH(C=NH)NH2], -OR100, NR101R102, -NO2, -NR101COR102, -SR100, a sulfoxide represented by -SOR101, a sulfone represented by - SO2R101, a sulfonate -SO3M, a sulfate -OSO3M, a sulfonamide represented by - SO NR101R102 cyano an azido -COR101 -OCOR101 -OCONR101R102 and a polyethylene 2 ' ' ' ' ' 5 glycol unit (-OCH2CH2)nR101 wherein Mis Hor a cation (such as Na+ or K+); R101, R102 and R103 are each independently selected from H, linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, a polyethylene glycol unit (-OCH2CH2)n-R104, wherein n is an integer from 1 to 24, an aryl having from 6 to 10 carbon atoms, a heterocyclic ring having from 3 to 10 carbon atoms and a heteroaryl having 5 to 10 carbon atoms; and R 104 10 is Hor a linear or branched alkyl having 1 to 4 carbon atoms, wherein the alkyl, alkenyl, alkynyl, aryl, heteroaryl and heterocyclyl in the groups represented by R100, R101, R102, R103 and R104 are optionally substituted with one or more (e.g., 2, 3, 4, 5, 6 or more) substituents independently selected from halogen, -OH, -CN, -NO2 and unsubstituted linear or branched alkyl having 1 to 4 carbon atoms.
Preferably, the substituents for the optionally substituted 15 alkyl, alkenyl, alkynyl, cyclic alkyl, cyclic alkenyl, cyclic alkynyl, carbocyclyl, aryl, heterocyclyl and heteroaryl described above include halogen, -CN, -NR102R103, -CF3, -OR101, aryl, heteroaryl, heterocyclyl, -SR101, -SOR101, -SO2R101 and -SO3M.
[00143] For sulfoxides, represented by -SOR101 as indicated in the preceding paragraph, both optical isomers (R and S configurations at the sulfur atom of the sulfoxide group) are 20 encompassed.
[00144] The number of carbon atoms in a group can be specified herein by the prefix "Cx-xx" or "Cx-Cxx", wherein x and xx are integers.
For example, "C1.4alkyl" or "Cl-C4 alkyl" is an alkyl group having from 1 to 4 carbon atoms.
[00145] The term "compound" or "cytotoxic compound," "cytotoxic dimer" and "cytotoxic 25 dimer compound" are used interchangeably.
They are intended to include compounds for which a structure or formula or any derivative thereof has been disclosed in the present invention or a structure or formula or any derivative thereof that has been incorporated by reference.
The term also includes, stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts (e.g., pharmaceutically acceptable salts) and prodrugs, and prodrug salts of WO 2020/219287 PCT /0S2020/027831 a compound of all the formulae disclosed in the present invention.
The term also includes any solvates, hydrates, and polymorphs of any of the foregoing.
The specific recitation of "stereoisomers," "geometric isomers," "tautomers," "solvates," "metabolites," "salt" "prodrug," "prodrug salt," "conjugates," "conjugates salt," "solvate," "hydrate," or 5 "polymorph" in certain aspects of the invention described in this application shall not be interpreted as an intended omission of these forms in other aspects of the invention where the term "compound" is used without recitation of these other forms.
[00146] The term "conjugate" as used herein refers to a compound described herein or a derivative thereof that is linked to a cell binding agent. 10
[00147] The term "chiral" refers to molecules that have the property of nonsuperimposability of the mirror image partner, while the term "achiral" refers to molecules that are superimposable on their mirror image partner.
[00148] The term "stereoisomer" refers to compounds that have identical chemical constitution and connectivity, but different orientations of their atoms in space that cannot be 15 interconverted by rotation about single bonds.
[00149] The term "diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another.
Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities.
Mixtures of diastereomers can separate under high resolution analytical 20 procedures such as crystallization, electrophoresis and chromatography.
[00150] The term "enantiomers" refer to two stereoisomers of a compound that are nonsuperimposable mirror images of one another.
[00151] Stereochemical definitions and conventions used herein generally follow S. P.
Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book 25 Company, New York; and Eli el, E. and Wilen, S., "Stereochemistry of Organic Compounds," John Wiley & Sons, Inc., New York, 1994.
The compounds of the invention can contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms.
It is intended that all stereoisomeric forms of the compounds of the invention, including but not 41 WO 2020/219287 PCT /0S2020/027831 limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present invention.
Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light.
In describing an optically active compound, the prefixes D and L, or Rand S, are used to 5 denote the absolute configuration of the molecule about its chiral center(s).
The prefixes d and 1 or ( +) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with(-) or 1 meaning that the compound is levorotatory. A compound prefixed with(+) or dis dextrorotatory.
For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer can 10 also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which can occur where there has been no stereoselection or stereospecificity in a chemical reaction or process.
The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, devoid of optical activity. 15
[00152] The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that are interconvertible via a low energy barrier.
For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations.
Valence tautomers include interconversions by reorganization of some of the bonding electrons. 20
[00153] The term "pharmaceutically acceptable salt" as used herein, refers to pharmaceutically acceptable organic or inorganic salts of a compound of the invention.
Exemplary salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, 25 gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate," ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 1, l '-methylene-bis-(2-hydroxy-3-naphthoate)) salts, alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt can involve the inclusion of another molecule such as an 30 acetate ion, a succinate ion or other counter ion.
The counter ion can be any organic or 42 WO 2020/219287 PCT /0S2020/027831 inorganic moiety that stabilizes the charge on the parent compound.
Furthermore, a pharmaceutically acceptable salt can have more than one charged atom in its structure.
Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions.
Hence, a pharmaceutically acceptable salt can have one or more 5 charged atoms and/or one or more counter ion.
[00154] If the compound of the invention is a base, the desired pharmaceutically acceptable salt can be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such 10 as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid, or the like. 15
[00155] If the compound of the invention is an acid, the desired pharmaceutically acceptable salt can be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.
Illustrative examples of suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine 20 and arginine, ammonia, primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.
[00156] As used herein, the term "solvate" means a compound that further includes a stoichiometric or non-stoichiometric amount of solvent such as water, isopropanol, acetone, 25 ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine dichloromethane, 2- propanol, or the like, bound by non-covalent intermolecular forces.
Solvates or hydrates of the compounds are readily prepared by addition of at least one molar equivalent of a hydroxylic solvent such as methanol, ethanol, 1-propanol, 2-propanol or water to the compound to result in salvation or hydration of the imine moiety. 43 WO 2020/219287 PCT /0S2020/027831
[00157] The phrase "pharmaceutically acceptable" indicates that the substance or composition must be compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
[00158] The term "leaving group" refers to a group of charged or uncharged moiety that 5 departs during a substitution or displacement.
Such leaving groups are well known in the art and include, but not limited to, halogens, esters, alkoxy, hydroxyl, tosylates, triflates, mesylates, nitriles, azide, carbamate, disulfides, thioesters, thioethers and diazonium compounds.
[00159] The term "reactive ester" refers to an ester having an easily displaceable leaving 10 group that can readily react with an amine group to form an amide bond.
Examples of reactive esters include, but are not limited to, N-hydroxysuccinimide ester, N-hydroxy sulfosuccinimide ester, nitrophenyl (e.g., 2 or 4-nitrophenyl) ester, dinitrophenyl (e.g., 2,4- dinitrophenyl) ester, sulfo-tetraflurophenyl (e.g., 4 sulfo-2,3,5,6-tetrafluorophenyl) ester, or pentafluorophenyl ester. 15
[00160] The term "reactive group" refers to a group that can react with a moiety located on another molecule, such as the cell-binding agent or the cytotoxic compound, to form a covalent bond.
The reactive group includes, but is not limited to an amine reactive group and a thiol reactive group.
[00161] The term "amine reactive group" refers to a group that can react with an amine group 20 to form a covalent bond.
Exemplary amine reactive groups include, but are not limited to, reactive ester groups, acyl halides, sulfonyl halide, imidoester, or a reactive thioester groups.
In certain embodiments, the amine reactive group is a reactive ester group.
In one embodiment, the amine reactive group is a N-hydroxysuccinimide ester or a N-hydroxy sulfo-succinimide ester. 25
[00162] The term "thiol-reactive group" refers to a group that can react with a thiol (-SH) group to form a covalent bond.
Exemplary thiol-reactive groups include, but are not limited to, maleimide, haloacetyl, aloacetamide, vinyl sulfone, vinyl sulfonamide or vinyl pyridine.
In one embodiment, the thiol-reactive group is maleimide. 44 WO 2020/219287 PCT /0S2020/027831
[00163] The term "bifunctional crosslinking agent," "bifunctional linker" or "crosslinking agents" refers to modifying agents that possess two reactive groups; one of which is capable ofreacting with a cell-binding agent while the other one reacts with the cytotoxic compound to link the two moieties together.
Such bifunctional crosslinkers are well known in the art s (see, for example, Isalm and Dent in Bioconjugation chapter 5, p218-363, Groves Dictionaries Inc.
New York, 1999).
For example, bifunctional crosslinking agents that enable linkage via a thioether bond include N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-lcarboxylate (SMCC) to introduce maleimido groups, or with N-succinimidyl-4-(iodoacetyl)aminobenzoate (SIAB) to introduce iodoacetyl groups.
Other bifunctional crosslinking 10 agents that introduce maleimido groups or haloacetyl groups on to a cell binding agent are well known in the art (see US Patent Applications 2008/0050310, 20050169933, available from Pierce Biotechnology Inc. P.O.
Box 117, Rockland, IL 61105, USA) and include, but not limited to, bis-maleimidopolyethyleneglycol (BMPEO), BM(PEO)2, BM(PEO)3, N-(~maleimidopropyloxy) succinimide ester (BMPS), y-maleimidobutyric acid N-succinimidyl 1s ester (GMBS), E-maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5- maleimidovaleric acid NHS, HBVS, N-succinimidyl-4-(N-maleimidomethyl)-cyclohexane-lcarboxy-( 6-amidocaproate), which is a "long chain" analog of SMCC (LC-SMCC), mmaleimidobenzoyl- N-hydroxysuccinimide ester (MBS), 4-( 4-N-maleimidophenyl)-butyric acid hydrazide or HCl salt (MPBH), N-succinimidyl 3-(bromoacetamido)propionate (SBAP), 20 N-succinimidyl iodoacetate (SIA), K-maleimidoundecanoic acid N-succinimidyl ester (KMUA), N-succinimidyl 4-(p-maleimidophenyl)-butyrate (SMPB), succinimidyl-6-(~mal eimi dopropi onami do )hexanoate ( SMPH), succinimi dy 1-( 4-viny 1 sulfony 1 )benzoate (SVSB), dithiobis-maleimidoethane (DTME), 1,4-bis-maleimidobutane (BMB), 1,4 bismaleimidyl-2,3-dihydroxybutane (BMDB), bis-maleimidohexane (BMH), bis- 2s mal eimi doethane (BM OE), sulfosuccinimi dy 1 4-(N-mal eimi do-methy 1 )cycl ohexane-1- carboxy late (sulfo-SMCC), sulfosuccinimidyl( 4-iodo-acetyl)aminobenzoate (sulfo-SIAB), mmaleimidobenzoyl- N-hydroxysulfosuccinimide ester (sulfo-MBS), N-(ymaleimidobutryloxy) sulfosuccinimide ester (sulfo-GMBS), N-(Emaleimidocaproyloxy) sulfosuccimido ester (sulfo-EMCS), N-(K- 30 maleimidoundecanoyloxy)sulfosuccinimide ester (sulfo-KMUS), and sulfosuccinimidyl 4-(pmal eimi dopheny 1 )butyrate ( sulfo-SMPB). .
[00164] Heterobifunctional crosslinking agents are bifunctional crosslinking agents having two different reactive groups.
Heterobifunctional crosslinking agents containing both an amine-reactive N-hydroxysuccinimide group (NHS group) and a carbonyl-reactive hydrazine group can also be used to link the cytotoxic compounds described herein with a cell-binding 5 agent (e.g., antibody).
Examples of such commercially available heterobifunctional crosslinking agents include succinimidyl 6-hydrazinonicotinamide acetone hydrazone (SANH), succinimidyl 4-hydrazidoterephthalate hydrochloride (SHTH) and succinimidyl hydrazinium nicotinate hydrochloride (SHNH).
Conjugates bearing an acid-labile linkage can also be prepared using a hydrazine-bearing benzodiazepine derivative of the present 10 invention.
Examples of bi functional crosslinking agents that can be used include succinimidyl-p-formyl benzoate (SFB) and succinimidyl-p-formylphenoxyacetate (SFPA).
[00165] Bifunctional crosslinking agents that enable the linkage of cell binding agent with cytotoxic compounds via disulfide bonds are known in the art and include N-succinimidyl-3- (2-pyridyldithio )propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio )pentanoate (SPP), 15 N-succinimidyl-4-(2-pyridyldithio )butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio )2- sulfo butanoate (sulfo-SPDB) to introduce dithiopyridyl groups.
Other bifunctional crosslinking agents that can be used to introduce disulfide groups are known in the art and are disclosed in U.S.
Patents 6,913,748, 6,716,821 and US Patent Publications 20090274713 and 20100129314 Alternatively, crosslinking 20 agents such as 2-iminothiolane, homocysteine thiolactone or S-acetylsuccinic anhydride that introduce thiol groups can also be used.
[00166] The term "linker," "linker moiety," or "linking group" as defined herein refers to a moiety that connects two groups, such as a cell binding agent and a cytotoxic compound, together.
Typically, the linker is substantially inert under conditions for which the two 25 groups it is connecting are linked. A bifunctional crosslinking agent can comprise two reactive groups, one at each ends of a linker moiety, such that one reactive group can be first reacted with the cytotoxic compound to provide a compound bearing the linker moiety and a second reactive group, which can then react with a cell binding agent.
Alternatively, one end of the bifunctional crosslinking agent can be first reacted with the cell binding agent to 30 provide a cell binding agent bearing a linker moiety and a second reactive group, which can 46 . then react with a cytotoxic compound.
The linking moiety can contain a chemical bond that allows for the release of the cytotoxic moiety at a particular site.
Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, peptidase labile bonds and esterase labile bonds (see for example US 5 Patents 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073).
Preferred are disulfide bonds, thioether and peptidase labile bonds.
Other linkers that can be used in the present invention include non-cleavable linkers, such as those described in are described in detail in U.S. publication number 20050169933, or charged linkers or hydrophilic linkers and are described in US 10 2009/0274713, US 2010/01293140 and WO 2009/134976
[00167] The term "self-immolative linker" refers to a linker that will allow for release of the cytotoxic compound when a remote site is activated.
In certain embodiments, the linker comprises a p-aminobenzyl unit.
In some such embodiments, a p-aminobenzyl alcohol is 15 attached to an amino acid unit via an amide bond, and a carbamate, methylcarbamate, or carbonate is made between the benzyl alcohol and the drug (Hamann et al. (2005) Expert Opin.
Ther.
Patents (2005) 15: 1087-1103).
In some embodiments, the linker comprises paminobenzyloxycarbonyl (P AB).
Other examples of self-immolative linkers include, but are not limited to, aromatic compounds that are electronically similar to the P AB group, such as 20 2-aminoimidazol-5-methanol derivatives (U.S.
Pat.
No. 7,375,078; Hay et al. (1999) Bioorg.
Med.
Chem.
Lett. 9:2237) and ortho- or para-aminobenzylacetals.
In some embodiments, spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-aminobutyric acid amides (Rodrigues et al ( 1995) Chemistry Biology 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al 25 (1972) J.
Amer.
Chem.
Soc. 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) J.
Org.
Chem. 55:5867).
Linkage of a drug to the a-carbon of a glycine residue is another example of a self-immolative linker that may be useful in ADC (Kingsbury et al (1984) J.
Med.
Chem. 27: 1447).
[00168] The term "amino acid" refers to naturally occurring amino acids or non-naturally 30 occurring amino acid.
In some embodiments, the amino acid is represented by NH2- 47 WO 2020/219287 PCT /0S2020/027831 C(Raa'R33)-C(=O)OH, wherein Raa and Raa' are each independently H, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms, aryl, heteroaryl or heterocyclyl or Raa and the N-terminal nitrogen atom can together form a heterocyclic ring (e.g., as in praline).
The term "amino acid residue" refers to the 5 corresponding residue when one hydrogen atom is removed from the amine and/or carboxy end of the amino acid, such as -NH-C(Raa'Raa)-C(=O)-.
[00169] The term "peptide" refers to short chains of amino acid monomers linked by peptide (amide) bonds.
In some embodiments, the peptides contain 2 to 20 amino acid residues.
In other embodiments, the peptides contain 2 to 10 or 2 to 8 amino acid residues.
In yet other 10 embodiments, the peptides contain 2 to 5 amino acid residues.
As used herein, when a peptide is a portion of a cytotoxic agent or a linker described herein represented by a specific sequence of amino acids, the peptide can be connected to the rest of the cytotoxic agent or the linker in both directions.
[00170] The term "cation" refers to an ion with positive charge.
The cation can be 15 monovalent (e.g., Na+, K+, etc.), bi-valent (e.g., Ca2+, Mg2+, etc.) or multi-valent (e.g., Al 3+ etc.).
Preferably, the cation is monovalent.
[00171] The term "antibody" means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen 20 recognition site within the variable region of the immunoglobulin molecule.
As used herein, the term "antibody" encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single chain Fv (scFv) mutants, multispecific antibodies (e.g., bispecific antibodies, biparatopic antibodies, etc.), multivalent antibodies ( e.g., trivalent, tetravalent, etc. antibodies that have three, four or more 25 antigen binding sites) chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity.
An antibody can be of any of the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g., IgG 1, 48 WO 2020/219287 PCT /0S2020/027831 IgG2, IgG3, IgG4, IgAl and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively.
The different classes of immunoglobulins have different and well known subunit structures and threedimensional configurations.
Antibodies can be naked or conjugated to other molecules such 5 as toxins, radioisotopes, etc.
As used herein "antibody" also includes is an activatable antibody (e.g., a probody).
By activatable is meant that the activatable antibody, exhibits a first level of binding to a target when the activatable antibody, is in an inhibited, masked, intact or uncleaved state (i.e., a first conformation), and a second level of binding to the target in the uninhibited, unmasked and/or cleaved state (i.e., a second conformation), where the 10 second level of target binding is greater than the first level of binding.
[00172] In some embodiments, an antibody is a non-naturally occurring antibody.
In some embodiments, an antibody is purified from natural components.
In some embodiments, an antibody is recombinantly produced.
In some embodiments, an antibody is produced by a hybridoma. 15
[00173] The term "antibody fragment" refers to a portion of an intact antibody and refers to the antigenic determining variable regions of an intact antibody.
Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single chain antibodies, and multispecific antibodies (e.g., bispecific, biparatopic) formed from antibody fragments.
The term "antigen-binding fragment" of an antibody 20 includes one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
It has been shown that the antigen-binding function of an antibody can be performed by certain fragments of a full-length antibody.
Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include (without limitation): (i) an Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and Cm domains (e.g., an 25 antibody digested by papain yields three fragments: two antigen-binding Fab fragments, and one Fe fragment that does not bind antigen); (ii) a single chain Fab (scFab ), a fragment consisting of the VL, VH, CL, and Cm domains, wherein the CL and VH domains are linked via a linker peptide; (iii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region (e.g., an antibody digested by pepsin yields 30 two fragments: a bivalent antigen-binding F(ab')2 fragment, and a pFc' fragment that does 49 WO 2020/219287 PCT /0S2020/027831 not bind antigen) and its related F(ab') monovalent unit; (iv) a Fd fragment consisting of the VH and Cm domains (i.e., that portion of the heavy chain which is included in the Fab); (v) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, and the related disulfide linked Fv; (vi) a dAb (domain antibody) or sdAb (single domain antibody) 5 fragment (Ward etal., Nature 341:544-546, 1989), which consists ofa VH domain; (vii) an isolated complementarity determining region (CDR); (viii) a single chain variable fragment (scFv), a fragment consisting of a VH and VL domain, connected via a linker peptide; and (ix) a tetravalent antibody, which may include various formats (structures) whereby the antibody comprises 4 antigen binding sites. 10
[00174] The term "monoclonal antibody" refers to a homogeneous antibody population involved in the highly specific recognition and binding of a single antigenic determinant, or epitope.
This is in contrast to polyclonal antibodies that typically include different antibodies directed against different antigenic determinants.
The term "monoclonal antibody" encompasses both intact and full-length monoclonal antibodies as well as antibody fragments 15 (such as Fab, Fab', F(ab')2, Fv), single chain (scFv) mutants, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site.
Furthermore, "monoclonal antibody" refers to such antibodies made in any number of manners including but not limited to by hybridoma, phage selection, recombinant expression, and transgenic animals. 20
[00175] The term "humanized antibody" refers to forms of non-human (e.g., murine) antibodies that are specific immunoglobulin chains, chimeric immunoglobulins, or fragments thereof that contain minimal non-human (e.g., murine) sequences.
Typically, humanized antibodies are human immunoglobulins in which residues from the complementary determining region (CDR) are replaced by residues from the CDR of a non-human species 25 (e.g., mouse, rat, rabbit, hamster) that have the desired specificity, affinity, and capability (Jones et al., Nature 321 :522-525, 1986; Riechmann et al., Nature 332:323-327, 1988; Verhoeyen et al., Science 239: 1534-1536, 1988).
[00176] In some instances, the Fv framework region (FR) residues of a human immunoglobulin are replaced with the corresponding residues in an antibody from a non- 50 . human species that has the desired specificity, affinity, and capability.
The humanized antibody can be further modified by the substitution of additional residues either in the Fv framework region and/or within the replaced non-human residues to refine and optimize antibody specificity, affinity, and/or capability.
In general, the humanized antibody will 5 comprise substantially all of at least one, and typically two or three, variable domains containing all or substantially all of the CDR regions that correspond to the non-human immunoglobulin whereas all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence.
The humanized antibody can also comprise at least a portion of an immunoglobulin constant region or domain (Fe), typically that of a human 10 immunoglobulin.
Examples of methods used to generate humanized antibodies are described in U.S.
Pats. 5,225,539 and 5,639,641, Roguska et al., Proc.
Natl.
Acad.
Sc:i. USA 91(3):969- 973, 1994; and Roguska et al., Protein Eng. 9(10):895-904, 1996 In some embodiments, a "humanized antibody" is a resurfaced antibody.
In some embodiments, a "humanized antibody" is a CDR-grafted antibody. 15
[00177] The term "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination.
The variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs) also known as hypervariable regions.
The CDRs in each chain are held together in close 20 proximity by the FRs and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies.
There are at least two techniques for determining CD Rs: (I) an approach based on cross-species sequence variability (i.e., Kabat et al.
Sequences <!/Proteins <!f lmm11nological Interest, 5th ed., 1991, National Institutes of Health, Bethesda Md.); and (2) an approach based on crystallographic studies of antigen-antibody 25 complexes (Al-lazikani et al., J.
Malec.
Biol. 273:927-948, 1997).
In addition, combinations of these two approaches are sometimes used in the art to determine CD Rs.
[00178] The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al., Sequences of Immunological Interest, 5th Ed., Public Health 30 Service, National Institutes of Health, Bethesda, Md. (1991)). 51 . .
[00179] The amino acid position numbering as in Kabat, refers to the numbering system used for heavy chain variable domains or light chain variable domains of the compilation of antibodies in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, Md. (1991) Using this numbering system, the actual linear amino acid sequence can contain fewer or additional amino acids corresponding to a shortening ot~ or insertion into, a FR or CDR of the variable domain.
For example, a heavy chain variable domain can include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g, residues 82a, 82b, and 82c, etc. according to Kabat) after heavy chain FR 10 residue 82.
The Kabat numbering of residues can be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.
Chothia refers instead to the location of the structural loops (Chothia and Lesk, J Mal.
Biol. 196:901-917, 1987).
The end of the Chothia CDR-Hl loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on 1s the length of the loop.
This is because the Kabat numbering scheme places the insertions at H35A and H35B - if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34.
The AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular' s AbM antibody modeling software.
Loop Kabat AbM Chothia Ll L24-L34 L24-L34 L24-L34 L2 L50-L56 L50-L56 L50-L56 L3 L89-L97 L89-L97 L89-L97 HI H3 I-H35B H26-H35B H26-H32 .34 (Kabat Numbering) HI H3 I-H35 H26-H35 H26-H32 (Chothia Numbering) H2 H50-H65 H50-H58 H52-H56 H3 H9S-Hl02 H95-Hl02 H95-Hl02 20
[00180] The EU index or EU index as in Kabat or EU numbering scheme refers to the numbering system based on the human IgGl Eu antibody of Edelman et al., 1969, Proc Natl Acad Sci USA 63 :78-85 52 WO 2020/219287 PCT /0S2020/027831
[00181] The term "human antibody" means an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human made using any technique known in the art.
In certain embodiments, the human antibody does not have non-human sequence.
This definition of a human antibody includes intact or full-length 5 antibodies, or antigen-binding fragments thereof.
[00182] The term "chimeric antibodies" refers to antibodies wherein the amino acid sequence of the immunoglobulin molecule is derived from two or more species.
Typically, the variable region of both light and heavy chains corresponds to the variable region of antibodies derived from one species of mammals (e.g., mouse, rat, rabbit, etc.) with the 10 desired specificity, affinity, and capability while the constant regions are homologous to the sequences in antibodies derived from another (usually human) to avoid or reduce the chance of eliciting an immune response in that species (e.g., human).
In certain embodiments, chimeric antibody may include an antibody or antigen-binding fragment thereof comprising at least one human heavy and/or light chain polypeptide, such as, for example, an antibody 15 comprising murine light chain and human heavy chain polypeptides.
[00183] The terms "epitope" or "antigenic determinant" are used interchangeably herein and refer to that portion of an antigen capable of being recognized and specifically bound by a particular antibody.
When the antigen is a polypeptide, epitopes can be formed both from contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a 20 protein.
Epitopes formed from contiguous amino acids are typically retained upon protein denaturing, whereas epitopes formed by tertiary folding are typically lost upon protein denaturing.
An epitope typically includes at least 3, and more usually, at least 5 or 8-10 amino acids in a unique spatial conformation. [00184] "Binding affinity" generally refers to the strength of the sum total of noncovalent 25 interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
Unless indicated otherwise, as used herein, "binding affinity" refers to intrinsic binding affinity which reflects a 1: 1 interaction between members of a binding pair (e.g., antibody and antigen).
The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd) or the half-maximal effective 53 WO 2020/219287 PCT /0S2020/027831 concentration (ECso).
Affinity can be measured by common methods known in the art, including those described herein.
Low-affinity antibodies generally bind antigen slowly and tend to dissociate readily, whereas high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods of measuring binding affinity are known 5 in the art, any of which can be used for purposes of the present invention.
Specific illustrative embodiments are described herein.
[00185] By "specifically binds," it is generally meant that an antibody binds to an epitope via its antigen-binding domain, and that the binding entails some complementarity between the antigen-binding domain and the epitope.
According to this definition, an antibody is said to 10 "specifically bind" to an epitope when it binds to that epitope, via its antigen-binding domain more readily than it would bind to a random, unrelated epitope.
The term "specificity" is used herein to qualify the relative affinity by which a certain antibody binds to a certain epitope.
For example, antibody "A" may be deemed to have a higher specificity for a given epitope than antibody "B," or antibody "A" may be said to bind to epitope "C" with a higher 15 specificity than it has for related epitope "D."
[00186] The term "immunoconjugate," "conjugate," or "ADC" as used herein refers to a compound or a derivative thereof that is linked to a cell binding agent (e.g., an antibody or antigen-binding fragment thereof).
[00187] The term "cysteine-engineered antibody" includes an antibody with at least one Cys 20 that is not normally present at a given residue of the antibody light chain or heavy chain.
Such Cys, which may also be referred to as "engineered Cys," can be engineered using any conventional molecular biology or recombinant DNA technology (e.g., by replacing the coding sequence for a non-Cys residue at the target residue with a coding sequence for Cys).
For example, if the original residue is Ser with a coding sequence of 5' -UCU-3 ', the coding 25 sequence can be mutated (e.g., by site-directed mutagenesis) to 5' -UGU-3 ', which encodes Cys.
In certain embodiments, the Cys engineered antibody of the invention has an engineered Cys in the heavy chain.
In certain embodiments, the engineered Cys is in or near the CH3 domain of the heavy chain.
In certain embodiments, the engineered Cys is at residue 442 of the heavy chain (EU/OU numbering).
The C442 residue can be conjugated with a 54 WO 2020/219287 PCT /0S2020/027831 cytotoxic drug / agent through the free thiol group of the C442 residue, such as through reacting with a thiol-reactive agent of the cytotoxic drug (e.g., a maleimido group).
[00188] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals in which a population of cells are characterized by unregulated cell growth. 5 "Tumor" and "neoplasm" refer to one or more cells that result from excessive cell growth or proliferation, either benign (noncancerous) or malignant (cancerous) including pre-cancerous lesions.
[00189] Examples of cancer include endometrial cancer, lung cancer (e.g., non-small-cell lung cancer), colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell 1 o carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular cancer, myeloid cancer, melanoma, and lymphoid cancer.
In certain embodiments, the cancer is nonsmall- cell lung cancer, colorectal cancer, gastric cancer or pancreatic cancer.
In certain embodiments, the cancer is non-small-cell lung cancer (squamous cell, nonsquamous cell, 15 adenocarcinoma, or large-cell undifferentiated carcinoma), colorectal cancer (adenocarcinoma, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, or squamous cell carcinoma) or breast cancer (e.g., triple negative breast cancer (TNBC)).
In certain embodiments, cancer is lymphoma and leukemia.
In certain embodiments, examples of cancers include AML, CML, ALL (e.g., B- 20 ALL), CLL, myelodysplastic syndrome, basic plasmacytoid DC neoplasm (BPDCN) leukemia, B-cell lymphomas including non-Hodgkin lymphomas (NHL), precursor B-cell lymphoblastic leukemia/ lymphoma and mature B-cell neoplasms, such as B-cell chronic lymphocytic leukemia (B-CLL) / small lymphocytic lymphoma (SLL ), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL ), 25 follicular lymphoma (FL), including low-grade, intermediate-grade and high-grade FL, cutaneous follicle center lymphoma, marginal zone B-cell lymphoma (MALT type, nodal and splenic type), hairy cell leukemia (HCL), diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, plasmacytoma, plasma cell myeloma, post-transplant lymphoproliferative disorder, Waldenstrom's macroglobulinemia, anaplastic large-cell lymphoma (ALCL), and 55 WO 2020/219287 PCT /0S2020/027831 Hodgkin's leukemia (HL ).
In certain embodiments, the cancer is BPDCN leukemia.
In certain embodiments, the cancer is ALL.
In other embodiments, the cancer is AML.
[00190] The term "subject" refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a 5 particular treatment.
Typically, the terms "subject," "patient," and "individual" are used interchangeably herein in reference to a human subject.
[00191] The term "pharmaceutical composition" refers to a preparation which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the composition 10 would be administered.
Such composition can be sterile.
[00192] A "therapeutically effective amount" as used herein is an amount of a compound or composition sufficient to carry out a specifically stated purpose.
The full therapeutic effect may not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
The particular "therapeutically effective amount" will 15 depend upon e.g., the age, weight and medical condition of the subject, as well as on the method of administration and the therapeutic or combination of therapeutics selected for administration. A "therapeutically effective amount" can be determined empirically and in a routine manner, in relation to the stated purpose.
[00193] As used herein, the term "treating," "treat," or "treatment" includes reversing, 20 reducing, or arresting the symptoms, clinical signs or underlying pathology of a condition in a manner to improve, or stabilize the subject's condition.
As used herein, and as well understood in the art, "treatment" is an approach for obtaining beneficial or desired results, including clinical results.
Beneficial or desired results include, but are not limited to, prevention, alleviation, amelioration, or slowing the progression of one or more symptoms or 25 conditions associated with a condition, diminishment of extent of disease, stabilized state of disease, delay or slowing of disease progression, amelioration or palliation of disease state, and remission (partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. 56 WO 2020/219287 PCT /0S2020/027831 Compounds
[00194] In one aspect, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt, thereof: Z-Li-D (Formula I) 5 wherein: D is represented by the following structural formula: ,NV\ 0 Riis -F, -CH3, or -CF 3; R2 is -H, -F, -0R3 , -SR3 , -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri 10 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, -xi'-(Ci-C6 15 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi' is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 20 heteroaryl, or benzyl; Z is -Hor -X2 • ' X2 is -0R6 , -SR6 , -S(0)R6 , -S(O)2R6, -SSR6 , or -N(R6)2; each R6 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 25 Li and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, Ci-C6 alkyl, Ci-C6 fluoroalkyl, Ci-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and 57 WO 2020/219287 PCT /0S2020/027831 each R7 is independently H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; with the proviso that ifRi is F, then Li is -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi( Ci-C6 alkylene)-, -Xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the 5 site covalently attached to Z; and Z is -X2 ; and with the proviso that if Riis F and R2 is -OMe, then -L i_z cannot be -NH2.
[00195] In some embodiments, the invention provides a compound of Formula I, or a pharmaceutically acceptable salt, thereof: Z-Li-D (Formula I) 10 wherein: D is represented by the following structural formula: ,NV\ 0 Riis -F, -CH3, or -CF 3; R2 is -H, -F, -0R3 , -SR3 , -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri 15 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, -xi'-(Ci-C6 20 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi' is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 25 heteroaryl, or benzyl; Z is -Hor -X2• ' 58 WO 2020/219287 PCT /0S2020/027831 each R6 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 s heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; with the proviso that ifR1 is F, then L1 is -(C1-C6 alkylene)-, -(C1-C6 alkylene)-X1- (C1-C6 alkylene)-, -X1'-(C1-C6 alkylene)-*, or -(C1-C6 alkylene)-X1-L2-*; where* is the 10 site covalently attached to Z; and Z is -X2 ; with the proviso that ifR1 is F and R2 is -OMe, then-L1-Z cannot be -NH2; and with the proviso that ifR1 is F and R2 is -Me, then-L1-Z cannot be -CH2OH.
[00196] In some embodiments, R1 is F and -L 1-Z is -(C1-C6 alkylene)-X2, -(C1-C6 alkylene)X1-( C1-C6 alkylene)-X2, -X1'-(C1-C6 alkylene)-X2, or -(C1-C6 alkylene)-X1-L2-X2.
In some 1s embodiments, R1 is F and -L 1-Z is -(C1-C6 alkylene)-OR6, -(C1-C6 alkylene)-SR6, -(C1-C6 alkylene)-S(O)R6, -(C1-C6 alkylene)-S(O)2R6, -(C1-C6 alkylene)-SSR6, or -(C1-C6 alkylene)N( R6)2.
In some embodiments, R1 is F and -L1-Z is -(C1-C6 alkylene)-X1-(C1-C6 alkylene)OR6 , -(C1-C6 alkylene)-X1-(C1-C6 alkylene)-SR6, -(C1-C6 alkylene)-X1-(C1-C6 alkylene)S( O)R6 , -(C1-C6 alkylene)-X1-(C1-C6 alkylene)-S(O)2R6, -(C1-C6 alkylene)-X1-(C1-C6 20 alkylene)-SSR6, or -(C1-C6 alkylene)-X1-(C1-C6 alkylene)-N(R6)2.
In some embodiments, R1 I• s F and -L 1 -Z I• s -X l' -(C1-C6 alkylene)-OR6, -X l' -(C1-C6 alkylene)-SR6, -X l' -(C1-C6 alkylene)-S(O)R6, -X l' -(C1-C6 alkylene)-S(O)2R6, -X l' -(C1-C6 alkylene)-SSR6, or -X l' -(C1-C6 alkylene)-N(R6)2.
In some embodiments, R1 is F and -L 1-Z is -(C1-C6 alkylene)-X1-L2-OR6, - (C1-C6 alkylene)-X1-L2-SR6, -(C1-C6 alkylene)-X1-L2-S(O)R6, -(C1-C6 alkylene)-X1-L2- 2s S(O)2R6• -(C1-C6 alkylene)-X1-L2-SSR6, or -(C1-C6 alkylene)-X1-L2-N(R6)2.
[00197] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some 59 WO 2020/219287 PCT /0S2020/027831 embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In some embodiments, R1 is -F and R2 is -methyl.
[00198] In some embodiments, -L1-Z is -H.
In some embodiments, -L1-Z is -(C1-C6 alkylene)-H, or -(C1-C6 alkylene)-X2.
In some embodiments, -L1-Z is -(C1-C6 alkylene)-H. 5 In some embodiments, -L1-Z is -(C1-C6 alkylene)-X2.
In some embodiments, -L1-Z is -(C1-C6 alkylene )-X2 .
In some embodiments, -L 1-Z is methyl, ethyl, propyl, or butyl.
[00199] In some embodiments, -L1-Z is -(C1-C4 alkylene)-OR6, -(C1-C4 alkylene)-SR6, or( C1-C4 alkylene)-N(R6)2.
In some embodiments, -L1-Z is -(C1-C4 alkylene)-OR6.
In some embodiments, -L1-Z is -(C1-C4 alkylene)-SR6.
In some embodiments, -L1-Z is -(C1-C4 10 alkylene)-N(R6)2.
[00200] In some embodiments, -L 1-Z is -CH2OH, -(CH2)2OH, -(CH2)3QH, -(CH2)4QH, - CH2OMe, -(CH2)2OMe, -(CH2)3QMe, -(CH2)4QMe, -CH2SH, -(CH2)2SH, -(CH2)3SH, - (CH2)4SH, -CH2SMe, -(CH2)2SMe, -(CH2)3SMe, -(CH2)4SMe, -CH2NH2, -(CH2)2NH2, - (CH2)3NH2, -(CH2)4NH2. 15
[00201] In some embodiments, -L1-Z is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-OR6, - (C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SR6, -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SR6, or -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SSR6.
In some embodiments, -L1-Z is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-OR6.
In some embodiments, -L1-Z is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SR6.
In some embodiments, -L1-Z is-(C1-Cs 20 alkylene)-S-(C1-Cs alkylene)-SR6.
In some embodiments, -L1-Z is -(C1-Cs alkylene)-S-(C1- Cs alkylene)-SSR6.
[00202] In some embodiments, -L1-Z is -CH2NHC(=O)CH2OH, -CH2NHC(=O)(CH2)2OH, - CH2NHC(=O)(CH2)3QH, -CH2NHC(=O)(CH2)4QH, -CH2NHC(=O)(CH2)sOH, - CH2NHC(=O)CH2OMe, -CH2NHC(=O)(CH2)2OMe, -CH2NHC(=O)(CH2)3QMe, - 25 CH2NHC(=O)(CH2)4QMe, -CH2NHC(=O)(CH2)sOMe, -CH2NHC(=O)CH2SH, - CH2NHC(=O)(CH2)2SH, -CH2NHC(=O)(CH2)3SH, -CH2NHC(=O)(CH2)4SH, - CH2NHC(=O)(CH2)sSH, -CH2NHC(=O)CH2SMe, -CH2NHC(=O)(CH2)2SMe, - CH2NHC(=O)(CH2)3SMe, -CH2NHC(=O)(CH2)4SMe, -CH2NHC(=O)(CH2)sSMe, - 60 WO 2020/219287 PCT /0S2020/027831 CH2SCH2OH, -CH2S(CH2)2OH, -CH2S(CH2)3QH, -CH2S(CH2)4QH, -CH2S(CH2)sOH, - CH2SCH2OMe, -CH2S(CH2)2OMe, -CH2S(CH2)3QMe, -CH2S(CH2)4QMe, - CH2S(CH2)sOMe,-CH2SCH2SH, -CH2S(CH2)2SH, -CH2S(CH2)3SH, -CH2S(CH2)4SH, - CH2S(CH2)sSH, -CH2SCH2SMe, -CH2S(CH2)2SMe, -CH2S(CH2)3SMe, -CH2S(CH2)4SMe, or s -CH2S(CH2)sSMe.
[00203] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
[00204] In some embodiments, each R6 is independently -H, methyl, or benzyl.
In some 10 embodiments, each R6 is independently -H.
In some embodiments, each R6 is methyl.
In some embodiments, each R6 is benzyl.
[00205] In some embodiments, -L1-Z is -X1'-(C1-C4 alkylene)-X2.
In some embodiments, - L 1-Z is -OCH2OH, -O(CH2)2OH, -O(CH2)3QH, -O(CH2)4QH, -SCH2OH, -S(CH2)2OH, - S(CH2)3QH, -S(CH2)4QH, -S(O)CH2OH, -S(O)(CH2)2OH, -S(O)(CH2)3QH, -S(O)(CH2)4QH, 1s -S(O)2CH2OH, -S(O)2(CH2)2OH, -S(O)2(CH2)3QH, -S(O)2(CH2)4QH, -OCH2SMe, - O(CH2)2SMe, - O(CH2)3SMe, -O(CH2)4SMe, -SCH2SMe, - S(CH2)2SMe, -S(CH2)3SMe, - S(CH2)4SMe, -S(O)CH2SMe, -S(O)(CH2)2SMe, -S(O)(CH2)3SMe, -S(O)(CH2)4SMe, - S(O)2CH2SMe, -S(O)2(CH2)2SMe, -S(O)2(CH2)3SMe, or -S(O)2(CH2)4SMe.
[00206] In some embodiments, -L1-Z is -(C1-C6 alkylene)-X1-L2-X2.
In some embodiments, - I sf''-.,/N P NH2 .f''-../So H ,0 20 L 1-Z is NH2 or O In some embodiments, -L 1-Z is I sf''-.,/ N P NH2 .f''-../So H ,0 NH2.
In some embodiments, -L 1-Z is 0
[00207] In another aspect, the invention provides a compound of Formula II, or a pharmaceutically acceptable salt thereof: E-A-Z'-L 1-D (Formula II) 61 WO 2020/219287 PCT /0S2020/027831 wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-* or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Li and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, Ci-C6 alkyl, Ci-C6 fluoroalkyl, Ci-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and 25 each R7 is independently H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to IO amino acids; wherein A is optionally substituted with one or more polyol; and 62 WO 2020/219287 PCT /0S2020/027831 Eis -C(=O)-L3-X3; L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to X3; Y1 is absent, -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; s X4 is -NR9C(=O)- or -C(=O)NR9 -; Y2 is absent, -(CReRdO)o-, or -(CR~dcRe'Rd'O)p-; n, m, o, and p are each independently 1-1 0; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 10 wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; or -SR10• ' 11 ~-s~ 11 each W' is independently -H, -N(Rgg)2, C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, 20 C3-C6 cycloalkyl, aryl, heteroaryl, or -(CH2CH2O)q-Rff; q is 1 to 24; each Raa, Rb\ Rec, Ree, and Rff are independently-Hor optionally substituted C1-C6 alkyl; 63 WO 2020/219287 each RYY and Rxx are independently-Hor C1-C6 alkyl; Rgg are each independently-Hor C1-C6 alkyl; and PCT /0S2020/027831 R9 and R10 are each independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. s
[00208] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In 10 some embodiments, R1 is -F and R2 is -methyl.
[00209] In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-O-CH2-NR8-*, -(C1-C4 alkylene)-S-CH2-NR8-*, or-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - (C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-NR8-*. 1s
[00210] In some embodiments, -L1-Z'-* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH-*, -(CH2)3QCH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, -(CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or -(CH2)4NH-*.
[00211] In some embodiments, -L 1-Z' -* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-OCH2- NR8-*, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)- 20 S-(C1-Cs alkylene)-S-CH2-NR8-*, or-(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-O-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SCH2- NR8-*.
In some embodiments, -L1-Z'-* is-(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2- 2s NR8-*.
[00212] In some embodiments, -L1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - 64 WO 2020/219287 PCT /0S2020/027831 CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3SCH2- NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)sS-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3Q-CH2-NH-*, - CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - 5 CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - CH2S(CH2)sS-CH2-NH-*.
[00213] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
In some embodiments, each R8 is independently -H, 10 methyl, or benzyl.
In some embodiments, each R8 is independently -H.
In some embodiments, each R8 is methyl.
In some embodiments, each R8 is benzyl.
[00214] In some embodiments, -L1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or-X1'-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - x1'-(C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -X1'-(C1-C4 15 alkylene)-S-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -X1'-(C1-C4 alkylene)-NR8-*.
[00215] In some embodiments, -L1-Z'-* is -OCH2O-CH2-NH-*, - O(CH2)2O-CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH2O-CH2-NH-*, - S(CH2)2O-CH2-NH-*, - S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH2O-CH2-NH-*, -S(O)(CH2)2O-CH2- NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, -S(O)2CH2O-CH2-NH-*, - 20 S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3Q-CH2-NH-*, -S(O)2(CH2)4Q-CH2-NH-*, -OCH2SCH2- NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH-*, -O(CH2)4S-CH2-NH-*, -SCH2SCH2- NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, - S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4SCH2- NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, -S(O)2(CH2)3S-CH2-NH-*, - 25 S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, - O(CH2)3-NH-*, -O(CH2)4S-NH*, -SCH2-NH-*, - S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, - S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, -S(O)2CH2-NH-*, -S(O)2(CH2)2- NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*. 65 WO 2020/219287 PCT /0S2020/027831
[00216] In some embodiments, -L1-Z'-* is -(C1-C6 alkylene)-X1-L2-Z'-*.
In some H rr(N'* sS''--,/~~ embodiments, -L 1-Z' -* is or 0 In some .f''---../So I ,,,_,,,,,, N,,,* embodiments, -L 1-Z' -* is H In some embodiments, -L 1-Z' -* is s
[00217] In the various embodiments disclosing -L 1-Z' -* herein, * is the site covalently attached to A
[00218] In some embodiments, A is a peptide comprising 2 to 8 amino acids.
In some embodiments, A is a peptide comprising 2 to 4 amino acids.
In some embodiments, at least one amino acid in said peptide is a L amino acid.
In some embodiments, each amino acid in 10 said peptide is a L amino acid.
In some embodiments, at least one amino acid in said peptide is a D amino acid.
[00219] In some embodiments, A is -(AA1)-(AA2)a1-*, where* is the site covalently attached to E; AA1 and AA2 are each independently an amino acid residue; and al is an integer from 1-9. 1s
[00220] In some embodiments, -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val-Ala-*, - Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -Ala-Lys-*, -LysAla-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-*, -Phe-Ala-*,-Ala-Phe-*, - Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-Arg-Phe *, -PhePhe- Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, -Ile-Ala-Leu- 20 * -Leu-Ala-Ile-* -Val-Ala-Val-* -Ala-Leu-Ala-Leu-* -Leu-Ala-Leu-Ala-* -~-Ala-Leu- ' ' ' ' ' JJ Ala-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, - Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -Ala- 66 WO 2020/219287 PCT /0S2020/027831 Leu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, - Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -ArgTyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*.
[00221] In some embodiments, -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cits *, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-D-Lys-*, -L-ValD- Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, -Val-D-Cit-*, -LAla- L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*.
[00222] In some embodiments, -AA1-(AA2)a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-*, -GlnLeu-*, -Leu-Gln-*, -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala- 10 Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly- *
[00223] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-AlaL- Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-*, -L-Gln-L-Leu-*, -L-Gln-D-Leu*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala- 1s L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-AlaD- Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly*, -Gly-D-Ala-Gly-Gly-*, Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, Gly-Gly-L-ValGly-*, -Gly-D-Val-Gly-Gly-*, Gly-Gly-D-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or Gly-Gly-LPhe- Gly-*. 20
[00224] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-LAla-*, - L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*.
[00225] In the various embodiments disclosing -AA1-(AA2)a1-*herein, * is the site covalently attached to E.
[00226] In some embodiments, A is substituted with one or more polyol.
In some 2s embodiments, E is substituted with one or more polyol.
In some embodiments, polyol is - (C1-C6 alkylene)-X5-Y3; wherein: X5 is -NR12C(=O)- or -C(=O)NR12-; Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 67 WO 2020/219287 PCT /0S2020/027831 0 OH OH \~~~OH
[00227] In some embodiments, wherein polyol is R12 OH OH ; wherein R12 is Hor methyl. 0 OH OH \~~~OH
[00228] In some embodiments, wherein polyol is R12 OH OH ; wherein R12 is Hor methyl. s
[00229] In some embodiments, Eis -C(=O)-(C1-C10 alkylene)-X3 .
In some embodiments, E IS '2.A~ o ~ ~ V or'\~SH '
[00230] In some embodiments, Eis -C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X3 ; 68 WO 2020/219287 X4 is -NR9C(=O)-; and or -SR10 . 11 ~-s~ 11
[00231] In some embodiments, Eis -C(=O)-Y1-(CH2)2-X4-(CH2)2-X3 ; Y1 is -(CH2O)n- or -(CH2CH2O)m-; X4 is -NHC(=O)-; 10 nis2;mis2to6; 11 ~ ~-s~ \t_ .. ~ II N 0 ' ' 69 PCT /0S2020/027831 WO 2020/219287 PCT /0S2020/027831 or -SR10 .
[00232] In another aspect, the invention provides a compound of Formula III, or a pharmaceutically acceptable salt thereof: CBA-E'-A-Z'-L i_D (Formula III) wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' 70 WO 2020/219287 PCT /0S2020/027831 each R8 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 5 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more polyol; 10 E' is -C(=O)-L3-X6-*; where* is the site covalently linked to CBA; L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to x6; Y1 is absent, -(CRaRbO)n- or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)- or -C(=O)NR9 -; Y2 is absent, -(CRcRdO)o-, or -(CR~dcRc'Rd'O)p-; n, m, o, and p are each independently 1-1 0; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, 20 -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 11 ~-NRaa_~~* 71 WO 2020/219287 PCT /0S2020/027831 CRbbRcc_*; where* is the site covalently attached to CBA; each Raa, Rb\ Rec, and Ree are independently-Hor optionally substituted C1-C6 alkyl; each RYY and Rxx are independently-Hor C1-C6 alkyl; s R9 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; and CBA is a cell binding agent.
[00233] In some embodiments, R1 is-Hor -F.
In some embodiments, R1 is -F.
In some embodiments, R2 is -H, -F, -OCF3, -Cf 3, -OMe, -OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, - 10 S(O)Et, -S(O2)Et, methyl, or ethyl.
In some embodiments, R2 is -F.
In some embodiments, R2 is -OMe, -SMe, -S(O)Me, or methyl.
In some embodiments, R2 is methyl.
In some embodiments, R1 is -F and R2 is -F.
In some embodiments, R1 is methyl and R2 is -F.
In some embodiments, R1 is -F and R2 is -methyl.
[00234] In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-O-CH2-NR8-*, -(C1-C4 1s alkylene)-S-CH2-NR8-*, or-(C1-C4 alkylene)-NR8-*.
In some embodiments, -L1-Z'-* is - (C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-S-CH2- NR8-*.
In some embodiments, -L1-Z'-* is -(C1-C4 alkylene)-NR8-*.
[00235] In some embodiments, -L1-Z'-* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH-*, -(CH2)3QCH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, -(CH2)3S-CH2NH-*, 20 -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or -(CH2)4NH-.
[00236] In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-OCH2- NR8-*, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)S-( C1-Cs alkylene)-S-CH2-NR8-*, or-(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-O-CH2- 2s NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SCH2- NR8-*.
In some embodiments, -L1-Z'-* is-(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2- 72 WO 2020/219287 PCT /0S2020/027831 NR8-*.
In some embodiments, -L1-Z'-* is -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2- NRs-*_
[00237] In some embodiments, -L1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - 5 CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3SCH2- NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)sS-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3Q-CH2-NH-*, - CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - 10 CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - CH2S(CH2)sS-CH2-NH-*.
[00238] In some embodiments, each Rs is independently -H, methyl, or benzyl.
In some embodiments, each Rs is independently -H.
In some embodiments, each Rs is methyl.
In some embodiments, each Rs is benzyl.
In some embodiments, each R8 is independently -H, 15 methyl, or benzyl.
In some embodiments, each R8 is independently -H.
In some embodiments, each R8 is methyl.
In some embodiments, each R8 is benzyl.
[00239] In some embodiments -L 1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or-X1'-(C1-C4 alkylene)-NR8-*.
In some embodiments -L1-Z'-* is - x1'-(C1-C4 alkylene)-O-CH2-NR8-*.
In some embodiments -L1-Z'-* is -X1'-(C1-C4 alkylene)- 20 S-CH2-NR8-*.
In some embodiments -L1-Z'-* is -X1'-(C1-C4 alkylene)-NR8-*.
[00240] In some embodiments -L 1-Z'-* is -OCH2O-CH2-NH-*, - O(CH2)2O-CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH2O-CH2-NH-*, -S(CH2)2O-CH2-NH-*, - S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH2O-CH2-NH-*, -S(O)(CH2)2O-CH2- NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, -S(O)2CH2O-CH2-NH-*, - 25 S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3Q-CH2-NH-*, -S(O)2(CH2)4Q-CH2-NH-*, -OCH2SCH2- NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH-*, -O(CH2)4S-CH2-NH-*, -SCH2SCH2- NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, - S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4SCH2- NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, -S(O)2(CH2)3S-CH2-NH-*, - 73 WO 2020/219287 PCT /0S2020/027831 S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, -O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, -S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, - S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, -S(O)2CH2-NH-*, -S(O)2(CH2)2- NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*.
[00241] In some embodiments, -L1-Z'-* is -(C1-C6 alkylene)-X1-L2-Z'-*.
In some H H ~N .... * sS'____,,N~ embodiments, -L 1-Z' -* is or 0 In some .f'~Su I ,,_,,,,,, N,,,* embodiments, -L 1-Z' -* is H In some embodiments, -L 1-Z' -* is
[00242] In the various embodiments disclosing -L 1-Z' -* herein, * is the site covalently 1 o attached to A
[00243] In some embodiments, A is a peptide comprising 2 to 8 amino acids.
In some embodiments, A is a peptide comprising 2 to 4 amino acids.
In some embodiments, at least one amino acid in said peptide is an L amino acid.
In some embodiments, each amino acid in said peptide is an L amino acid.
In some embodiments, at least one amino acid in said 1s peptide is a D amino acid.
[00244] In some embodiments, A is -(AA1)-(AA2)a1-*, where* is the point of attachment to E', AA1 and AA2 are each independently an amino acid residue; and al is an integer from 1- 9.
[00245] In some embodiments, -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val-Ala-*, - 20 Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -Ala-Lys-*, -LysAla-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-*, -Phe-Ala-*,-Ala-Phe-*, - 74 WO 2020/219287 PCT /0S2020/027831 Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-Arg-Phe *, -PhePhe- Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, -Ile-Ala-Leu* -Leu-Ala-Ile-* -Val-Ala-Val-* -Ala-Leu-Ala-Leu-* -Leu-Ala-Leu-Ala-* -~-Ala-Leu- ' ' ' ' ' JJ Ala-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, - s Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -AlaLeu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, - Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -ArgTyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*.
[00246] In some embodiments, -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cit- 10 *, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-D-Lys-*, -L-ValD- Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, -Val-D-Cit-*, -LAla- L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*.
[00247] In some embodiments, -AA1-(AA2)a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-* -GlnLeu-*, -Leu-Gln-*, -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala- 1s Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly- *
[00248] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-AlaL- Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-*, -L-Gln-L-Leu-*, -L-Gln-D-Leu*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala- 20 L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-AlaD- Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly- * ,-Gly-D-Ala-Gly-Gly-*, Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, Gly-Gly-L-Val-Gly*, -Gly-D-Val-Gly-Gly-*, Gly-Gly-D-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or Gly-Gly-L-PheGly-*. 2s
[00249] In some embodiments, -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, - L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*.
[00250] In the various embodiments disclosing -AA1-(AA2)a1-* herein, * is the site covalently attached to E'. 75 WO 2020/219287 PCT /0S2020/027831
[00251] In some embodiments, A is substituted with one or more polyol.
In some embodiments, E' is substituted with one or more polyol.
In some embodiments, polyol is - (C1-C6 alkylene)-X5-Y3; wherein: X5 is -NR12C(=O)- or -C(=O)NR12-; Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, s C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 0 OH OH \~~~OH
[00252] In some embodiments, polyol is R12 OH OH ; wherein R12 is H or methyl. 0 OH OH \~~~OH
[00253] In some embodiments, wherein polyol is R12 OH OH ; wherein R12 is Hor methyl. 10
[00254] In some embodiments, E' is -C(=O)-(C1-C10 alkylene)-X6-*.
In some embodiments, E' is 76 WO 2020/219287 PCT /0S2020/027831 ,.... N, N a-!( * l_;y 0 , -C(=O)CH2CH2-C(=O)-CRbbRcc_*, or -C(=O)CH2CH2-NRee_C(=O)- CRbbRcc_*; where* is the site covalently attached to CBA.
In some embodiments, RYY, Rxx, Raa, Rbb are each independently-Hor C1-C6 alkyl. s
[00255] In some embodiments, E' is -C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X6- Y1 is -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)-; and 11 ~-NRaa_~~* CRbbRcc_*; where* is the site covalently attached to CBA.
[00256] In some embodiments, E' is -C(=O)-Y1-(CH2)2-X4-(CH2)2-X6-*; Y1 is -(CH2O)n-, or -(CH2CH2O)m-; 1s X4 is -NHC(=O)-; 77 WO 2020/219287 PCT /0S2020/027831 n is 2; m is 2 to 6; 11 ~-NRaa_~~* s CRbbRcc_*; where* is the site covalently attached to the CBA.
[00257] In some embodiments, the CBA comprises a -SH group that covalently links with E' /'(ii N, ~N o-fZ O ~MS-CBA o)~YN'( \~o o d CN O S-CBA j-NUS-CBA H \: ' ' S-CBA ' 78 WO 2020/219287 PCT /0S2020/027831 HO S-CBA ~
[00258] In another aspect, the invention provides a compound of Formula IV, or a pharmaceutically acceptable salt thereof: E-A-Z'-L i_D (Formula IV) 5 wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri 10 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-* or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi· is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 25 heteroaryl, or benzyl; 79 WO 2020/219287 PCT /0S2020/027831 L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, s heteroaryl, or benzyl; A is a peptide comprising 2 to IO amino acids; wherein A is optionally substituted with one or more polyol; Eis -C(=O)O-L3-X3; L3 is -(C1-C10 alkylene)-; 10 wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, -OR9 , -SR9 , -N(R9)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R9 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; and X3 is
[00259] In some embodiments, Eis -C(=O)O-L3-X3 and L3 is -(C1alkylene)-.
In some embodiments, L3 is -CH2-.
[00260] In another aspect, the invention provides a compound of Formula V, or a pharmaceutically acceptable salt thereof: 20 A-Z'-L1-D (Formula V) wherein: D is represented by the following structural formula: ,NV\ 0 R1 is -H -F -CH3 or -CF3· ' ' ' ' 80 WO 2020/219287 PCT /0S2020/027831 R2 is -H, -F, -0R3, -SR3, -S(O)R4, -S(O)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-* or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; xi' is -0-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Li and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, Ci-C6 alkyl, Ci-C6 fluoroalkyl, Ci-C6 20 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; each R7 is independently H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; and A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more polyol. 25
[00261] In some embodiments, the compound is a compound of Formula I and is any one of the following compounds from the below table: Table lA. 81 WO 2020/219287 Compound No. a b C 7a 6a d 6c Structure 82 OH OH PCT /0S2020/027831 WO 2020/219287 Compound No. e 8a 7b ...,..s F Structure HO~O NH PCT /0S2020/027831
[00262] In some embodiments, the compound is a compound of Formula I and is a compound of any one of the following from the below table: Table. lB Compound No. f 83 Structure s~s, OH 0 WO 2020/219287 Compound No. g 35a h J 8p Structure F Mes~ NH f s 84 OH PCT /0S2020/027831 WO 2020/219287 Compound No. 7c k m 8e 33a Structure Q s 85 _,- OH PCT /0S2020/027831 WO 2020/219287 Compound No. 8b 8c 34a 34b n PCT /0S2020/027831 Structure .,.,.s F II .,.,.s F
[00263] In some embodiments, the compound is a compound of Formula II and is a compound of any one of the following from the below table: 86 WO 2020/219287 Table. 2 Compound No. p q 25b 25a PCT /0S2020/027831 Structure H = 0 H = 0 N : II N : ~SH ( 'l("'N~ 'l("'N S O H = 0 H OHO O H O ~ H 0 >--N~ NylN~N 0N""s~o \....4 0 = H O = H NH 0 H O I H 0 >--N~N0N"nN0N/'..S~O \....4 0 = H O = H NH 87 WO 2020/219287 Compound No. r s t 22a u PCT /0S2020/027831 Structure H O ~ H 0 \O~O~N0N~N0N/"-...S,,,,--...._S 0 0 = H O = H \_ 0 0 0~o~0~N~N~ H μ rlO O 1 H O 1 H 0 1(N~N,,r(N~N,,r(N'-"OJNH 0 H O = H 0 F 0 H O H O H )lN~N~N~N0N~N...__,,,S...._,,,,,.....S 4 0 H O - H 0 0 ~ ~ ~ V ~ I N 88 OH WO 2020/219287 Compound No.
V w X y z PCT /0S2020/027831 Structure O Ho Ho H 0 )lN~NJN--yN0N--YN-.._,,,S0NH 4 0 H O - H 0 0 ~ ~ ~ V :,... I N 0 O H O H 0 )lN~~JHN~N0N~N...._,,,OJNH 4 0 0 - H 0 0 y ~ ~ :,... I N 89 OHO WO 2020/219287 Compound No. aa 22e 22c ab 22d PCT /0S2020/027831 Structure 0 H O H 8~s""~~NA,,.Nr('N~N~o) II H. I O H O 0 0 ---:::---::: o Ho~ r(N~NH 0 0 ZO NH2 I/ H HO H O ~~N~o~o~N0N N.....,,,.o~NH 0 0 0 "rH 0 I~ ~ 0 H O ~ H 0 J--N~NyAN~NYN"'o---r0 4 0 = H O = H NH 90 OH OH WO 2020/219287 Compound No. ac 22b ad 32a ae PCT /0S2020/027831 Structure I Hol Hol H ~-l&N~r~,,)"N!'~")"N-S~S 0 \__ I 9H 9H OH 7' 7' --rr-N~ F~ O HO HO I QH QH ZO N~OH OH OH 5lNJN ~1~~~'0y'--:: ¼ HO - 0 .o 0 NH 91 WO 2020/219287 Compound No. 32b 28a 28c af PCT /0S2020/027831 Structure 0 H O I H 0 )-..N~N0N_,r(N0N-O~O ~ 0 = H O = H NH ,.....s F 92 WO 2020/219287 Compound No. 28b ag ah PCT /0S2020/027831 Structure rlO O y H 0 l(N~~~Ny.llN-..0 0 H O = H 93 WO 2020/219287 Compound No. ak al PCT /0S2020/027831 Structure I QH QH ZO N~OH 0 OH OH 'f O H 0 yf~N NJN""O 0 H O H 0 H O f H 0 ~t--l~N~N'J(N_)lN"'O 4 o=Ho H
[00264] In some embodiments, where the compound comprises a sulfoxide and the sulfoxide is either the R or S configuration.
In some embodiments, the compound is any one of the following: 94 WO 2020/219287 PCT /0S2020/027831 II ,s F II ,, .. s F
[00265] In some embodiments, the compound is any one of the following: S~SH O~ ,,,..,. \:'' l "'-/ 'SSH NH HS~O NH OH 0 95 WO 2020/219287 PCT /0S2020/027831 5 OH 'or Synthesis of Compounds 96 WO 2020/219287 PCT /0S2020/027831
[00266] The compounds described herein are prepared by the general synthetic routes described in the following schemes.
[00267] In some embodiments, the compounds described herein are prepared as outlined in Scheme 1.
Scheme 1.
General Synthetic Scheme for Preparing RNH2 Compounds (A-6) ~-IS::: BCl3/AICl3 -~ NCB.X F NH2 n CH2Cl2 A-1a -DMSO n = 1 to 7 X = Cl, Br or I A-2 P(OEth Benzene then HCI/MeOH
[00268] In some embodiments, the compounds described herein are prepared as outlined in Scheme 2.
Scheme 2.
General Synthetic Scheme for Preparing ROH Compounds (B-2) n = 1 to 7 X = Cl, Br or I 8-1 HMPA/H2O (5:1) O 100 °c OH
[00269] In some embodiments, the compounds described herein are prepared as outlined in Scheme 3.
Scheme 3.
General Synthetic Scheme for Preparing RNHRc1 Compounds (C-4) 97 WO 2020/219287 n = 1 to 7 X = Cl, Br or I Rc1 = alkyl, benzene C-1 C-2 PPTS!Toluene reflux PCT /0S2020/027831
[00270] In some embodiments, the compounds described herein are prepared as outlined in Scheme 4.
Scheme 4.
General Synthetic Scheme for Preparing RS(CH2)nOH Compounds (D-2) n = 1 to 7 x = Br, I, Cl m = 1 to 7 D-1 Hs-f-COH m DIPEA
[00271] In some embodiments, the compounds described herein are prepared as outlined in Scheme 5.
Scheme 5.
General Method for Preparing Thiol-Bearing Camptothecin Derivative (E-4) DMTMM NMM DTT .• 0 ,· 0 E-3 _, OH E-4 _, OH 10
[00272] In some embodiments, vis I to 4.
In some embodiments, R is alkyl, aryl, or heteroaryl.
In some embodiments, R is methyl, ethyl, phenyl, or pyridyl.
[00273] In some embodiments, the compounds described herein are prepared as outlined in Scheme 6. 98 WO 2020/219287 PCT /0S2020/027831 Scheme 6.
General Method for Preparing Thioaminal-Peptide Linkages That Can Be Further Derivatized to Incorporate Thiols or Maleimides 0 H j__ H 0 Fmoc-NH-Peptide-NH___}l._OH _P_b(_OA_c_)4 _ Fmoc-N-Peptide N/"-O...,_,.....- ~F~ Fmoc-N-Peptide___jj__ /'-SH F-2 H II --- F-3 NH F-1 0 Seal vial 1) H 0 Fmoc-N-Peptide___jj__N/"-O')( 0 TFA F-6 H o O 2) Morpholine - H F H s-Yi:S-.,,N'](Peptide-NH2 Vo 0 ( _\ ~ Peptide-N-1lt hs,S-R s .....Yr.S--' ']( H \) ; Vo O V 2 OTT s ( As-.,,~ '](Peptide-~-\f: 2 sH -.Y (tO O V o F-10 0 0 s,,----~_Jj__Peptide-N~SH O H v2 DMTMM _. 0 NMM F F-12 ..___, OH then OTT \HoJRM \ HO 1 ,,----N_Jj__Peptide-N RM S O H 0 RM = -Alkyl-Mal , -PEG-Mal F-15
[00274] In some embodiments, vis I to 4.
In some embodiments, v2 is I to 4.
In some s embodiments, R is alkyl, aryl, or heteroaryl.
In some embodiments, R is methyl, ethyl, phenyl, or pyridyl.
[00275] In some embodiments, the compounds described herein are prepared as outlined in Scheme 7. 99 WO 2020/219287 G-1 F-7 8 ~S........,NJlPeptide-NH2 V H PCT /0S2020/027831 Scheme 7. o ~ 0 H S ........,)l N NI ~s N Peptide-NI ~ V H H O ~ 0 0 N 00 00 ~~ 0 N~OH I OH OH G-3
[00276] In some embodiments, n is 1 to 10.
In some embodiments, n is 1 to 5.
In some embodiments, vis 1 to 10.
In some embodiments, vis 1 to 5. s
[00277] In some embodiments, the compounds described here are prepared as outlined in Scheme 8.
Scheme 8.
ICH3, NaH
[00278] In some embodiments, vis 1 to 10.
In some embodiments, vis 1 to 5. 10 Cell-Binding Agents
[00279] Cell-binding agents in the immunoconjugates of the present invention can be of any kind presently known, or that become known, including peptides and non-peptides that binds to a cell or cell component (e.g., receptor, protein, DNA, RNA, etc.).
Generally, these can be antibodies (such as polyclonal antibodies and monoclonal antibodies, especially monoclonal 1s antibodies) or fragments thereof, lymphokines, hormones, growth factors, vitamins (such as 100 WO 2020/219287 PCT /0S2020/027831 folate etc., which can bind to a cell surface receptor thereof, e.g., a folate receptor), nutrienttransport molecules (such as transferrin), probodies, nanobodies, or any other cell-binding molecule or substance.
[00280] In certain embodiments, the cell-binding agent is an antibody, a single chain 5 antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, a monoclonal antibody fragment ( or "antigenbinding portion" or "antigen-binding fragment") that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment ( or "antigen-binding portion" or "antigenbinding fragment") that specifically binds to the target cell, a domain antibody (e.g., sdAb ), 10 or a domain antibody fragment that specifically binds to the target cell.
[00281] In certain embodiments, the cell-binding agent is a humanized antibody, a humanized single chain antibody, or a humanized antibody fragment (or "antigen-binding portion" or "antigen-binding fragment").
[00282] In certain embodiments, the cell-binding agent is a resurfaced antibody, a resurfaced 15 single chain antibody, or a resurfaced antibody fragment ( or "antigen-binding portion" or "antigen-binding fragment").
[00283] In certain embodiments, the cell-binding agent is an antibody or an antigen-binding portion thereof (including antibody derivatives), the CBA may bind to a ligand on the target cell, such as a cell-surface ligand, including cell-surface receptors. 20
[00284] In certain embodiments, the cell-binding agent (CBA) binds to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes.
In some embodiments, the CBA binds to cells expressing any one or more of 5T4, ADAM-9, ALK, AMHRII, ASCT2, Axl, B7-H3, BCMA, C4.4a, CA6, CA9, CanAg, CD123, CD138, 25 CD142, CD166, CD184, CD19, CD20, CD205, CD22, CD248, CD25, CD3, CD30, CD33, CD352, CD37, CD38, CD40L, CD44v6, CD45, CD46, CD48, CD51, CD56, CD7, CD70, CD71, CD74, CD79b, CDH6, CEACAM5, CEACAM6, cKIT, CLDN18.2, CLDN6, CLL-1, c-MET, Cripto, CSP-I, CXCR5, DLK-1, DLL3, DPEP3, Dysadherin, EFNA4, EGFR, 101 WO 2020/219287 PCT /0S2020/027831 EGFRviii, ENPP3, EpCAM, EphA2, EphA3, ETBR, FGFR2, FGFR3, FLT3, FOLR-alpha, FSH, GCC, GD2, GD3, Globo H, GPC-1, GPC3, gpNMB, HER-2, HER-3, HLA-DR, HSP90, IGF-IR, IL-13R, ILIRAP, IL7R, Interleukin-4 Receptor (IL4R), KAAG-1, LAMP-I, Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, LIV-I, LRP-1, LRRC15, Ly6E, 5 MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MTI-MMP, MTX3, MTX5, MUCI, MUC16, NaPi2b, Nectin-4, NOTCH3, OAcGD2, OX00IL, p-Cadherin, PD-LI, Phosphatidylserine (PS), Polymorphic epithelial mucin (PEM), Prolactin Receptor (PRLR), PSMA, PTK7, RNF43, RORI, ROR2, SAIL, SLAMF7, SLC44A4, SLITRK6, SSTR2, STEAP-1, STING, STn, TIM-I, TM4SF1, TNF- 10 alpha, TRA, TROP-2, Tumor-associated glycoprotein 72 (TAG-72), tumor-specific epitope of mucin-1 (TA-MUCI), CDS, TIM-3, UPK2, or UPKlb antigen.
[00285] In certain embodiments, the cell-binding agent is a cysteine-engineered antibody or antigen-binding fragment thereof that specifically binds to cells expressing any one or more of the 5T4, ADAM-9, ALK, AMHRII, ASCT2, Axl, B7-H3, BCMA, C4.4a, CA6, CA9, 15 CanAg, CD123, CD138, CD142, CD166, CD184, CD19, CD20, CD205, CD22, CD248, CD25, CD3, CD30, CD33, CD352, CD37, CD38, CD40L, CD44v6, CD45, CD46, CD48, CD51, CD56, CD7, CD70, CD71, CD74, CD79b, CDH6, CEACAM5, CEACAM6, cKIT, CLDN18.2, CLDN6, CLL-1, c-MET, Cripto, CSP-I, CXCR5, DLK-1, DLL3, DPEP3, Dysadherin, EFNA4 , EGFR, EGFRviii, ENPP3, EpCAM, EphA2, EphA3, ETBR, FGFR2, 20 FGFR3, FLT3, FOLR-alpha, FSH, GCC, GD2, GD3, Globo H, GPC-1, GPC3, gpNMB, HER-2, HER-3, HLA-DR, HSP90, IGF-IR, IL-13R, ILIRAP, IL7R, Interleukin-4 Receptor (IL4R), KAAG-1, LAMP-I, Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, LIV-I, LRP-1, LRRC15, Ly6E, MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MTI-MMP, MTX3, MTX5, MUCI, MUC16, NaPi2b, 25 Nectin-4, NOTCH3, OAcGD2, OX00IL, p-Cadherin, PD-LI, Phosphatidylserine (PS), Polymorphic epithelial mucin (PEM), Prolactin Receptor (PRLR), PSMA, PTK7, RNF43, RORI, ROR2, SAIL, SLAMF7, SLC44A4, SLITRK6, SSTR2, STEAP-1, STING, STn, TIM-I, TM4SF1, TNF- alpha, TRA, TROP-2, Tumor-associated glycoprotein 72 (TAG-72), tumor-specific epitope ofmucin-1 (TA-MUCI), CDS, TIM-3, UPK2, orUPKlb antigen. 102 ), .
[00286] In certain embodiments, the CBA is an antibody selected from the group consisting of an anti-CD37 antibody (e.g., as disclosed in USPN 8,765,917 an anti-CD19 antibody (e.g., the huB4 antibody as disclosed in USPN 9,555,126, 5 and an anti-EGFR antibody (e.g., the huML66 antibody as disclosed in USPNs 9,238,690 8,790,649, and 9,125,896
[00287] In certain embodiments, the CBA is an anti-CD 123 antibody or antigen-binding fragment thereof may comprise: a) at least one light chain variable region or fragment thereof 10 comprising three sequential complementarity-determining regions (CDR) CORL I, CDRL2, and CDRL3, respectively, wherein CORL! has the amino acid sequence of RASQDINSYLS (SEQ ID NO: 1), CDRL2 has the amino acid sequence ofRVNRL VD (SEQ ID NO:2), and, CDRL3 has the amino acid sequence ofLQYDAFPYT (SEQ ID NO:3); and b) at least one heavy chain variable region or fragment thereof comprising three sequential 15 complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, wherein, CDRHl has the amino acid sequence of SSIMH (SEQ ID NO:4), CDRH2 has the amino acid sequence ofYIKPYNDGTKYNEKFKG (SEQ ID NO:5), and, CDRH3 has the amino acid sequence ofEGGNDYYDTMDY (SEQ ID NO:6).
[00288] In certain embodiments, the anti-CD123 antibody or antigen-binding fragment 20 thereof comprises a heavy chain variable region (VH) having the amino acid sequence of QVQLVQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYND GTKYNEKFKGRATLTSDRSTSTA YMELSSLRSEDTA VYYCAREGGNDYYDTMDY WGQGTLVTVSS (SEQ ID NO:7), wherein CDRH I, CDRH2, and CDRH3 are doubleunderlined; 25 and a light chain variable region (VL) having the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASODINSYLSWFQQKPGKAPKTLIYRVNRLVDG VPSRFSGSGSGNDYTL TISSLQPEDF ATYYCLOYDAFPYTFGQGTKVEIKR (SEQ ID NO:9), wherein CDRd, CDRL2, and CDRL3 are double underlined. 103 .
[00289] In certain embodiments, the anti-CD123 antibody has a heavy chain full length sequence of QVQL VQSGAEVKKPGASVKVSCKASGYIFTSSIMHWVRQAPGQGLEWIGYIKPYND GTKYNEKFKGRATLTSDRSTSTA YMELSSLRSEDTAVYYCAREGGNDYYDTMDY 5 WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGT AALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSRDEL TKNQVSL TCLVKGFYPSDIA VEWESNGQPENNY 10 KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLCLSPG (SEQ ID NO:8), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain full length sequence of DIQMTQSPSSLSASVGDRVTITCRASODINSYLSWFQQKPGKAPKTLIYRVNRL VDG VPSRFSGSGSGNDYTL TISSLQPEDF ATYYCLOYDAFPYTFGQGTKVEIKRTV AAPSV 15 FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 10), wherein CDRd, CDRL2, and CDRL3 are underlined.
[00290] In certain embodiments, an anti-CD123 antibody or antigen-binding fragment thereof is provided as an activatable antibody or activatable antibody-binding antibody 20 fragment as further described below.
In certain other embodiments, the anti-CD 123 activatable antibody or activatable CD 123 antibody-binding antibody fragment can be conjugated to a compound of Formula I.
[00291] In certain embodiments, the CBA is an anti-CD33 antibody or an antigen-binding fragment thereof as described in U.S.
Pat.
Nos. 7,342,110 and 7,557,189 •
[00292] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof may comprise: a) at least one light chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRd, CDRL2, and CDRL3, 104 WO 2020/219287 PCT /0S2020/027831 respectively, wherein CDRd has the amino acid sequence ofKSSQSVFFSSSQKNYLA (SEQ ID NO: 11), CDRL2 has the amino acid sequence ofWASTRES (SEQ ID NO: 12), and, CDRL3 has the amino acid sequence of HQYLSSRT (SEQ ID NO: 13); and b) at least one heavy chain variable region or fragment thereof comprising three sequential 5 complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, wherein, CDRHl has the amino acid sequence of SYYIH (SEQ ID NO: 14), CDRH2 has the amino acid sequence ofVIYPGNDDISYNQKFQG (SEQ ID NO:15), and, CDRH3 has the amino acid sequence ofEVRLRYFDV (SEQ ID NO:16).
[00293] In certain embodiments, the anti-CD33 antibody or antigen-binding fragment thereof 10 comprises a heavy chain variable region (VH) having the amino sequence of QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGN DDISYNOKFOGKATLTADKSSTTAYMQLSSLTSEDSAVYYCAREVRLRYFDVWGQ GTTVTVSS (SEQ ID NO: 17), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain variable region (VL) having the amino acid sequence of 15 EIVL TQSPGSLA VSPGERVTMSCKSSOSVFFSSSOKNYLA WYQQIPGQSPRLLIYWA STRESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHOYLSSRTFGQGTKLEIKR (SEQ ID NO: 19), wherein CDRd, CDRL2, and CDRL3 are double-underlined.
[00294] In certain embodiments, the anti-CD33 antibody has a heavy chain full length sequence of 20 QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGN DDISYNOKFOGKATLTADKSSTTAYMQLSSLTSEDSAVYYCAREVRLRYFDVWGQ GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD 25 GVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALP APIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLTCL VKGFYPSDIA VEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 18), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; 105 . and a light chain full length sequence of EIVL TQSPGSLA VSPGERVTMSCKSSOSVFFSSSOKNYLA WYQQIPGQSPRLLNW A STRESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHOYLSSRTFGQGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD 5 SKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:20), wherein CORL I, CDRL2, and CD Rd are double-underlined.
[00295] In certain embodiments, the anti-CD33 antibody is huMy9-6 antibody.
[00296] In certain embodiments, an anti-CD33 antibody or antigen-binding fragment thereof is provided as an activatable antibody or activatable antibody-binding antibody 10 fragment as further described below.
In certain other embodiments, the anti-CD33 activatable antibody or activatable CD33 antibody-binding antibody fragment can be conjugated to a compound of Formula I.
[00297] In certain embodiment, the CBA is an anti-ADAM9 antibody or an antigen-binding fragment thereof as described in WO2018/l 19196 and U.S.
Provisional Application Nos 15 62/690052 and 62/691342.
[00298] In certain embodiments, the anti-ADAM9 antibody or antigen-binding fragment thereof is a humanized anti-ADAM9 antibody or antigen-binding fragment thereof that specifically binds to human ADAM9 and cyno ADAM9.
[00299] In certain embodiments, the humanized anti-ADAM9 antibody or ADAM9-binding 20 fragment thereof is optimized to have at least a 100-fold enhancement in binding affinity to cyno ADAM9 and retains high affinity binding to human ADAM9 as compared to the chimeric or murine parental antibody.
[00300] In certain embodiments, the anti-ADAM9 antibody or antigen-binding fragment thereof (e.g., the humanized anti-ADAM9 antibody or antigen-binding fragment thereof) 25 comprises: a) at least one light chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRd, CDRL2, and CDRL3, respectively, wherein CDRd has the amino acid sequence ofKASQSVDYSGDSYMN (SEQ 106 WO 2020/219287 PCT /0S2020/027831 ID NO:21), CDRL2 has the amino acid sequence of AASDLES (SEQ ID NO:22), and, CDRL3 has the amino acid sequence of QQSHEDPFT (SEQ ID NO:23); and b) at least one heavy chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, 5 wherein, CDRHl has the amino acid sequence of SYWMH (SEQ ID NO:24), CDRH2 has the amino acid sequence ofEIIPIFGHTNYNEKFKS (SEQ ID NO:25), and, CDRH3 has the amino acid sequence of GGYYYYPRQGFLDY (SEQ ID NO:26).
[00301] In certain embodiments, the anti-ADAM9 antibody or antigen-binding fragment thereof (e.g., the humanized anti-ADAM9 antibody or antigen-binding fragment thereof) 10 comprises a heavy chain variable region (VH) having the amino sequence of EVQL VESGGG L VKPGGSLRLSCAASGFTFS SYWMHWVRQA PGKGLEWVGE IIPIFGHTNY NEKFKSRFTI SLDNSKNTL Y LQMGSLRAED TA VYYCARGG YYYYPRQGFL DYWGQGTTVT VSS (SEQ ID NO:27), wherein CDRHl, CDRH2, and CDRH;3 are double-underlined; 15 and a light chain variable region (VL) having the amino acid sequence of DIVMTQSPDSLA VSLGERATISCKASOSVDYSGDSYMNWYQQKPGQPPKLLIYAAS DLES GIPARFSGSG SGTDFTLTIS SLEPEDFATYYCOOSHEDPFTFGQGTKLEI K (SEQ ID NO:28), wherein CDRd, CDRL2, and CDRL3 are double-underlined.
[00302] In certain embodiments, the anti-ADAM9 antibody has a heavy chain full length 20 sequence of EVQL VESGGG L VKPGGSLRL SCAASGFTFS SYWMHWVRQA PGKGLEWVGE IIPIFGHTNY NEKFKSRFTI SLDNSKNTL Y LQMGSLRAED TA VYYCARGG YYYYPROGFL DYWGQGTTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC L VKDYFPEPV TVSWNSGAL T SGVHTFPA VL QSSGL YSLSS VVTVPSSSLG 25 TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCP APEL LGGPSVFLFP PKPKDTLY,IJ. ~PEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCL VKGFYP SDIA VEWESN GQPENNYKTT 107 ).
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLCLS PG (SEQ ID NO:29), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain full length sequence of DIVMTQSPDSLA VSLGERA TISCKASOSYDYSGDSYMNWYQQKPGQPPKLLIY AAS 5 DLESGIPARFSGSGSGTDFTL TISSLEPEDF A TYYCOOSH EDPFTFGQGTKLEIKRTV A APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTL TLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:30); wherein CORL I, CDRL2, and CDRd are double-underlined.
[00303] In certain embodiments, an anti- ADAM9 antibody or antigen-binding fragment 10 thereof is provided as an activatable antibody or activatable antibody-binding antibody fragment as further described below.
In certain other embodiments, the anti- ADAM9 activatable antibody or activatable ADAM9 antibody-binding antibody fragment can be conjugated to a compound of Formula I.
[00304] In certain embodiments, the CBA is an anti-folate receptor antibody (i.e., FOLRI or 15 FRa) (e.g., as described in U.S.
Patent 8,709,432, U.S.
Patent No. 8,557,966, and WO201 l 106528
[00305] In certain embodiments, the anti-FRa antibody or antigen-binding fragment thereof may comprise: a) at least one light chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRLl, CDRL2, and CD Rd, 20 respectively, wherein CORL I has the amino acid sequence of KASQSVSFAGTSLMH (SEQ ID NO:31 ), CDRL2 has the amino acid sequence of RASNLEA (SEQ ID NO:32), and, CDRd has the amino acid sequence ofQQSREYPYT (SEQ ID NO:33); and b) at least one heavy chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, 25 wherein, CDRHl has the amino acid sequence of GYFMN (SEQ ID NO:34) or GYTFTGYFMN (SEQ ID NO:37), CDRH2 has the amino acid sequence of RIHPYDGDTFYNQKFQG (SEQ ID NO:35) or RIHPYDGDTF (SEQ ID NO:38), and, CDRH3 has the amino acid sequence ofYDGSRAMDY (SEQ ID NO:36).
In certain 108 WO 2020/219287 PCT /0S2020/027831 embodiments, the anti-FRa antibody or antigen-binding fragment thereof comprises a) a light chain variable region comprising a CDRd having an amino sequence set forth in SEQ ID NO:31, a CDRL2 having an amino sequence set forth in SEQ ID NO:32, and a CDRL3 having an amino sequence set forth in SEQ ID NO:33; and b) a heavy chain variable region 5 comprising a CDRHl having an amino sequence set forth in SEQ ID NO:34, a CDRH2 having an amino sequence set forth in SEQ ID NO:35, and a CDRH3 having an amino sequence set forth in SEQ ID NO:36.
In certain embodiments, the anti-FRa antibody or antigen-binding fragment thereof comprises a) a light chain variable region comprising a CDRd having an amino sequence set forth in SEQ ID NO:31, a CDRL2 having an amino sequence set forth in 10 SEQ ID NO:32, and a CDRL3 having an amino sequence set forth in SEQ ID NO:33; and b) a heavy chain variable region comprising a CDRHl having an amino sequence set forth in SEQ ID NO:37, a CDRH2 having an amino sequence set forth in SEQ ID NO:38, and a CDRH3 having an amino sequence set forth in SEQ ID NO:36.
[00306] In certain embodiments, the anti- FRa antibody or antigen-binding fragment thereof 15 comprises a heavy chain variable region (VH) having the amino sequence of QVQL VQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYD GDTFYNOKFOGKATLTVDKSSNTAHMELLSLTSEDF A VYYCTRYDGSRAMDYWG QGTTVTVSS (SEQ ID NO:39), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain variable region (VL) having the amino acid sequence of 20 DIVL TQSPLSLA VSLGQP AIISCKASOSVSFAGTSLMHWYHQKPGQQPRLLIYRASN LEAGVPDRFSGSGSKTDFTLNISPVEAEDAATYYCOOSREYPYTFGGGTKLEIKR (SEQ ID NO:40), or DIVL TQSPLSLA VSLGQP AIISCKASOSVSFAGTSLMHWYHQKPGQQPRLLIYRASN LEAGVPDRFSGSGSKTDFTL TISPVEAEDAATYYCOOSREYPYTFGGGTKLEIKR 25 (SEQ ID NO:41), wherein CDRd, CDRL2, and CDRL3 are double-underlined.
[00307] In certain embodiments, the anti-FRa antibody has a heavy chain full length sequence of 109 WO 2020/219287 PCT /0S2020/027831 QVQL VQSGAEVVKPGASVKISCKASGYTFTGYFMNWVKQSPGQSLEWIGRIHPYD GDTFYNOKFOGKATLTVDKSSNTAHMELLSLTSEDF A VYYCTRYDGSRAMDYWG QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTS GVHTFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK 5 THTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALP APIEKTI SKAKGQPREPQVYTLPPSRDELTKNQVSLTCL VKGFYPSDIA VEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:42), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; 10 and a light chain full length sequence of DIVL TQSPLSLA VSLGQP AIISCKASOSVSFAGTSLMHWYHQKPGQQPRLLIYRASN LEAGVPDRFSGSGSKTDFTLNISPVEAEDAATYYCOOSREYPYTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID 15 NO:43), or DIVL TQSPLSLA VSLGQP AIISCKASOSVSFAGTSLMHWYHQKPGQQPRLLIYRASN LEAGVPDRFSGSGSKTDFTL TISPVEAEDAATYYCOOSREYPYTFGGGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID 20 NO:44); wherein CDRd, CDRL2, and CDRL3 are double-underlined.
[00308] In certain embodiments, the anti-FRa antibody is huMovl9 or M9346A antibody.
[00309] In certain embodiments, an anti-FRa antibody or antigen-binding fragment thereof is provided as an activatable antibody or activatable antibody-binding antibody fragment as further described below.
In certain other embodiments, the anti-FRa activatable 25 antibody or activatable FRa antibody-binding antibody fragment can be conjugated to a compound of Formula I.
[00310] In certain embodiments, the CBA is an anti-EpCAM antibody or antigen-binding fragment thereof.
In certain embodiments, the anti-EpCAM antibody or antigen-binding 110 WO 2020/219287 PCT /0S2020/027831 fragment thereof may comprise: a) at least one light chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRd, CDRL2, and CDRL3, respectively, wherein CDRd has the amino acid sequence of RSSRSLLHSDGFTYL Y (SEQ ID NO:45), CDRL2 has the amino acid sequence of 5 QTSNLAS (SEQ ID NO:46), and, CDRL3 has the amino acid sequence of AQNLELPNT (SEQ ID NO:47); and b) at least one heavy chain variable region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, wherein, CDRHl has the amino acid sequence ofNYYIH (SEQ ID NO:48), CDRH2 has the amino acid sequence ofWIYPGNVYIQYNEKFKG (SEQ ID 10 NO:49), and, CDRH3 has the amino acid sequence ofDGPWFAY (SEQ ID NO:50).
[00311] In certain embodiments, the anti-EpCAM antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) having the amino acid sequence of QVQL VQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQRLEYIGWIYPGN VYIOYNEKFKGRATLTADKSASTA YMELSSLRSEDTA VYYCARDGPWFAYWGQG 15 TLVTVSS (SEQ ID N0:52), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain variable region (VL) having the amino acid sequence of DIVL TQTPLSLSVTPGQP ASISCRSSRSLLHSDGFTYL YWFLQKPGQSPQLLIYOTSN LASGVPDRFSSSGSGTDFTLKISRVEAEDVGVYYCAONLELPNTFGQGTKLEIK (SEQ ID N0:51), wherein CDRd, CDRL2, and CDRL3 are double-underlined. 20
[00312] In certain embodiments, the anti-EpCAM antibody has a heavy chain full length sequence of QVQL VQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAPGQRLEYIGWIYPGN VYIOYNEKFKGRATLTADKSASTA YMELSSLRSEDTA VYYCARDGPWFAYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV 25 HTFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT CPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAKTKPREEQYNSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALP APIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCL VKGFYPSDIA VEWESNGQPENNYKTTP 111 WO 2020/219287 PCT /0S2020/027831 PVLDSDGSFFL YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLCLSPG (SEQ ID N0:54), wherein CDRHl, CDRH2, and CDRH3 are double-underlined; and a light chain full length sequence of DIVL TQTPLSLSVTPGQP ASISCRSSRSLLHSDGFTYL YWFLQKPGQSPQLLIYOTSN 5 LASGVPDRFSSSGSGTDFTLKISRVEAEDVGVYYCAONLELPNTFGQGTKLEIKRTV AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFNRGEC (SEQ ID N0:53), wherein CDRd, CDRL2, and CDRL3 are double-underlined.
[00313] In certain embodiments, the CBA is an anti-EpCAM antibody or antigen- 10 binding fragment thereof may comprise: a) at least one light chain variable (VL) region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRd, CDRL2, and CDRL3, respectively, wherein CDRd has an amino acid sequence selected from SEQ ID NOs:78, 45, 79, 80 and 82; CDRL2 has the amino acid sequence of SEQ ID NO:46; and a CDRL3 has amino an acid sequence selected from SEQ ID NOs:47, 15 81, 83, 84, 85, 86, and 87, and b) at least one heavy chain variable (VH) region or fragment thereof comprising three sequential complementarity-determining regions (CDR) CDRHl, CDRH2, and CDRH3, respectively, wherein, wherein CDRHl has an amino acid sequence selected from SEQ ID NOs: 48, 57, 58, 60, 61, 62, 68, 69, 70, 77 and 88; CDRH2 has an amino acid sequence selected from SEQ ID NOs:49, 56, 59, 63, and 64; and a CDRH3 has an 20 amino acid sequence selected from SEQ ID NOs:55, 65, 66, 67, 71, 72, 73, 74, 75 and 76.
[00314] In certain embodiments, an anti-EpCAM antibody or antigen-binding fragment thereof is provided as an activatable antibody or activatable antibody-binding antibody fragment as further described below.
In certain other embodiments, the anti-EpCAM activatable antibody or activatable EpCAM antibody-binding antibody fragment can be 25 conjugated to a compound of Formula I.
[00315] Variants in the CD Rs of the anti-EpCAM antibody or antigen-binding fragment are summarized in the Tables 3-6 below. 112 WO 2020/219287 PCT /0S2020/027831
[00316] Table 3. huEpCAM-23 4.2 (CDRs and variable domains) huEpCAM23_ RSSRSLLHSDGFTYL QTSNLAS (SEQ AQNLELPNT VLGv4 Y (SEQ ID NO:45) ID NO:46) (SEQ ID NO:47) huEpCAM23_ NYYIH WIYPGNVYIQYNEKF DGPWFAY VHGv2 (SEQ ID NO:48) KG (SEQ ID NO:49) (SEQ ID NO:50) VL DIVL TQTPLSLSVTPGQPASISCRSSRSLLHSDGFTYL YWFLQK huEpCAM23_ PGQSPQLLIYOTSNLASGVPDRFSSSGSGTDFTLKISRVEAEDV VLGv4 GVYYCAQNLELPNTFGQGTKLEIK (SEQ ID NO:51) VH QVQL VQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAP huEpCAM23_ GQRLEYIGWIYPGNVYIOYNEKFKGRATLTADKSASTAYMEL VHGv2 SSLRSEDTA VYYCARDGPWFA YWGQGTL VTVSS (SEQ ID NO:52) s
[00317] Table 4.
Humanized variants of huEpCAM-23 (full length sequence) huEpCAM23 DIVL TQTPLSLSVTPGQPASISCRSSRSLLHSDGFTYL YWFLQK - VLGv4 PGQSPQLLIYOTSNLASGVPDRFSSSGSGTDFTLKISRVEAEDV GVYYCAQNLELPNTFGQGTKLEIKRTV AAPSVFIFPPSDEQLK SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVY ACEVTHQGLSSPVTKSFN RGEC (SEQ ID NO:53) huEpCAM23 QVQL VQSGAEVKKPGASVKVSCKASGYTFTNYYIHWVRQAP - VHGv2-C442 GQRLEYIGWIYPGNVYIOYNEKFKGRATLTADKSASTAYMEL SSLRSEDTA VYYCARDGPWFA YWGQGTL VTVSSASTKGPSVF PLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH TFPA VLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV DKKVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISR TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVL TVLHQDWLNGKEYKCKVSNKALP APIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFL YSKLTVDKSRWQQGN VFSCSVMHEALHNHYTQKSLCLSPG (SEQ ID NO:54)
[00318] Table 5.
EpCAM23 variant heavy chain CDR sequences VH-CDRl VH-CDR2 VH-CDR3 Murine and Chimeric muEpcam23 NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID N0:48) (SEQ ID N0:49) (SEQ ID N0:55) chEpcam23 NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID N0:48) (SEQ ID N0:49) (SEQ ID N0:55) Humanized Variants 113 WO 2020/219287 PCT /0S2020/027831 VH-CDRl VH-CDR2 VH-CDR3 huEpCAM23 VHGvl NYYIH WIYPGNVYIQYSQKFQG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:56) (SEQ ID NO:55) huEpCAM23 VHGv2 NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23 VHGv3 NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23 VHGv4 NYYIH WIYPGNVYIQYSQKFQG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:56) (SEQ ID NO:55) Affinity Variants huEpCAM23HCGv2a NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2b SYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:57) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2c NYNIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:58) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2d NYYIH WIYPGDVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:59) (SEQ ID NO:55) huEpCAM23HCGv2e NYFIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:60) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2f NYSIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:61) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2g NYWIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:62) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2h NYYIH WFYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:63) (SEQ ID NO:55) huEpCAM23HCGv2i/2o NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2j NYYIH WINPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:64) (SEQ ID NO:55) huEpCAM23HCGv2k NYYIH WIYPGNVYIQYNEKFKG EGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:65) huEpCAM23HCGv21 NYYIH WIYPGNVYIQYNEKFKG DGPYFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:66) huEpCAM23HCGv2m/ NYYIH WIYPGNVYIQYNEKFKG DGAWFAY huEpCam23 HG2-1565-A (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:67) Heavy Chain huEpCAM23HCGv2n NYYMH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:68) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2p NYYIH WIYPGNVYIQYNEKFKG DGPWFAY 114 WO 2020/219287 PCT /0S2020/027831 VH-CDRl VH-CDR2 VH-CDR3 (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2q NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2r NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCAM23HCGv2s NYYIH WIYPGNVYIQYNEKFKG DGPWFAY (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:55) huEpCam23HG2-1361-H NYHIH WIYPGNVYIQYNEKFKG DGPWFAY Heavy Chain (SEQ ID NO:69 (SEQ ID NO:49) (SEQ ID NO:55) huEpCam23HG2-1361-D NYDIH WIYPGNVYIQYNEKFKG DGPWFAY Heavy Chain (SEQ ID NO:70) (SEQ ID NO:49) (SEQ ID NO:55) huEpCam23HG2-1565-Y NYYIH WIYPGNVYIQYNEKFKG DGYWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:71) huEpCam23HG2-1565-S NYYIH WIYPGNVYIQYNEKFKG DGSWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:72) huEpCam23HG2-1565-F NYYIH WIYPGNVYIQYNEKFKG DGFWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:73) huEpCam23HG2-1565-G NYYIH WIYPGNVYIQYNEKFKG DGGWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:74) huEpCam23HG2-1565-T NYYIH WIYPGNVYIQYNEKFKG DGTWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:75) huEpCam23HG2-1565-V NYYIH WIYPGNVYIQYNEKFKG DGVWFAY Heavy Chain (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID NO:76) huEpCam23HG2-1361-I NYIIH WIYPGNVYIQYNEKFKG DGPWFAY Heavy Chain (SEQ ID NO:77) (SEQ ID NO:49) (SEQ ID NO:55) huEpCam23HG2-1361-L NYLIH WIYPGNVYIQYNEKFKG DGPWFAY Heavy Chain (SEQ ID NO:88) (SEQ ID NO:49) (SEQ ID NO:55)
[00319] Table 6.
EpCAM23 variant light chain CDR sequences Antibody VL-CDRl VL-CDR2 VL-CDR3 Murine and Chimeric muEpcam23 RSSKSLLHSDGFTYL Y QTSNLAS AQNLELPNT (SEQ ID NO:78) (SEQ ID NO:46) (SEQ ID NO:47) chEpcam23 RSSKSLLHSDGFTYL Y QTSNLAS AQNLELPNT (SEQ ID NO:78) (SEQ ID NO:46) (SEQ ID NO:47) Humanized Variants huEpCAM23 VLG RSSRSLLHSDGFTYL Y QTSNLAS AQNLELPNT vl (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:47) 115 WO 2020/219287 PCT /0S2020/027831 AntibodI VL-CDRl VL-CDR2 VL-CDR3 huEpCAM23 VLG RSSKSLLHSDGFTYL Y QTSNLAS AQNLELPNT v2 (SEQ ID NO:78) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23 VLG RSSKSLLHSDGFTYL Y QTSNLAS AQNLELPNT v3 (SEQ ID NO:78) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23 VLG RSSRSLLHSDGFTYL Y QTSNLAS AQNLELPNT v4 (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:47) Affinity Variants huEpCAM23LCGv4 RSSRSLLHSNGFTYL Y QTSNLAS AQNLELPNT a (SEQ ID NO:79) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23LCGv4 RSSRSLLHSDGITYL Y QTSNLAS AQNLELPNT b (SEQ ID NO:80) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS AQNLELPWT C (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:81) huEpCAM23LCGv4 RSSRSLLHSDGFTYLS QTSNLAS AQNLELPNT e (SEQ ID NO:82) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS AQNLELPNT f (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:47) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS QQNLELPNT g (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:83) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS LQNLELPNT h (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:84) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS AQYLELPNT i (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:85) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS AQGLELPNT j (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:86) huEpCAM23LCGv4 RSSRSLLHSDGFTYL Y QTSNLAS AQSLELPNT k (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID NO:87)
[00320] In certain embodiments, the antibody described herein is a murine, non-human mammal, chimeric, humanized, or human antibody.
For example, the humanized antibody may be a CDR-grafted antibody or resurfaced antibody.
In certain embodiments, the antibody is a full-length antibody.
In certain embodiments, the antigen-binding fragment s thereof is an Fab, Fab', F(ab')2, Fd, single chain Fab (scFab), single chain Fv or scFv, disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgG11CH2, minibody, F(ab')3, tetrabody, triabody, diabody, duobody, single-domain antibody, DVD-lg, Fcab, mAb2, (scFv)2, or scFv-Fc. 116 ), ), ), ),
[00321] In certain embodiments, the cell-binding agent is an alternative protein scaffold, such as a peptide targeting a somatostatin receptor (see Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Wurth R, Thellung S, et al.
Peptide receptor targeting in cancer: the somatostatin paradigm.
Int J Pept 2013;2013 :926295), an inhibitor cystine knot (also known as ICK 5 or Knottin; see Knottins: disulfide-bonded therapeutic and diagnostic peptides.
Drug Discov Today Technol 2012;9( I ):e l-e70; Moore SJ, Cochran JR.
Engineering knottins as novel binding agents.
Methods Enzymol 2012;503:223-51 ), a duobody (see Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, el al.
Controlled Fab-arm exchange for the generation of stable bi specific IgG I.
Nat Protoc 2014;9( I 0):2450-63), a 10 hexabody (see de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, el al. A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biol 2016;14(1):el002344); a Single chain Fab (scFab) fragment (see Koerber JT, Hornsby MJ, Wells JA.
An improved single-chain Fab platform for efficient display and recombinant 15 expression. J Mol Biol 2015;427(2):576-86; Hust M, Jostock T, Menzel C, Voedisch B, Mohr A, Brenneis M, et al.
Single chain Fab (scFab) fragment. BMC Biotechnol 2007;7:14), a target identified by drug affinity responsive target stability (DARTS) (see Pai MY, Lomenick B, Hwang H, Schiestl R, McBride W, Loo JA, et al.
Drug affinity responsive target stability (DARTS) for small-molecule target identification.
Methods in molecular 20 biology 2015; 1263 :287-98), a Centyrin (a protein scaffold based on a consensus sequence of fibronectin type III (FN3) repeats; see U.S.
Patent Publication 2010/0255056, 2010/0216708 and 2011/0274623 an Ankyrin Repeat Protein (e.g., a designed ankyrin repeat protein, known as DARPin; see U.S.
Patent Publication Nos. 2004/0132028, 2009/0082274, 2011/0118146, and 2011/0224100, 25 and also see C.
Zahnd el al., ( 'all(:er Res. (20 I 0) 70: 1595-1605; Zahnd el al., .I.
Biol.
Chem. (2006) 281(46):35167-35175; and Binz, H.K., Amstutz, P. & Pluckthun, A., Nature Biotechnology (2005) 23:1257-1268 an ankyrinlike repeats protein or synthetic peptide (see e.g., U.S.
Patent Publication No. 2007/0238667; U.S.
Patent No. 7,101,675; WO 2007/147213; and WO 2007/062466 30 an Adnectin (a fibronectin domain scaffold protein; see US Patent Publication Nos. 2007/0082365; 2008/0139791 Knottins (small 117 . disulfide rich proteins characterized by disulfide through disulfide knot), Bicyclic peptides (also referred to as Bicycles; see Heinis C, Rutherford T, Freund S, Winter G.
Phage-encoded combinatorial chemical libraries based on bicyclic peptides.
Nat Chem Biol 2009;5(7):502-7; Teufel DP, Bennett G, Harrison H, van Rietschoten K, Pavan S, Stace C, et al.
Stable and 5 Long-Lasting, Novel Bi cyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema. J Med Chem 2018;61 (7):2823-36), A vi body (including diabodies, triabodies, and tetrabodies; see U.S.
Publication Nos. 2008/0152586 and 2012/0171115), dual receptor retargeting (DART) molecules (P.A.
Moore el al., Hlood, 2011; 117( 17):4542-4551; Veri MC, el al., Arthritis Rheum, 20 IO Mar 30; 62(7): 1933-43; Johnson S, el al. .I Mo/ Hiol, 10 20 IO Apr 9;399(3):436-49), and cell penetrating supercharged proteins (Methods in /s'nzymol. 502, 293-319 (2012).
Activatable CBAs
[00322] In additional embodiments, the provided CBA is an activatable antibody or an activatable antigen-binding antibody fragment (collectively as AA).
In some embodiments, 15 the activatable antibody or activatable antigen-binding antibody fragment comprises an antibody or antigen-binding antibody fragment (e .. g, antibodies or antigen-binding antibody fragments described herein) specifically binds to a ligand on the target cell ( or "a target") coupled to a masking moiety (MM), such that coupling of the MM reduces the ability of the antibody or antigen-binding antibody fragment to bind the target.
In some embodiments, the 20 MM is coupled via a sequence that includes a substrate for a protease, for example, a protease that is active in diseased tissue and/or a protease that is co-localized with the target at a treatment site in a subject.
The activatable antibodies are preferably stable in circulation, activated at intended sites of therapy and/or diagnosis but not in normal, e.g., healthy tissue or other tissue not targeted for treatment and/or diagnosis, and, when activated, exhibit 25 binding to the target that is at least comparable to the corresponding, unmodified antibody.
In some embodiments, the AAs are those described in WO 2009/025846, WO 2010/081173, WO 2015/048329, WO 2015/116933 and WO 2016/118629
[00323] In some embodiments, the activatable antibody or antibody fragment comprises: 118 . (a) a cleavable moiety (CM) coupled to the antibody or antibody fragment (collectively as "AB"), wherein the CM is a polypeptide that functions as a substrate for a protease; and (b) a masking moiety (MM) coupled to the antibody or antibody fragment, wherein the MM inhibits the binding of the antibody or antibody fragment to the ligand when the activatable antibody is in an uncleaved state, wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: (MM)-(CM)-(AB) or (AB)-(CM)-(MM).
[00324] In some embodiments, the masking moiety (or "mask") is an amino acid 10 sequence that is coupled or otherwise attached to the antibody and is positioned within the activatable antibody construct such that the masking moiety reduces the ability of the antibody to specifically bind the target.
Suitable masking moieties are identified using any of a variety of known techniques.
For example, peptide masking moieties are identified using the methods described in WO 2009/025846
[00325] The Kd of the AB modified with a MM towards the target can be at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or greater, or between 5-10, 10-100, 10-1,000, 10-10,000, 10-100,000, 10-l,000,000, 10- 10,000,000, 100-1,000, 100-10,000, 100-100,000, 100- 20 1,000,000, I 00-10,000,000, 1,000-10,000, 1,000- I 00,000, 1,000-1,000,000, 1000- 10,000,000, I 0,000-100,000, I 0,000-1,000,000, I 0,000-10,000,000, I 00,000-1,000,000, or I 00,000-10,000,000 times greater than the Kd of the AB not modified with an MM or the parental AB towards the target.
Conversely, the binding af1inity of the AB modified with a MM towards the target can be at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 25 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or greater, or between 5-10, 10-100, 10- 1,000, 10-10,000, 10-100,000, 10-1,000,000, 10-10,000,000, 100-1,000, 100-10,000, 100-100,000, 100- 1,000,000, 100-10,000,000, 1,000-10,000, 1,000- 100,000, l,000-1,000,000, 1000-10,000,000, 10,000- 100,000, 10,000-1,000,000, 10,000- 119 WO 2020/219287 PCT /0S2020/027831 10,000,000, 100,000-1,000,000, or 100,000-10,000,000 times lower than the binding affinity of the AB not modified with an MM or the parental AB towards the target.
[00326] The dissociation constant (Kd) of the MM towards the AB is generally greater than the Kd of the AB towards the target.
The Kd of the MM towards the AB can be at least 5 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 100,000, 1,000,000 or even 10,000,000 times greater than the Kd of the AB towards the target.
Conversely, the binding affinity of the MM towards the AB is generally lower than the binding affinity of the AB towards the target.
The binding affinity of MM towards the AB can be at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 100,000, 1,000,000 or even 10,000,000 times 10 lower than the binding affinity of the AB towards the target.
[00327] When the AB is modified with a MM and is in the presence of the target, specific binding of the AB to its target can be reduced or inhibited, as compared to the specific binding of the AB not modified with an MM or the specific binding of the parental AB to the target.
When compared to the binding of the AB not modified with an MM or the 15 binding of the parental AB to the target, the AB 's ability to bind the target when modified with an MM can be reduced by at least 50%, 60%, 70%, 80%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and even 100% for at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, 96, hours, or 5, 10, 15, 30, 45, 60, 90, 120, 150, 180 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater when measured in vivo or in a Target Displacement in vitro 20 immunoabsorbant assay, as described WO 2010/081173.
[00328] The MM can inhibit the binding of the AB to the target.
The MM can bind the antigen binding domain of the AB and inhibit binding of the AB to its target.
The MM can sterically inhibit the binding of the AB to the target.
The MM can allosterically inhibit the binding of the AB to its target.
In these embodiments when the AB is modified or coupled to 25 a MM and in the presence of target, there is no binding or substantially no binding of the AB to the target, or no more than .001 %, .01 %, .1 %, 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 50% binding of the AB to the target, as compared to the binding of the AB not modified with an MM, the parental AB, or the AB not coupled to an MM to the target, for at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, 96, hours, or 5, 120 WO 2020/219287 PCT /0S2020/027831 10, 15, 30, 45, 60, 90, 120, 150, 180 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater when measured in vivo or in a Target Displacement in vitro immunoabsorbant assay, as described WO 2010/081173.
[00329] When an AB is coupled to or modified by a MM, the MM can 'mask' or reduce, 5 or inhibit the specific binding of the AB to its target.
When an AB is coupled to or modified by a MM, such coupling or modification can effect a structural change which reduces or inhibits the ability of the AB to specifically bind its target.
[00330] An AB coupled to or modified with an MM can be represented by the following formulae (in order from an amino (N) terminal region to carboxyl (C) terminal region): 10 (MM)-(AB) (AB)-(MM) (MM)-L-(AB) (AB)-L-(MM) where MM is a masking moiety, the Ab is an antibody or target-binding antigen fragment, 15 and Lis a linker.
In many embodiments, it may be desirable to insert one or more linkers, e.g., flexible linkers, into the composition so as to provide for flexibility.
[00331] In certain embodiments, the MM is not a natural binding partner of the Ab.
In some embodiments, the MM contains no or substantially no homology to any natural binding partner of the Ab.
In some embodiments, the MM is no more than 5%, 10%, 15%, 20%, 25%, 20 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% similar to any natural binding partner of the Ab.
In some embodiments, the MM is no more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% identical to any natural binding partner of the Ab.
In some embodiments, the MM is no more than 25% identical to any natural binding partner of the Ab.
In some embodiments, the MM is no more 25 than 50% identical to any natural binding partner of the Ab.
In some embodiments, the MM is no more than 20% identical to any natural binding partner of the Ab.
In some embodiments, the MM is no more than 10% identical to any natural binding partner of the Ab. 121 .
[00332] The activatable antibodies provided herein can also include a cleavable moiety (CM).
Such AAs exhibit activatable/switchable binding, to the AB's target. AAs generally include an antibody or antibody fragment (AB), modified by or coupled to a masking moiety (MM) and a modifiable or cleavable moiety (CM).
In some embodiments, the CM contains 5 an amino acid sequence that serves as a substrate for a protease of interest.
In other embodiments, the CM provides a cysteine-cysteine disulfide bond that is cleavable by reduction.
In yet other embodiments the CM provides a photolytic substrate that is activatable by photolysis.
[00333] In some embodiments, the cleavable moiety (or "substrate") includes an amino 10 acid sequence that is a substrate for a protease, usually an extracellular protease.
Suitable substrates are identified using any of a variety of known techniques.
For example, peptide substrates are identified using the methods described in US Patent Nos. 7,666,817 and 8,563,269; and WO 2014/026136 (See also, Boulware et al., Biotechnol Bioeng. 106(3):339-346 15 (2010)).
Optionally, the CM comprises a cysteine-cysteine pair capable of forming a disulfide bond, which can be cleaved by action of a reducing agent.
The CM is positioned such that when the CM is cleaved by a cleaving agent (e.g., a protease substrate of a CM is cleaved by the protease and/or the cysteine-cysteine disulfide bond is disrupted via reduction by exposure to a reducing agent), in the presence of a target, resulting in a cleaved state, the 20 Ab binds the target, and in an uncleaved state, in the presence of the target, binding of the Ab to the target is inhibited by the MM.
It should be noted that the amino acid sequence of the CM may overlap with or be included within the MM, such that all or a portion of the CM facilitates "masking" of the Ab when the activatable antibody is in the uncleaved conformation. 25
[00334] In some embodiments, the CM may be selected based on a protease that is colocalized in tissue with the desired target of the activatable antibody. A variety of different conditions are known in which a target of interest is co-localized with a protease, where the substrate of the protease is known in the art.
For example, the target tissue can be a cancerous tissue, particularly cancerous tissue of a solid tumor.
There are many reports in the 122 WO 2020/219287 PCT /0S2020/027831 literature of increased levels of proteases having known substrates in a number of cancers, e.g., solid tumors.
See, e.g., La Rocca et al, (2004) British J. of Cancer 90(7): 1414-1421.
[00335] Exemplary substrates can include but are not limited to substrates cleavable by one or more of the following enzymes: MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP- 5 14, PLASMIN, PSA, PSMA, CATHEPSIND, CATHEPSINK, CATHEPSIN S, ADAMlO, ADAM12, ADAMTS, Caspase-1, Caspase-2, Caspase-3, Caspase-4, Caspase-5, Caspase-6, Caspase-7, Caspase-8, Caspase-9, Caspase-10, Caspase-11, Caspase-12, Caspase-13, Caspase-14, and TACE.
[00336] In some embodiments, the CM is a polypeptide ofup to 15 amino acids in length. 10
[00337] In some embodiments, the CM is a polypeptide that includes a first cleavable moiety (CMl) that is a substrate for at least one matrix metalloprotease (MMP) and a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP).
In some embodiments, each of the CMl substrate sequence and the CM2 substrate sequence of the CM1- CM2 substrate is independently a polypeptide ofup to 15 amino acids in length. 15
[00338] In some embodiments the CM is a substrate for legumain, plasmin, TMPRSS-3/4, MMP-9, MTl-MMP, cathepsin, caspase, human neutrophil elastase, beta-secretase, uPA, or PSA.
[00339] The Kd of the Ab modified with a MM and a CM towards the target can be at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 20 1,000,000, 5,000,000, 10,000,000, 50,000,000 or greater, or between 5-10, 10-100, 10-1,000, 10-10,000, 10-100,000, 10-1,000,000, 10- 10,000,000, 100-1,000, 100-10,000, 100-100,000, 100-1,000,000, 100-10,000,000, 1,000-10,000, 1,000- 100,000, 1,000-l,000,000, 1000- 10,000,000, 10,000-100,000, 10,000-1,000,000, 10,000-10,000,000, 100,000-1,000,000, or 100,000-10,000,000 times greater than the Kd of the Ab not modified with an MM and a CM 25 or the parental Ab towards the target.
Conversely, the binding affinity of the Ab modified with a MM and a CM towards the target can be at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or greater, or between 5-10, 10-100, 10-1,000, 10-10,000, 10-100,000, 10- 123 . 1,000,000, 10-10,000,000, 100-1,000, 100-10,000, 100-100,000, 100-1,000,000, 100- 10,000,000, 1,000-10,000, 1,000-100,000, 1,000-l,000,000, 1000- 10,000,000, 10,000- 100,000, 10,000-1,000,000, 10,000-10,000,000, 100,000-1,000,000, or 100,000- 10,000,000 times lower than the binding affinity of the Ab not modified with an MM and a CM or the 5 parental Ab towards the target.
[00340] When the Ab is modified with a MM and a CM and is in the presence of the target but not in the presence of a modifying agent (for example an enzyme, protease, reduction agent, light), specific binding of the Ab to its target can be reduced or inhibited, as compared to the specific binding of the Ab not modified with an MM and a CM or the 10 parental Ab to the target.
When compared to the binding of the parental Ab or the binding of an Ab not modified with an MM and a CM to its target, the Ab 's ability to bind the target when modified with an MM and a CM can be reduced by at least 50%, 60%, 70%, 80%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% and even 100% for at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, 96 hours, or 5, 10, 15, 30, 45, 60, 90, 120, 150, 180 days, or 1, 15 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or greater when measured in vivo or in a Target Displacement in vitro immunoabsorbant assay, as described in WO201008 l l 7
[00341] As used herein, the term cleaved state refers to the condition of the AA following modification of the CM by a protease and/or reduction of a cysteine-cysteine 20 disulfide, bond of the CM, and/or photoactivation.
The term uncleaved state, as used herein, refers to the condition of the AA in the absence of cleavage of the CM by a protease and/or in the absence reduction of a cysteine-cysteine disulfide bond of the CM, and/or in the absence of light.
As discussed above, the term AA is used herein to refer to an AA in both its uncleaved (native) state, as well as in its cleaved state.
It will be apparent to the ordinarily 25 skilled artisan that in some embodiments a cleaved AA may lack an MM due to cleavage of the CM by protease, resulting in release of at least the MM (e.g., where the MM is not joined to the AA by a covalent bond (e.g., a disulfide bond between cysteine residues).
[00342] By activatable or switchable is meant that the AA exhibits a first level of binding to a target when in a inhibited, masked or uncleaved state (i.e., a first conformation), 124 WO 2020/219287 PCT /0S2020/027831 and a second level of binding to the target in the uninhibited, unmasked and/or cleaved state (i.e., a second conformation), where the second level of target binding is greater than the first level of binding.
In general, the access of target to the Ab of the AA is greater in the presence of a cleaving agent capable of cleaving the CM than in the absence of such a cleaving agent. 5 Thus, when the AA is in the uncleaved state, the Ab is inhibited from target binding and can be masked from target binding (i.e., the first conformation is such the Ab can not bind the target), and in the cleaved state the AB is not inhibited or is unmasked to target binding.
[00343] The CM and AB of the AA may be selected so that the AB represents a binding moiety for a target of interest, and the CM represents a substrate for a protease that is co- 10 localized with the target at a treatment site in a subject.
Alternatively or in addition, the CM is a cysteine-cysteine disulfide bond that is cleavable as a result of reduction of this disulfide bond. AAs contain at least one of a protease-cleavable CM or a cysteine-cysteine disulfide bond, and in some embodiments include both kinds of CMs.
The AAs can alternatively or further include a photolabile substrate, activatable by a light source.
The AAs disclosed 15 herein find particular use where, for example, a protease capable of cleaving a site in the CM is present at relatively higher levels in target-containing tissue of a treatment site (for example diseased tissue; for example for therapeutic treatment or diagnostic treatment) than in tissue of non- treatment sites (for example in healthy tissue).
The AAs disclosed herein also find particular use where, for example, a reducing agent capable of reducing a site in the 20 CM is present at relatively higher levels in target-containing tissue of a treatment or diagnostic site than in tissue of non- treatment non-diagnostic sites.
The AAs disclosed herein also find particular use where, for example, a light source, for example, by way of laser, capable of photolysing a site in the CM is introduced to a target-containing tissue of a treatment or diagnostic site. 25
[00344] In some embodiments AAs can provide for reduced toxicity and/or adverse side effects that could otherwise result from binding of the Ab at non-treatment sites if the Ab were not masked or otherwise inhibited from binding its target.
Where the AA contains a CM that is cleavable by a reducing agent that facilitates reduction of a disulfide bond, the ABs of such AAs may selected to exploit activation of an Ab where a target of interest is 30 present at a desired treatment site characterized by elevated levels of a reducing agent, such 125 WO 2020/219287 PCT /0S2020/027831 that the environment is of a higher reduction potential than, for example, an environment of a non- treatment site.
[00345] In general, an AA can be designed by selecting an Ab of interest and constructing the remainder of the AA so that, when conformationally constrained, the MM 5 provides for masking of the Ab or reduction of binding of the Ab to its target.
Structural design criteria to be taken into account to provide for this functional feature.
[00346] AAs exhibiting a switchable phenotype of a desired dynamic range for target binding in an inhibited versus an uninhibited conformation are provided.
Dynamic range generally refers to a ratio of (a) a maximum detected level of a parameter under a first set of 1 o conditions to (b) a minimum detected value of that parameter under a second set of conditions.
For example, in the context of an AA, the dynamic range refers to the ratio of (a) a maximum detected level of target protein binding to an AA in the presence of protease capable of cleaving the CM of the AA to (b) a minimum detected level of target protein binding to an AA in the absence of the protease.
The dynamic range of an AA can be 15 calculated as the ratio of the equilibrium dissociation constant of an AA cleaving agent (e.g., enzyme) treatment to the equilibrium dissociation constant of the AA cleaving agent treatment.
The greater the dynamic range of an AA, the better the switchable phenotype of the AA. AAs having relatively higher dynamic range values (e.g., greater than 1) exhibit more desirable switching phenotypes such that target protein binding by the AA occurs to a 20 greater extent (e.g., predominantly occurs) in the presence of a cleaving agent (e.g., enzyme) capable of cleaving the CM of the AA than in the absence of a cleaving agent.
[00347] AAs can be provided in a variety of structural configurations.
Exemplary formulae for AAs are provided below.
It is specifically contemplated that the N- to Cterminal order of the AB, MM and CM may be reversed within an AA.
It is also specifically 25 contemplated that the CM and MM may overlap in amino acid sequence, e.g., such that the CM is contained within the MM.
[00348] For example, AAs can be represented by the following formula (in order from an amino (N) terminal region to carboxyl (C) terminal region: 126 WO 2020/219287 PCT /0S2020/027831 (MM)-(CM)-( AB) (AB)-(CM)-(MM) where MM is a masking moiety, CM is a cleavable moiety, and AB is an antibody or fragment thereof.
It should be noted that although MM and CM are indicated as distinct components in the formula above, in all exemplary embodiments (including 5 formulae) disclosed herein it is contemplated that the amino acid sequences of the MM and the CM could overlap, e.g., such that the CM is completely or partially contained within the MM.
In addition, the formulae above provide for additional amino acid sequences that may be positioned N-terminal or C-terminal to the AA elements.
[00349] In certain embodiments, it may be desirable to insert one or more linkers, e.g., 10 flexible linkers, into the AA construct so as to provide for flexibility at one or more of the MM-CM junction, the CM-AB junction, or both.
For example, the AB, MM, and/or CM may not contain a sufficient number of.residues (e.g., Giy, Ser, Asp, Asn, especially Giy and Ser, particularly Giy) to provide the desired flexibility.
As such, the switchable phenotype of such AA constructs may benefit from introduction of one or more amino acids to provide for 15 a flexible linker.
In addition, as described below, where the AA is provided as a conformationally constrained construct, a flexible linker can be operably inserted to facilitate formation and maintenance of a cyclic structure in the uncleaved AA.
[00350] For example, in certain embodiments an AA comprises one of the following formulae (where the formula below represent an amino acid sequence in either N- to C- 20 terminal direction or C- to N-terminal direction): (MM)-L1-(CM)-(AB) (MM)-(CM)-L1-(AB) (MM)-L1-(CM)-L2-(AB) CyClo[L1-(MM)-L2-(CM)-L3-(AB)] 25 wherein MM, CM, and AB are as defined above; wherein L1, L2 and L3 are each independently and optionally present or absent, are the same or different flexible linkers that include at least I flexible amino acid (e.g., Gly); and wherein CyClo where present, the AA is in the form of a cyclic structure due to the presence of a disulfide bond between a pair of cysteines in the AA.
In addition, the formulae above provide for additional amino acid 127 WO 2020/219287 PCT /0S2020/027831 sequences that may be positioned N-terminal or C-terminal to the AA elements.
It should be understood that in the formula CyClo[L1-(MM)-L2-(CM)-L3-(AB)], the cysteines responsible for the disulfide bond may be positioned in the AA to allow for one or two tails, thereby generating a lasso or omega structure when the AA is in a disulfide-bonded structure (and 5 thus conformationally constrained state).
The amino acid sequence of the tail(s) can provide for additional AA features, such as binding to a target receptor to facilitate localization of the AA, increasing serum half- life of the AA, and the like.
Targeting moieties (e.g., a ligand for a receptor of a cell present in a target tissue) and serum half-life extending moieties ( e.g., polypeptides that bind serum proteins, such as immunoglobulin (e.g., IgG) or serum albumin 10 (e.g., human serum albumin (HSA)). [003 51] Linkers suitable for use in the AAs described herein are generally ones that provide flexibility of the modified AB or the AA to facilitate the inhibition of the binding of the AB to the target.
Such linkers are generally referred to as flexible linkers.
Suitable linkers can be readily selected and can be of any of a suitable of different lengths, such as from 1 15 amino acid (e.g., Gly) to 20 amino acids, from 2 amino acids to 15 amino acids, from 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids, or 7 amino acids to 8 amino acids, and may be 1, 2, 3, 4, 5, 6, or 7 amino acids.
[00352] Exemplary flexible linkers include glycine polymers (G)n, glycine-serine 20 polymers (including, for example, (GS)n, (GSGGS)n and (GGGS)n, where n is an integer of at least one), glycine- alanine polymers, alanine-serine polymers, and other flexible linkers known in the art.
Glycine and glycine-serine polymers are relatively unstructured, and therefore may be able to serve as a neutral tether between components.
Glycine accesses significantly more phi-psi space than even alanine, and is much less restricted than residues 25 with longer side chains (see Scheraga, Rev.
Computational Chem. 11173-142 (1992)).
Exemplary flexible linkers include, but are not limited to Gly-Gly-Ser-Gly, Gly-Gly-Ser-GlyGly, Gly- Ser-Gly-Ser-Gly, Gly-Ser-Gly-Gly-Gly, Gly-Gly-Gly-Ser-Gly, Gly-Ser-Ser-SerGly, and the like.
The ordinarily skilled artisan will recognize that design of an AA can include linkers that are all or partially flexible, such that the linker can include a flexible 128 . linker as well as one or more portions that confer less flexible structure to provide for a desired AA structure.
[00353] In addition to the elements described above, the modified ABs and AAs can contain additional elements such as, for example, amino acid sequence N- or C-terminal of 5 the AA.
For example, AAs can include a targeting moiety to facilitate delivery to a cell or tissue of interest.
Moreover, the AA can be provided in the context of a scaffold protein to facilitate display of the AA on a cell surface.
[00354] In some embodiments, the activatable antibody, also includes a signal peptide.
In some embodiments, the signal peptide is conjugated to the activatable antibody, via a 10 spacer.
In some embodiments, the spacer is conjugated to the activatable antibody, in the absence of a signal peptide.
In some embodiments, the spacer is joined directly to the MM of the activatable antibody.
In some embodiments, the spacer is joined directly to the MM of the activatable antibody, in the structural arrangement from N-terminus to C- terminus of spacer-MM-CM-AB.
[00355] Suitable spacers and spacer technology is known in the art and can routinely be used to incorporate spacers in some embodiments of the provided activatable antibodies.
See, for example, WO 2016/179285 (e.g., at pages 52-53)
[00356] In some embodiments, the activatable antibody is exposed to and cleaved by a 20 protease such that, in the activated or cleaved state, the activated antibody includes a light chain sequence that includes at least a portion of LP2 and/or CM sequence after the protease has cleaved the CM.
[00357] The CM is specifically cleaved by at least one protease at a rate of about 0.001- 1500 x 104 M·1s-1 or at least 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2.5, 5, 7.5, 10, 15, 20, 25, 25 50, 75, 100, 125, 150, 200, 250, 500, 750, 1000, 1250, or 1500 x 104 M·1s-1.
In some embodiments, the CM is specifically cleaved at a rate of about 100,000 M·1s·1.
In some embodiments, the CM is specifically cleaved at a rate from about 1 x 102 to about 1 x 106 M" 1s-1 (i.e., from about 1 xl02 to about 1 x 106 M·1s-1).
For specific cleavage by an enzyme, 129 . contact between the enzyme and CM is made.
When the activatable antibody, comprising an Ab (e.g., an antibody or EpCAM-binding antibody fragment) coupled to a MM and a CM is in the presence of the target and sufficient enzyme activity, the CM can be cleaved.
Sufficient enzyme activity can refer to the ability of the enzyme to make contact with the CM and effect 5 cleavage.
It can readily be envisioned that an enzyme may be in the vicinity of the CM but unable to cleave because of other cellular factors or protein modification of the enzyme.
Production of Cell-Binding Agent-Drug Conjugates
[00358] In order to link the any one of the cytotoxic compounds or derivative thereof described herein to the cell-binding agent, the cytotoxic compound can comprise a linking 10 moiety with a reactive group bonded thereto.
These compounds can be directly linked to the cell-binding agent.
Representative processes for linking the cytotoxic compounds having a reactive group bonded thereof with the cell-binding agent to produce the cell-binding agentcytotoxic agent conjugates are described in the Examples.
[00359] In some embodiments, a bifunctional crosslinking reagent can be first reacted with 15 the cytotoxic compound to provide the compound bearing a linking moiety with one reactive group bonded thereto (i.e., drug-linker compound), which can then react with a cell binding agent.
Alternatively, one end of the bifunctional crosslinking reagent can first react with the cell binding agent to provide the cell binding agent bearing a linking moiety with one reactive group bonded thereto, which can then react with a cytotoxic compound.
The linking moiety 20 can contain a chemical bond that allows for the release of the cytotoxic moiety at a particular site.
Suitable chemical bonds are well known in the art and include disulfide bonds, thioether bonds, acid labile bonds, photolabile bonds, peptidase labile bonds and esterase labile bonds (see for example US Patents 5,208,020; 5,475,092; 6,441,163; 6,716,821; 6,913,748; 7,276,497; 7,276,499; 7,368,565; 7,388,026 and 7,414,073).
Preferred are disulfide bonds, 25 thioether and peptidase labile bonds.
Other linkers that can be used in the present invention include non-cleavable linkers, such as those described in are described in detail in U.S. publication number 2005/0169933, or charged linkers or hydrophilic linkers and are described in US 2009/0274713, US 2010/01293140 and WO 2009/134976 130 .
[00360] In some embodiments, a solution of a cell-binding agent (e.g., an antibody) in aqueous buffer may be incubated with a molar excess of a bifunctional crosslinking agent, 5 such as N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2- pyridyldithio )butanoate (SPDB), N-succinimidyl-4-(2-pyridyldithio )2-sulfo butanoate (sulfoSPDB) to introduce dithiopyridyl groups.
The modified cell-binding agent (e.g, modified antibody) is then reacted with the thiol-containing cytotoxic compound described herein, to produce a disulfide-linked cell-binding agent-cytotoxic agent conjugate of the present 10 invention.
[00361] In another embodiment, the thiol-containing cytotoxic compound described herein, can react with a bifunctional crosslinking agent such as N-succinimidyl-4-(2- pyridyldithio )pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio )butanoate (SPDB ), Nsuccinimidyl- 4-(2-pyridyldithio )2-sulfo butanoate (sulfo-SPDB) to form a cytotoxic agent- 15 linker compound, which can then react with a cell-biding agent to produce a disulfide-linked cell-binding agent-cytotoxic agent conjugate of the present invention.
The cytotoxic agentlinker compound can be prepared in situ without purification before reacting with the cellbinding agent.
Alternatively, the cytotoxic agent-linker compound can be purified prior to reacting with the cell-binding agent. 20
[00362] The cell binding agent-cytotoxic agent conjugate may be purified using any purification methods known in the art, such as those described in US Patent No. 7,811,572 and US Publication No.2006/0182750 For example, the cell-binding agent-cytotoxic agent conjugate can be purified using tangential flow filtration, adsorptive chromatography, adsorptive filtration, selective 25 precipitation, non-absorptive filtration or combination thereof.
Preferably, tangential flow filtration (TFF, also known as cross flow filtration, ultrafiltration and diafiltration) and/or adsorptive chromatography resins are used for the purification of the conjugates.
[00363] The number of cytotoxic molecules bound per antibody molecule can be determined spectrophotometrically by measuring the ratio of the absorbance at 280 nm and 330 nm.
In 131 some embodiments, an average of 1-10 cytotoxic compounds/antibody molecule(s) can be linked by the methods described herein.
In some embodiments, the average number of linked cytotoxic compounds per antibody molecule (DAR) is 2-12.
In some embodiments, the DAR value is 2-10.
In some embodiments, the DAR value is 2-8.
In some embodiments, the DAR 5 value is 2.5-4.0.
In some embodiments, the DAR value is 4-8.
In some embodiments, the DAR value is 5-8.
In some embodiments, the DAR value is 6-8.
In some embodiments, the DAR value is 6.5-8.
In some embodiments, the DAR value is 7-8.
In some embodiments, the DAR value is 7.1-8.
In some embodiments, the DAR value is 7.2-8.
In some embodiments, the DAR value is 7.3-8.
In some embodiments, the DAR value is 7.4-8.
In some 10 embodiments, the DAR value is 7.5-8.
In some embodiments, the DAR value is 7.6-8.
In some embodiments, the DAR value is 7.7-8.
In some embodiments, the DAR value is 7.8-8.
In some embodiments, the DAR value is 7.9-8.
In some embodiment, a composition (e.g., pharmaceutical composition) comprising the conjugates of the invention has a DAR value between 2 and 12, between 2 and 10, more specifically between 6 and 8.
In some 15 embodiments, the average number of linked cytotoxic compounds per antibody molecule (DAR) is 7-8, and more specifically 8.
[00364] In some embodiments, when the antibody is linked to the cytotoxic agent through a cysteine thiol group, the conjugate has 1 cytotoxic compounds per antibody molecule.
In some embodiments, the conjugate has 1 or 2 cytotoxic compounds per antibody molecule.
In 20 some embodiments, the conjugate has 2 cytotoxic compounds per antibody molecule.
In some embodiments, the average number of linked cytotoxic compounds per antibody molecule (DAR) is 1.5 to 2.5, more specifically 1.8-2.2.
In some embodiments, a composition (e.g, pharmaceutical composition) comprising the conjugates of the invention has a DAR value between 1.0 and 2.5, between 1.5 and 2.5, more specifically between 1.8 25 and 2.2 or between 1.9 and 2.1.
[00365] Representative processes for preparing the cell-binding agent-drug conjugates of the present invention are described in 8,765,740 and U.S.
Application Publication No. 2012/0238731. 132 ™ Compositions
[00366] The present invention includes a composition (e.g., a pharmaceutical composition) comprising any one of the compounds described herein, derivatives thereof, or conjugates thereof, (and/or solvates, hydrates and/or salts thereof) and a carrier (a pharmaceutically 5 acceptable carrier).
[00367] The pharmaceutical compositions described herein can be administered in any number of ways for either local or systemic treatment.
Administration can be topical (such as to mucous membranes including vaginal and rectal delivery) such as transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders; pulmonary 10 (e.g, by inhalation or insuftlation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal); oral; or parenteral including intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial (e.g., intrathecal or intraventricular) administration.
In some particular embodiments, the administration is intravenous.
The pharmaceutical compositions described 15 herein can also be used in vitro or in ex vivo.
[00368] Suitable pharmaceutically acceptable carriers, diluents, and excipients are well known and can be determined by those of ordinary skill in the art as the clinical situation warrants.
Examples of suitable carriers, diluents and/or excipients include: (1) Dulbecco's phosphate buffered saline, pH about 7.4, containing or not containing about 1 mg/mL to 25 20 mg/mL human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), and (3) 5% (w/v) dextrose; and may also contain an antioxidant such as tryptamine and a stabilizing agent such as Tween 20.
Methods of Use
[00369] The present compositions are useful for inhibiting abnormal cell growth or treating a 25 proliferative disorder in a mammal (e.g., human).
[00370] The present invention includes a method of inhibiting abnormal cell growth or treating a proliferative disorder, an autoimmune disorder, destructive bone disorder, infectious disease, viral disease, fibrotic disease, neurodegenerative disorder, pancreatitis or 133 WO 2020/219287 PCT /0S2020/027831 kidney disease in a mammal (e.g., human) comprising administering to said mammal a therapeutically effective amount of cytotoxic compounds described herein, derivatives thereof, or conjugates thereof, (and/or solvates and salts thereof) or a composition thereof.
[00371] In certain embodiments, the proliferative disorder in a mammal is cancer, including 5 hematologic cancer, leukemia, or lymphoma.
In certain embodiments, the proliferative disorder is a cancer of a lymphatic organ, or a hematological malignancy.
In some embodiments, the cancer is a lymphoma or a leukemia.
[00372] For example, the cancer may be selected from the group consisting of: acute myeloid leukemia (AML, including CD33-low AML, P-glycoprotein positive AML, relapsed AML, 10 or refractory AML), chronic myelogenous leukemia (CML), including blastic crisis of CML and Abelson oncogene associated with CML (Bcr-ABL translocation), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), including, but not limited to, acute B lymphoblastic leukemia or B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), including Richter's syndrome or Richter's transformation of 15 CLL, hairy cell leukemia (HCL), acute promyelocytic leukemia (APL), B-cell chronic lymphoproliferative disease (B-CLPD), atypical chronic lymphocytic leukemia (preferably with a marked CDI le expression), diffuse large B-cell lymphoma (DLBCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), including mantel cell leukemia (MCL), and small lymphocytic lymphoma (SLL), Hodgkin's lymphoma, 20 systemic mastocytosis, and Burkitt's lymphoma.
[00373] In some embodiments, the cancer is endometrial cancer, lung cancer, colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, esophageal cancer, breast cancer (e.g., triple negative breast cancer (TNBC)), head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, 25 testicular cancer, myeloid cancer, melanoma, and lymphoid cancer.
In some embodiments, the lung cancer is non-small cell lung cancer or small-cell lung cancer.
In further embodiments, compounds of the present invention may be useful in the treatment of nonsmall- cell lung cancer (squamous cell, nonsquamous cell, adenocarcinoma, or large-cell undifferentiated carcinoma), colorectal cancer (adenocarcinoma, gastrointestinal carcinoid 134 WO 2020/219287 PCT /0S2020/027831 tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, leiomyosarcoma, or squamous cell carcinoma) or breast cancer (e.g., triple negative breast cancer (TNBC)).
[00374] The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not 5 intended to be limiting of the present invention.
EXAMPLES
[00375] The following abbreviations are used for the following terms: DAR Drug to antibody ratio; DIPEA 10 DMF Dii sopropy 1 ethy lamine; Dimethy lformami de; DMSO Dimethylsulfoxide; DMTMM chloride; EDTA ( 4-( 4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium 15 EPPS Ethylenediaminetetraacetic acid; 3-[4-(2-Hydroxyethyl)-l-piperazinyl]propanesulfonic acid; 9-Fluoroenylmethoxycarbonyl; Hexamethylphosphoramide; Fmoc HMPA 1.V.
NMM PPTS SEC SEM TCEP TEA TFA Intravenous; N-methylmorpholine; Pyridinium p-toluenesulfonate; Size exclusion chromatography; Standard error of the mean; 3,3',3"-phosphinetriyltripropanoic acid hydrochloride; Triethylamine; and Trifluoroacetic acid.
[00376] FIG. I and FIG. 2 depict the synthesis of camptothecin building blocks. FIG. 3, FIG. 4, and FIG. 5 depict the synthesis of the side chains. FIG. 6 and FIG. 7 depict the coupling of the camptothecin building blocks to the side chains. FIG. 8 depicts the synthesis of 135 WO 2020/219287 PCT /0S2020/027831 additional camptothecin metabolites. FIG. 9 depicts the coupling of camptothecin building blocks to side chains. FIG. IO depicts the synthesis of additional camptothecin compounds.
[00377] FIG. 11 depicts compounds used for comparison, which include a generic Ab-999 structure of an ADC bearing the 999 moiety linked through reduced inter-chain di sulfides of s an antibody.
Compounds 998 and 999 were prepared as described in US patent 2016/0297890 Al and references therein.
Example 1.
Synthesis of Compounds 2a-2e CICH2CH2CI reflux ~Cl F~NH2 2a [00378] 2a: To flask containing anhydrous 1,2-dichloroethane (80 mL) was added IM boron 10 trichloride in dichloromethane (16 mL, 16 mmol) then cooled to 0 °C with an ice water bath. la (2.5 g, 20 mmol) was added in portions then stirred at 0 °C for 10 min, then chloroacetonitrile (2.7 mL, 23.5 mmol) was added followed by the addition of aluminum chloride (3.5 g, 26 mmol).
The ice bath was removed and the reaction solution was gradually warmed to room temperature.
After stirring at room temperature for IO min, the reaction 1s mixture was heated at reflux for 39 h.
The reaction solution was cooled to room temperature and cold water ( 40 mL) was added slowly followed by the addition of 5% HCl water solution.
After 30 min, it was diluted with dichloromethane (80 mL).
The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and filtered.
The filtrate was stripped under reduced pressure and the residue was purified by reverse phase HPLC 20 (200 g C 18 column, 80 mL/min, CH3CN/H2O, 25% CH3CN for 5 min then to 95% CH3CN in 22 min then 95% CH3CN for 5 min) to give compound 2a as an off-white solid (1.52 g, yield 38%). MS (ESI): (M + Ht calcd. 202.0, found 202.2.
I o S~CI F~NH 2b 2 136 WO 2020/219287 PCT /0S2020/027831 [00379] 2b: AlCb (1.0 g, 7.7 mmol) and toluene (3.4 mL) were added to a 100 mL flask equipped with magnetic stirring. A solution of lb (1.0 g, 6.4 mmol) in toluene (3.85 mL) was added to the flask under a nitrogen atmosphere followed by 1 M BCh in toluene (3.85 mL, 7.6 mmol). 2-chloroacetonitrile (1.7 mL, 26.6 mmol) was added dropwise over 5 approximately 2 min then the flask was fit with a reflux condenser and heated in a 114 °C oil bath for 3h.
The heating bath was removed and after 4 min a thermometer was placed in the flask.
After cooling to 50 °C the reaction mixture was poured into deionized water (50 mL) then extracted with ethyl acetate (2 x 60 mL ).
The organic layer was separated, dried over anhydrous Na2SO4 then solvent was removed by rotary evaporation under vacuum.
The 10 residue was taken up in a minimum volume of ethyl acetate then purified on an 80 g silica column eluting with 92:8 hexanes:ethyl acetate.
Fractions containing pure desired product were combined and solvent was removed by rotary evaporation under vacuum to give 0.69 g of desired product 2b (46% yield) as a yellow solid. MS (M+ H)+ 233.8; 1H NMR (400 MHz, Chloroform-d) 8 7.79 (d, J = 7.9 Hz, lH), 6.40 (d, J = l 1.0 Hz, lH), 4.62 (s, 3H), 2.39 15 (s, 3H), 1.54 (s, 4H). ~Cl FMNH2 2a ~~' :M,,u Bn F NH2 2e [00380] 2e: To a solution of compound 2a (155 mg, 0.77 mmol) in anhydrous dichloromethane (1.5 mL) was added benzylamine (0.68 mL, 6.2 mmol) and the reaction mixture was stirred at room temperature for 6 hours.
The reaction solution was stripped 20 under reduced pressure and the residue was purified by silica gel chromatography (12 g silica column, CH2Ch/MeOH, 0 to 10% MeOH in 16 minutes) to give 156 mg of 2e (74% yield).
MS (ESI): m/z 273.4 (M + Ht.
NC~Br BCl3/AICl3 CICH2CH2CI reflux ~Br F~NH2 2c [00381] 2c: To flask containing anhydrous 1,2-dichloroethane (50 mL) was added 1 M boron 25 trichloride in dichloromethane (9.95 mL, 9.95 mmol) then cooled to O 0c with an ice water 137 WO 2020/219287 PCT /0S2020/027831 bath. la (1.56 g, 12.4 mmol) was added in portions then stirred at 0 0c for 10 minutes, 5- bromovaleronitrile (1.72 mL, 14.9 mmol) was added followed by the addition of aluminum chloride (2.16 g, 16.2 mmol).
The ice bath was removed and the reaction solution was gradually warmed to room temperature.
After stirring at room temperature for 10 minutes, 5 the reaction mixture was heated at reflux for 39.5 hours.
The reaction solution was cooled to room temperature and cold water (25 mL) was added slowly followed by the addition of 5% HCl water solution.
After 30 minutes, it was diluted with dichloromethane (50 mL).
The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and filtered.
The filtrate was stripped under reduced pressure and the residue was purified by 10 reverse phase HPLC (100 g Cl8 column, CH3CN/H2O, 25% CH3CN for 5 minutes then to 95% CH3CN in 15 minutes then 95% CH3CN for 5 minutes) to give compound 2c as an offwhite solid (1.42 g, yield 40%). MS (ESI): m/z 289.2 (M + Ht.
I s~ F¼NH2 1b BCl3, AICl3 Br~ CN CICH2CH2CI reflux 45 h I o s~Br F~NH2 2d [00382] 2d: To a dried flask contained anhydrous 1,2-dichloroethane (40 mL) was added 15 boron trichloride (4.73 mL, 4.73 mmol, 1 Min CH2Ch) and cooled to 0 0c with an ice water bath.
Compound lb (0.93 g, 5.92 mmol) was added in portions and after stirring at 0 0c for 10 minutes, 5-bromovaleronitrile (0.819 mL, 7.1 mmol) was added followed by the addition of aluminum chloride (1.025 g, 7.69 mmol).
The ice bath was removed and the reaction solution was gradually warmed to room temperature.
After stirred at room temperature for 20 10 minutes, the reaction mixture was heated at reflux for 45 hours.
The reaction solution was cooled to room temperature and cold water (25 mL) was added slowly followed by 5 mL 5% HCl water solution.
After 30 minutes, it was diluted with dichloromethane (50 mL).
The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and filtered.
The filtrate was stripped under reduced pressure and the residue was purified by 25 reverse phase HPLC (100 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 95% CH3CN in 15 minutes then 95% CH3CN for 5 minutes) to give compound 2d as an offwhite solid (0.776 g, yield 41%). MS (ESI): m/z 321.0 (M + Ht. 138 WO 2020/219287 PCT /0S2020/027831 Example 2.
General procedure for Compounds 4a- 4d 1~ c1~ I :-... I F ~ NH O ••• 0 2b 2 3 -• OH I PPTS S F [00383] 4b: Compound 3 (777 mg, 2.95 mmol), 2b (690 mg, 2.95 mmol) and PPTS (37 mg, 0.15 mmol) were suspended in a 50 mL flask equipped with a reflux condenser containing s anhydrous toluene (10 mL ).
The reaction was heated to reflux with magnetic stirring under an argon atmosphere overnight then allowed to cool to room temperature.
The mixture was vacuum filtered and the solids were washed with toluene (5 mL) to give 1.08 g desired product 4b as a brown solid (79% yield). MS (M + H)+ 461, MS (M-H) 459. ~Cl F)l;lNH2 2a PPTS (0.05 eq) Toluene reflux, 40 h F 0 1 o [003 84] 4a: Prepared by the general procedure, a solution of compound 2a (3 .15 g, 15. 64 mmol) and compound 3 (3.92 g, 14.89 mmol) in toluene (200 mL) with PPTS (187 mg, 0.75 mmol) was refluxed for 40 hours to give 4a (4.74 g) in 74% yield. MS (ESI): m/z 429.2. 431.0 (M + Ht. 1H NMR (400 MHz, DMSO-d6) 8 8.37 (d, J = 8.3, 1.2 Hz, lH), 8.10 - 7.90 (m, lH), 7.33 (d, J = 2. l Hz, lH), 6.55 (d, J = 4.8 Hz, lH), 5.85 - 5.20 (m, 6H), 2.61 - 2.45 1s (m, 3H), 1.98-1.76 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H). HRMS (M + Ht calcd. 429.1017, found 429.1023. ~Br F~NH2 2c PPTS Toluene [00385] 4c: Following the general procedure, a solution of compound 2c (1.695 g, 5.88 mmol) and compound 3 (1.548 g, 5.88 mmol) in toluene (50 mL) with PPTS (0.074 g, 0.294 139 WO 2020/219287 PCT /0S2020/027831 mmol) was refluxed for 21.5 hours.
Solvent was evaporated and residue was taken up in a minimum volume of 10% methanol in CH2Ch then purified by silica gel chromatography ( 40 g silica column, CH2Ch/MeOH, 0 to 10% MeOH over 20 min) to give 4c (2.56 g) in 84% yield after silica gel chromatography (40 g silica column, CH2Ch/MeOH, 0 to 10% MeOH in s 20 minutes). MS (ESI): m/z 515.2 and 517.1 (M + H)+, 513.1 and 515.1 (M - H)". 1H NMR (400 MHz, DMSO-d6) 8 8.39- 8.17 (m, lH), 7.89 (d, J= 10.9 Hz, lH), 7.31 (s, lH), 6.52 (d, J = 6.2 Hz, lH), 5.44 (s, 2H), 5.31 (s, 2H), 3.65 (t, J = 6.7 Hz, 2H), 3.28 - 3.09 (m, 2H), 2.51 (t, J = 1.8 Hz, 3H), 2.15 - 1.95 (m, 2H), 1.95 - 1.71 (m, 4H), 0.88 (t, J = 7.4 Hz, 3H). HRMS (M + Ht calcd. 515.0981, found 515.0992.
I o 8 ~Br F~NH2 2d 0 rt:J~O 0 ~H 3 PPTS Tolune reflux 4d [00386] 4d: Following the general procedure, a solution of compound 2d (776 mg, 2.42 mmol) and compound 3 (670 mg, 2.54 mmol) in toluene (20 mL) with PPTS (30 mg, 0.12 mmol) was refluxed for 24 hours to give 4d (1.02 g) in 77% yield after silica gel chromatography ( 40 g silica column, CH2Ch/MeOH, 0 to 10% MeOH in 23 minutes). MS 1s (ESI): m/z 547.0 and 548.9 (M + H)+, 544.8 and 546.8 (M - H)". ~N~n F~N~O _, OH Ga Br~ O OH Br~ DMTMM ~NH NMM -D-MF-/H_2_0 _(5-:1)► F 0 _, OH 4e [00387] 4e: To a solution of 6a (10 mg, 0.024 mmol) in DMF (0.5 mL) was added NMM (3μL, 0.027 mmol) and 6-bromohexalic acid (7.2 mg, 0.037 mmol) and the solution is cooled to O 0c with an ice bath and DMTMM (13.5 mg, 0.049 mmol) in deionized water was added. 20 The ice bath was removed and the reaction mixture was stirred at room temperature for 3 hours.
The reaction solution was stripped under reduced pressure and the residue was purified by silica gel chromatography ( 4 g column, CH2Ch/MeOH, 0 to 10% MeOH in 15 minutes) to give 15 mg of 4e (yield 98%). MS (ESI): m/z 586.1 (M + H)+, 588.0 (M + Ht. 140 WO 2020/219287 Example 3.
Synthesis of Compounds Sa-Se and Sp HMPA/H20 (5.6:1) 101 OC PCT /0S2020/027831
[00388] Sa: A solution of compound 4c (860 mg, 1,67 mmol) in HMPA (5 mL) and deionized water (0.9 mL) was heated at 101 °c for 18 hours.
The reaction mixture was 5 cooled to room temperature and the solution was loaded on a C 18 cartridge and purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 95% CH3CN in 15 minutes then 95% CH3CN for 5 minutes) to give Sa as a solid which was contaminated with impurities.
It was further purified by silica gel chromatography (CH2Ch/MeOH, 0 to 20% MeOH) to give 392 mg of Sa as an off-white solid (51 % yield). 10 MS (ESI): m/z 453.2 (M + H)+, 451.1 (M -H)". 1HNMR (400 MHz, Methanol-d4) 8 8.00 (dd, J = 8.2, 1. 1 Hz, lH), 7.52 - 7.33 (m, 2H), 5.53 (d, J = 16.1 Hz, lH), 5.33 (d, J = 16.1 Hz, lH), 5.18 - 4.96 (m, 2H), 3.66 (q, J = 7.2, 6.7 Hz, 2H), 3.24 - 3.06 (m, 2H), 2.45 (dd, J = 20.1, 2.7 Hz, 3H), 1.94 (tdd, J = 7.1, 6.0, 2.0 Hz, 2H), 1.88 - 1.66 (m, 4H), 1.00 (td, J = 7.4, 2.5 Hz, 3H). 13C NMR (101 MHz, Methanol-d4) 8 173.32, 163.68, 161.19, 157.56, 151.44, 15 151.09, 148.68, 148.56, 146.06, 144.46, 128.10, 127.89, 127.22, 125.66, 125.60, 124.26, 118.92, 111.91, 111.69, 97.96, 72.74, 65.28, 60.97, 49.40, 32.15, 30.80, 29.00, 25.96, 14.09, 14.06, 6.75; HRMS (M + Ht calcd. 453.1826, found 453.1832.
I s HMPA/H20 I (5.6:1) s F 101 °C F
[00389] Sb: Prepared from 4d using the Sa procedure.
Yield (48% yield). MS (ESI): m/z 20 (M + H)+ 485.7. 2-mercaptoethanol, TEA 141 WO 2020/219287 PCT /0S2020/027831
[00390] Sc: Compound 4a (100 mg, 0.23 mmol) was dissolved in anhydrous DMF (2 mL) to which was added 2-mercaptoethanol (0.2 mL, 2.8 mmol) followed by TEA (0.13 mL, 0.94 mmol) and magnetically stirred for 20 min.
The reaction mix was injected onto 250 g medium pressure Cl8 column that was pre-equilibrated with 95:5 deionized water containing s 0.2% formic acid: acetonitrile.
The column was eluted at 50 mL/min with 95:5 deionized water containing 0.2% formic acid: acetonitrile for 5 min then with a linear gradient of 5% acetonitrile at 5 min to 95% acetonitrile at 35 min.
Fractions containing desired product were combined, frozen and lyophilized to give 85 mg of Sc (78% yield). MS (ESI): m/z 4 71.4 (M + Ht. 1HNMR (400 MHz, DMSO-d6) 8 8.25 (d, J= 8.2 Hz, lH), 7.78 (d, J= 10.8 Hz, lH), 10 7.27 (s, lH), 6.52 (s, lH), 5.42 (s, 2H), 5.22 (s, 2H), 4.87 (t, J = 5.4 Hz, lH), 4.47 - 4.28 (m, 2H), 3.56 (q, J = 6.3 Hz, 2H), 3.33 (s, 2H), 2.62 (t, J = 6.6 Hz, 2H), 2.48 - 2.44 (m, 3H), 1.87 (hept, J= 7.1, Hz, 2H), 0.88 (t, J= 7.3 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) 8 172.44, 163.07, 160.58, 156.69, 152.16, 149.97, 148.66, 148.53, 145.48, 140.06, 128.18, 128.16, 127.28, 127.07, 126.61, 126.54, 123.59, 119.09, 112.56, 112.35, 96.77, 72.36, 65.26, 60.83, 1s 49.69, 34.38, 30.31, 28.78, 15.24, 15.20, 7.75. HRMS (M + Ht calcd. 471.1390, found 471.1393.
[00391] Sd : Prepared similarly to Sc by the reaction of 1,3-propanedithiol with 4a (60% yield). MS (ESI): m/z 501.7 (M + Ht. 1,2-ethanedithiol, TEA 20
[00392] Se: Prepared similarly to Sc by the reaction of 1,2-ethanedithiol with 4a (47% yield).
MS (ESI): (M + Ht calcd. 487.1, found 487.3. 142 WO 2020/219287 PCT /0S2020/027831
[00393] Sp: Compound Se (28 mg, 0.057 mmol) was dissolved in anhydrous THF (1 mL) to which was added 60% NaH emulsion in mineral oil (5 mg, 2.1 mmol) with magnetic stirring.
After 2 min, iodomethane (20 μL, 0.32 mmol) was added.
After 20 min solvent was evaporated under vacuum and residue was taken up in anhydrous DMF (1 mL) then purified s by medium pressure Cl8 chromatography.
Column 100 g Cl8, 50 mL/min, 0.2% formic acid in deionized water with 5% acetonitrile from 0 - 5 min then a linear gradient of 5% - 95% from 5 min - 28 min. fractions containing desired product were combined, frozen and lyophilized to give 15 mg of Sp as a yellow solid (54% yield). 1H NMR (400 MHz, DMSOd6) 8 8.40 -8.27 (m, lH), 7.89 (d, J = 10.8 Hz, lH), 7.31 (s, lH), 6.52 (s, lH), 5.43 (s, 2H), 10 5.39 (s, lH), 5.32 (s, lH), 4.57 - 4.39 (m, 2H), 2.84 - 2.69 (m, 3H), 2.44 (m, lH), 2.07 (m, lH), 2.02 (s, 3H), 1.87 (m, 2H), 1.23 (s, lH), 0.87 (t, J = 7.3 Hz, 3H). HRMS (M + Ht calcd. 501.1318; found 501.1322.
Example 4.
Synthesis of Compound 5a NaN3 DMSO 1s [00394] 5a: A solution of 4a (2 g, 4.66 mmol) and sodium azide (0.455 g, 7.0 mmol) in 25 mL anhydrous DMSO was stirred at room temperature for 6 h followed by dilution with deionized water (200 mL).
The product precipitated and was collected by vacuum filtration then dried under vacuum to give 2.03 g of 5a in (100% yield). MS (ESI): (M + Ht calcd. 435.1, found 436.2, MS (ESI): (M - H)· calcd. 433.1, found 434.2. 20 Example 5.
Synthesis of Compound 6a P(OEth Benzene HCI/MeOH [00395] 6a: To a solution of 5a (2.03 g, 4.66 mmol) in anhydrous benzene (60 mL) was added triethyl phosphite (1.94 g, 11.66 mmol) and the solution was flushed with argon then 143 WO 2020/219287 PCT /0S2020/027831 heated at reflux for 4 hours.
The reaction was cooled to room temperature and 3M methanolic HCl (30 mL) was added and heated at reflux (80 °c bath) for 38 h.
The reaction was allowed to cool to room temperature then vacuum filtered to give 6a (1.016 g) as offwhite solid.
The filtrate was concentrated and the residue was purified by silica gel 5 chromatography (12 g silica column, CH2Ch/MeOH, 0 to 20% MeOH in 16 minutes) to give an additional 6a (0.079 g). 1.09 g of combined 6a was obtained (57% yield). 1H NMR ( 400 MHz, DMSO-d6) 8 8.62 (s, 3H), 8.43 (d, J = 8.0 Hz, IH), 7.99 (d, J = 10.7 Hz, IH), 7.35 (s, IH), 5.59 (s, 2H), 5.45 (s, 2H), 4.70 (d, J = 6.0 Hz, 2H), 2.55 (s, 3H), 1.88 (hept, J = 7.1 Hz, 2H), 0.88 (t, J = 7.3 Hz, 3H). MS (ESI): m/z calcd. 410.2, found 410.4 (M + H)\ 408.1 (M - 10 H)".
Example 6.
Synthesis of Compound 7a 6a HO~O OH DMTMM TEA [00396] 7a: To a solution of 6a (7.5 mg, 0.018 mmol) in DMF (0.5 mL) was added triethylamine (2.6 μL, 0.018 mml) and glycolic acid (1.5 mg, 0.020 mmol).
The solution was 15 cooled to 0 0c with an ice bath and DMTMM (10.1 mg, 0.037 mmol) in deionized water (0.1 mL) was added.
The ice bath was removed and the reaction mixture was stirred at room temperature for 2 hours.
The reaction solution was stripped under reduced pressure and the residue was purified by silica gel chromatography (4 g silica column, CH2Ch/MeOH, 0 to 20% MeOH in 15 minutes) to give the desired product 7a (8 mg, yield 93%). MS (ESI): m/z 20 468.2 (M + Ht, 466.1 (M-H)". 1HNMR (400 MHz, DMSO-d6) 8 0.88 (t, J= 7.3 Hz, 3H), 1.79 - 1.98 (m, 3H), 2.55 (s, OH), 3.84 (d, J = 5.6 Hz, 3H), 4.85 (d, J = 6.0 Hz, 2H), 5.44 (s, 3H), 5.51 (s, 2H), 5.58 (t, J = 5.7 Hz, IH), 6.53 (s, IH), 7.32 (s, IH), 7.90 (d, J = 10.8 Hz, IH), 8.48 (d, J= 1.2, 8.3 Hz, IH), 8.76 (t, J= 6.0 Hz, IH). 13C NMR (101 MHz, DMSO-d6) 8 172.95, 172.89, 157.23, 152.85, 150.44, 149.07, 145.85, 140.12, 129.27, 127.97, 124.28, 25 119.63, 97.23, 72.83, 65.74, 61.91, 54.06, 50.54, 49.58, 44.06, 37.34, 30.72, 15.74, 8.22.
HRMS (M + Ht calcd. 468.1571, found 468.1593. 144 WO 2020/219287 Example 7.
Synthesis of Compound 6c 0~ ~~'Bn O ; j FMNH O 2 II' 2e 3 / OHO PPTS Toluene reflux PCT /0S2020/027831 [00397] 6c: A stirring solution of compound 2e (129 mg, 0.47 mmol), compound 3 (125 mg, 0.47 mmol) and PPTS (131 mg, 0.52 mmol) in anhydrous toluene (10 mL) was briefly placed s under vacuum then heated at reflux for 20 hours.
The reaction solution was cooled to room temperature and stripped and the residue was purified by silica gel chromatography (12 g column, CH2Ch/MeOH, 0 to 20% MeOH in 16 minutes) to give 196 mg impure product as black solid.
It was further purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 20% to 60% CH3CN in 15 minutes then 95% CH3CN for 5 minutes) to give 6c (31 mg, yield 10 13%). MS (ESI): m/z 500.4 (M + H)+, 498.3 (M - H)".
Example 8.
Synthesis of Compound 7c 6c DMTMM/TEA Ho-----y -----OH F [00398] 7c: To the solution of 6c (8.5 mg, 0.017 mmol) in DMF (0.5 mL) was added triethylamine (2.4 μL, 0.017 mml) and glycolic acid (1.9 mg, 0.026 mmol).
The solution was 1s cooled to O 0c with an ice bath and DMTMM (9.4 mg, 0.034 mmol) in deionized water (0.1 mL) was added.
The ice bath was removed and the reaction mixture was stirred at room temperature for 3 hours.
The reaction solution was stripped under reduced pressure (35 °c bath) and the residue was purified by semi-prep HPLC (Cl8 column, CH3CN/H2O, 25% to 65% CH3CN in 23 minutes) to give 2.5 mg of 7c (26% yield). MS (ESI): m/z 558.5 (M + H)+, 20 556.3 (M - H)".
Example 9.
Synthesis of Side Chains 145 WO 2020/219287 PCT /0S2020/027831 0 9 OH QH JI.. , ll,_ HO~ ,r::::<'o NHV 0 ; ; NH V \ OH OH I ~ 9 10 HO [00399] 11: N-Methyl-D-Glucamine 9 (3.94 g, 20.19 mmol) and Z-L-Glu-OBn 10 (5 g, 13.46 mmol) were weighed into a 200 mL flask to which DMF (50 mL) was added and magnetically stirred.
Then DIPEA (2.351 ml, 13.46 mmol) was added followed by as a s suspension ofDMTMM (5.22 g, 18.85 mmol) in DMF (30 mL) and deionized water (10 mL).
After 2 h 113rd of the reaction was loaded on a 450 g Cl8 cartridge that was pre-equilibrated with 95:5 deionized water: acetonitrile.
The column was eluted at 100 mL/min with 95:5 Deionized water:acetonitrile for 5 min then with a linear gradient of 5% acetonitrile to 95% acetonitrile over 38 min.
Chromatography was repeated two more times and fractions 10 containing pure desired product were pooled.
Solvent was removed by rotary evaporation under vacuum.
Methanol (100 mL) was added and evaporated 2 times to give 5 g of desired product 11 as a thick colorless oil (68% yield). MS (ESI): MS (M + Ht calcd. 549.2, found 549.3, MS (ESI): (M - H)· calcd 547.2, found 547.2. J0 l 9 0 ~o NH._)Lo Pd-C/H2 V \ OH OH / HO~ )::-O ~H ~H I 11 1s [00400] 12: Compound 11 (5 g, 9.1 mmol) was suspended in 95:5 methanol:deionized water (100 mL) in a 250 mL PARR shaker flask to which was added 10% Pd-C (0.13 g, 1.222 mmol) and hydrogenated at 30 PSI H2 for 45 min, adding H2 periodically to reestablish pressure.
The solution was vacuum filtered through celite filter aid.
The clear colorless filtrate was concentrated under by rotary evaporation under vacuum then left under vacuum 20 over night to give 2.8 g of desired product 12 as a white solid (94% yield). 1H NMR ( 400 MHz, DMSO-d6) 8 4.09 - 3.98 (m, lH), 3.84 (dt, J = 6. l, 3.1 Hz, lH), 3.79 (d, J = 6.0 Hz, lH), 3.75 (ddd, J = 7.5, 4.2, 2.3 Hz, lH), 3.72 - 3.59 (m, 3H), 3.56- 3.51 (m, lH), 3.48 (dd, 146 WO 2020/219287 PCT /0S2020/027831 J = 15.0, 3.6 Hz, lH), 3.13 (s, 2H), 2.97 (s, lH), 2.78 - 2.49 (m, 2H), 2.22 - 2.06 (m, 2H).
MS (ESI): MS (M -H)· calcd. 323.1, found 323.4. [00401] 14b: Compound 13b (1.4, 4.5 mmol) was added to a magnetically stirred solution of s 12 (1.4 g, 4.3 mmol) in DMF (10 mL) and DIPEA (1. 1 mL, 6.3 mmol).
After stirring for 15 min the reaction was injected onto a medium pressure 350 g Cl8 column that was preequilibrated with 98:2 deionized water containing 0.1 % formic acid : acetonitrile.
The column was eluted at 100 mL/min at 2% acetonitrile for 5 min then with a linear gradient of 2% acetonitrile at 5 min to 60% acetonitrile at 35 min detecting at 214 and 306 nm.
Fractions 10 containing pure product were combined, frozen and lyophilized to give 1.3 g of desired product 14b as a white solid (58% yield). MS (M + H)+ 518.5, 1HNMR (400 MHz, DMSOd6) 8 8.03 (dd, J = 15.3, 7.7 Hz, lH), 6.99 (s, 3H), 4.79 (d, J = 65.9 Hz, lH), 4.33 (d, J = 30.0 Hz, lH), 4.22-4.07 (m, lH), 3.75 (p, J= 4.2 Hz, lH), 3.57 (ddt, J= 11.4, 6.7, 3.6 Hz, lH), 3.52 - 3.39 (m, 2H), 3.39 - 3.30 (m, 3H), 3.30 - 3.19 (m, lH), 2.97 (s, 2H), 2.80 (s, 2H), 2.45 1s - 2.21 (m, lH), 2.08 (h, J = 3.4 Hz, 2H), 2.01 - 1.85 (m, lH), 1.76 (qd, J = 8.5, 3.9 Hz, lH), 1.59 - 1.39 (m, 3H), 1.30 - 1.08 (m, 2H). ~N'lr'~~OH 0 0 -.
OH ~H ( 14a HO~ ):::o : : N 6H 6H I [00402] 14a: Compound 13a (1.4, 5.3 mmol) was added to a magnetically stirred solution of 12 (1.8 g, 5.5 mmol) in DMF (10 mL) and DIPEA (1. 1 mL, mmol).
After stirring for 15 min 20 the reaction was injected onto a medium pressure 350 g Cl8 column that was pre-equilibrated with 98:2 deionized water containing 0.1 % formic acid : acetonitrile.
The column was eluted at 100 mL/min at 2% acetonitrile for 5 min then with a linear gradient of 2% acetonitrile at 5 147 WO 2020/219287 PCT /0S2020/027831 min to 60% acetonitrile at 35 min detecting at 214 and 306 nm.
Fractions containing pure product were combined, frozen and lyophilized to give 1 .4 g of 14a as a white solid (55% yield). 1H NMR (400 MHz, DMSO-d6) 8 8.33 (dd, J = 9.2, 7.7 Hz, lH), 7.08 (d, J = I. 1 Hz, 2H), 4.24 (qd, J = 8.8, 4.8 Hz, lH), 3.86 (dt, J = 8.2, 4.0 Hz, lH), 3.76 - 3.63 (m, 4H), 3.62 - 5 3.43 (m, 4H), 3.41 - 3.29 (m, lH), 3.08 (s, 2H), 2.91 (s, 2H), 2.61 (q, J = 1.8 Hz, lH), 2.40 (dd, J = 10.0, 6.4 Hz, lH), 2.02 (tdd, J = 12.6, 10.3, 9.1, 5.8 Hz, lH), 1.93 - 1.76 (m, lH). MS (ESI): MS (M + Ht calcd. 476.2, found 476.4.
[00403] Fmoc protected peptides 15a, 15b, 15c and 15d were prepared by solid phase synthesis using standard procedures. 10 Example 10.
Method for converting Fmoc-peptide-Gly-OH to Fmoc-peptideNHCH20Ac (Compounds 16a-16d) [00404] 16a: Compound 15a (2.5 g, 4.9 mmol) was dissolved in anhydrous DMF (40 mL) and magnetically stirred in a 100 mL flask as copper (II) acetate (0.334 g, 1.84 mmol), acetic 15 acid (0.64 mL, 11.1 mmol), and lead tetraacetate (2.5 g, 5.6 mmol) were added.
The flask was heated in a 60 °C oil bath for 15 min.
The oil bath was removed and the reaction was allowed to cool to room temperature.
Approximately½ of the mixture was purified on a 350 g medium pressure C 18 column that was equilibrated with 90: 10 deionized water containing 0.3% formic acid:acetonitrile.
The column was eluted at 100 mL/min with 10% acetonitrile 20 for 5 min then with a linear gradient of 10% acetonitrile from 5 min to 95% acetonitrile at 38 min.
This procedure was repeated for the other½ of reaction mixture and fractions containing desired product 16a were combined, frozen and lyophilized to give 1.2 g of white semi-solid (62% yield). 1HNMR (400 MHz, DMSO-d6) 8 8.86 (t, J= 6.9 Hz, lH), 7.97 (dd, J = 16.1, 7.4 Hz, 2H), 7.89 (dt, J = 7.6, 0.9 Hz, 2H), 7.72 (t, J = 7.1 Hz, 2H), 7.53 (d, J = 7.5 25 Hz, lH), 7.42 (td, J = 7.5, 1.2 Hz, 2H), 7.33 (td, J = 7.5, 1.2 Hz, 2H), 5.13 - 5.01 (m, 2H), 148 WO 2020/219287 PCT /0S2020/027831 4.30 - 4.17 (m, 4H), 4.06 (t, J = 7.3 Hz, lH), 3.32 (s, lH), 1.99 (s, 3H), 1.27 - 1.13 (m, 9H).
MS (ESI): MS (M + Nat calcd. 547.2, found 547.5. [00405] 16b was prepared from Fmoc-Ala-Ala-Gly-OH 15b in 55% yield. MS (M + Na)+ 476.7. s [00406] 16c was prepared from Fmoc-Leu-Gln-Gly-OH 15c in 46% yield. MS (M + Na)+ 575.6. [00407] 16d was prepared from Fmoc-Ala-D-Ala-Ala-Gly-OH 15d in 52% yield. MS (M + Na)+ 547.3.
Example 11.
Method for reacting benzyl-2-hydroxyacetate with Fmoc-peptide- 10 NHCH20Ac (Compounds 17a-17d) [00408] 17a: Compound 16a (142 mg, 0.27 mmol) and benzyl-2-hydroxyacetate (226 mg, 1.36 mmol) were suspended in a solution of 20% TFA in dichloromethane (7 mL) and magnetically stirred at room temperature for 30 min.
Solvent was rotary evaporated under 1s vacuum and the residue was taken up in a minimum volume ofDMF then purified on a 200 g C 18 medium pressure column that was pre-equilibrated with 90: 10 deionized water containing 0.1 % formic acid : acetonitrile.
The column was then eluted at 60 mL/min with 10% acetonitrile for 5 min followed by a linear gradient of 10% acetonitrile from 5 min to 95% acetonitrile at 38 min.
Fractions containing desired product were combined, frozen and 20 lyophilized to give 102 mg of white solid 17a (59% yield). MS (ESI): MS (M + Nat calcd. 653.3, found 653.5. [00409] 17b was prepared from 16b in 61% yield. MS (M + Na)+ 582.7. [00410] 17c was prepared from 16c in 52% yield. MS (M + H)+ 659.5. [00411] 17d was prepared from 16d in 56% yield. MS (M + Na)+ 653.4. 149 WO 2020/219287 PCT /0S2020/027831 Example 12.
Conversion of Fmoc-Peptide-NHCH20CH2COOBn to H-PeptideNHCH20CH2COOBn (Compounds 18a-18d) ,.., H O H 0 o N LI ~N LI O Morpholine V ~N .....,.....N,,..._O~;..-o _, II! H ! H t' ,1 0 • 0 • 0 "" 17a [00412] 18a: Compound 17a (100 mg, 0.16 mmol) was dissolved in DMF (4 mL) to which s morpholine (0.6 mL, 6.9 mmol) was added and magnetically stirred.
After 1 h the reaction mixture was purified on a 200 g Cl8 medium pressure column that was pre-equilibrated with 95:5 deionized water containing 0.1 % formic acid: acetonitrile.
The column was then eluted at 60 mL/min with 5% acetontrile for 5 min followed by a linear gradient of 5% acetonitrile from 5 min to 70% acetonitrile at 38 min.
Fractions containing desired product were 10 combined, frozen and lyophilized to give 50 mg of white solid 18a (76 % yield). MS (ESI): MS (M + Ht calcd. 409.2, found 409.6. [00413] 18b was prepared from 17b in 80% yield. MS (M + H)+ 338.3. [00414] 18c was prepared from 17c in 61 % yield. MS (M + H)+ 437.6. [00415] 18d was prepared from 17d in 61% yield. MS (M + H)+ 409.6. 1s Example 13.
Conversion of H-Peptide-NHCH20CH2COOBn to H-PeptideNHCH20CH2COOH (Compounds 19a-19d) 18a 19a [00416] 19a: In a 100 mL PARR shaker flask, H-Ala-Ala-Ala-NHCH2OCH2COOBn 18a (50 mg, 0.12 mmol) was dissolved in 5:95 deionized water: methanol (50 mL) to which was 20 added 10% palladium on carbon (0.1 g) and reaction was hydrogenated in a PARR shaker at 30 PSI H2 for 1 h.
The solution was vacuum filtered through celite filter aid and solvent was 150 WO 2020/219287 PCT /0S2020/027831 removed from the filtrate by rotary evaporation under vacuum to give 35 mg of desired product 19a as a thick oil (91 % yield). MS (ESI): MS (M + Ht calcd. 319 .2, found 319 .3. [00417] 19b was prepared from 18b in 92% yield. MS (M + H)+ 248.3. [00418] 19c was prepared from 18c in 83% yield. MS (M + H)+ 347.4. s [00419] 19d was prepared from 18d in 81 % yield. MS (M + H)+ 319. 5.
Example 14.
Method for preparing Mal-(CH2)s-CO-PeptideNHCH2OCH2COOH compounds (Compounds 20a-20d) olHo o HolHo H2N0N'r(N0N-o"fo ----.. }-.N~N0N'r(N0N-o"fo : H O : H OH ~ O : H O : H OH 19a O 20a [00420] 20a: Mal-(CH2)s-COONHS 13b (46 mg, 0.15 mmol) was dissolved in anhydrous 10 DMF (2 mL) to which was added DIPEA (0.1 mL, 0.31 mmol) and H-Ala-Ala-AlaNHCH2OCH2COOH 19a (30 mg, 0.093 mmol).
The reaction was magnetically stirred for 15 min then purified on a 50 g Cl8 medium pressure column that was pre-equilibrated with 95:5 deionized water containing 0.1 % formic acid : acetonitrile.
The column was then eluted at 40 mL/min with 5% acetonitrile for 5 min followed by a linear gradient of 5% acetonitrile from 1s 5 min to 90% acetonitrile at 38 min.
Fractions containing desired product were combined, frozen and lyophilized to give 30 mg of white solid 20a (63 % yield). MS (ESI): MS (M - H)· calcd. 510.2, found 510.l. 1HNMR (400 MHz, DMSO-d6) 8 12.16 (s, lH), 8.64- 8.48 (m, lH), 7.97 (dd, J = 7.3, 3.2 Hz, 2H), 7.89 (d, J = 7.5 Hz, lH), 7.00 (s, 2H), 4.3 - 4.7 (m, 4H), 4.21 (dt, J = 10.3, 7.2 Hz, 4H), 3.55 (t, J = 6.4 Hz, 2H), 3.37 (t, J = 7.1 Hz, 2H), 2.41 (t, J = 20 6.4 Hz, 2H), 2.08 (t, J= 7.4 Hz, 2H), 1.47 (p, J= 7.2 Hz, 4H), 1.27- 1.10 (m, 6H). [00421] 20b was prepared from 19b in 83% yield. MS (M + H)+ 441.4. [00422] 20c was prepared from 19c in 83% yield. MS (M-H)- 655.4. 0 0 H2 !-N~13b00 ,N,/(_ 0 : 0 ~I Pd/C O C H O ¼ μ O H O C H O H,NJN~~JN,-,'o°.,-..._..,o-..,)0 ----- H2N-!-N-"yN-!-N......._O-----YOH O O }-N~N0N'°"i(NJN,...__O-----YOH = H g = H g MeOH - H o - H o DMF ~ o O H o O H o 100% o 18d 19d 20d 151 WO 2020/219287 PCT /0S2020/027831 [00423] 20d: To a solution of compound 18d (99.7 mg, 0.24 mmol) in methanol (3 mL) was added Pd (10% on carbon, 26 mg, 0.024 mmol) and the reaction flask was purged with hydrogen.
It was hydrogenated with a hydrogen balloon at room temperature for 3 hours and then filtered.
The filtrate was stripped to give compound 19d as a white solid (78 mg, yield s 100%). 41.9 mg (0.13 mmol) was taken and dissolved in anhydrous DMF (0.5 mL) and 6- maleimidohexanoic acid N-hydroxysuccinimide ester 13b ( 40.6 mg, 0.13 mmol) was added.
The obtained colorless clear solution was stirred at room temperature for 24 hours.
It was stripped under reduced pressure and the residue was purified by reverse phase HPLC (Cl8 column and eluted with CH3CN/H2O, 10 to 50% CH3CN in 15 minutes then then 95% 10 CH3CN for 5 minutes) to give compound 20d (30.8 mg, yield 45%). MS (ESI): m/z 512.4 (M + H)+, 510.4 (M - H)".
Example 15.
Synthesis of Compounds 21a and 21b [00424] 21a: Compound 16a (300 mg, 0.57 mmol) and 6-mercaptohexanoic acid (254 mg, 1s 1.7 mmol) were suspended in a solution of 20% TFA in dichloromethane (10 mL) and magnetically stirred at room temperature for 30 min.
Solvent was rotary evaporated under vacuum and the residue was taken up in a minimum volume ofDMF then purified on a 200 g Cl8 medium pressure column that was pre-equilibrated with 95:5 deionized water containing 0.1% formic acid: acetonitrile.
The column was then eluted at 60 mL/min with 10% 20 acetonitrile for 5 min followed by a linear gradient of 5% acetonitrile from 5 min to 95% acetonitrile at 38 min.
Fractions containing desired product were combined, frozen and lyophilized to give 202 mg of white solid 21a (58 % yield). MS (M + Na)+ 613.9. [00425] 21b was prepared similarly to 21a from 16d and 6-mercaptohexanoic acid in 60 % yield. MS (M + H)+ 613.7. 152 WO 2020/219287 PCT /0S2020/027831 Example 16.
Synthesis of Compound 22a O H O ,¼-H O ~NHO 2 .J-.N~N.__.Jl.N N_,Jl.N-0~0 DMTMM ~ • • g i H O i H 6H I " " N I 0 0 F~N...-. ~ ✓ O 20a 6a -..., OH 0 H O l H 0 ~N0N'l'(N0N-O~O 0 o•Ho•N~HOH 22a --:--: N O I.-,: ,,. :.-- I F N _,. OH 0 [00426] 22a: Compound 6a (20 mg, 0.049 mmol) and DMTMM (18 mg, 0.065 mmol) in 85:15 DMF:deionized water (0.8 mL) were magnetically stirred as 20a (35 mg, 0.068 mmol) s and TEA (0.04 mL, 0.28 mmol) were sequentially added.
After lh the reaction mixture was loaded onto a 50 g medium pressure silica column that was equilibrated with dichloromethane and run at 30 mL/min with dichloromethane using a linear gradient of 0% to 100% of 20% methanol in dichloromethane over 40 min.
Fractions containing pure product were combined and solvent was removed by rotary evaporation under vacuum to give 16 mg 10 of a brown solid 22a (36 % yield). MS (M + Na)+ 925.6. 1HNMR (400 MHz, DMSO-d6) 8 0.88 (t, J= 7.3 Hz, 3H), 1.11-1.23 (m, 15H), 1.46 (p, J= 7.3 Hz, SH), 1.79-1.95 (m, 2H), 2.07 (t, J = 7.4 Hz, 2H), 3.04 - 3.16 (m, 2H), 3.88 (s, 2H), 4.18 (dd, J = 7.1, 11.0 Hz, 2H), 4.50 - 4.65 (m, 2H), 4.86 (d, J = 5.9 Hz, 2H), 5.44 (s, 2H), 5.49 (s, 2H), 6.53 (s, lH), 7.00 (s, 2H), 7.32 (s, lH), 7.91 (d, J = 10.0 Hz, lH), 7.97 (d, J = 7.0 Hz, 2H), 8.43 (d, J = 8.3 Hz, 1s lH), 8.65 (t, J = 6.6 Hz, lH), 8.73 (t, J = 5.9 Hz, lH). 13C NMR (101 MHz, DMSO-d6) 8 180.20, 173.96, 172.96, 172.89, 172.56, 172.36, 171.54, 170.03, 163.99, 157.27, 156.21, 152.90, 150.48, 145.85, 139.87, 134.92, 129.28, 128.06, 124.24, 119.65, 97.28, 72.84, 70.18, 67.29, 65.74, 50.53, 48.81, 48.68, 48.60, 46.26, 41.01, 37.44, 35.26, 30.71, 28.24, 26.23, 25.09, 18.33, 18.24, 18.18, 15.77, 15.74, 9.12, 8.21. HRMS (M + Ht calcd. 903.3688, found 20 903.3676.
Example 17.
Synthesis of Compound 22c O HOcHO )-. N~N ._,.,.llN"lf' N ..)lN,--..0-"i(OH \_{ 0 C H O C H 0 20d 153 DMTMM NMM DMF/H20 (5:1) WO 2020/219287 PCT /0S2020/027831 [00427] 22c: To the solution of 6a (8 mg, 0.02 mmol) in DMF (0.5 mL) was added NMM (2.2 μL, 0.02 mmol) and compound 20d (10 mg, 0.02 mmol).
The solution was cooled to 0 0c with an ice bath and DMTMM (10.8 mg, 0.04 mmol) in deionized water (0.1 mL) was added.
The ice bath was removed and the reaction mixture was stirred at room temperature 5 for 3 hours.
The reaction solution was stripped under reduced pressure (35 °c bath) and the residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 95% CH3CN in 12 minutes then at 95% CH3CN for 5 minutes).
The product fractions were combined and lyophilized to give a white solid.
It was further purified by silica gel chromatography ( 4 g silica column, CH2Ch/MeOH, 0 to 20% MeOH in 15 10 minutes) to give the desired product 22c (9.8 mg, yield 55%). MS (ESI): m/z 903.9 (M + Ht, 901.9 (M-H)", 947.9 (M + HCOOH-H)".
Example 18.
Synthesis of Compound 22b 20a DMTMM NMM DMF/H20 (5:1) [00428] 22b: To the solution of 6c (10.7 mg, 0.022 mmol) in DMF (0.5 mL) was added 15 NMM (2.4 μL, 0.022 mmol) and compound 20a (11 mg, 0.022 mmol).
The solution was cooled to O 0c with an ice bath and DMTMM (11.9 mg, 0.043 mmol) in deionized water (0.1 mL) was added.
The ice bath was removed and the reaction mixture was stirred at room temperature for 3 hours.
The reaction solution was stripped under reduced pressure (35 °c bath) and the residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 20 25% CH3CN for 3 minutes then to 95% CH3CN in 12 minutes then at 95% CH3CN for 5 minutes) to give the desired product 22b (4 mg, yield 18%). MS (ESI): m/z 1015.9 (M + Na)+, 991.9 (M-H)", 1037.9 (M + HCOOH-H)".
Example 19.
Synthesis of Compound 22d [00429] 22d: Prepared similarly to 22c by the reaction of 6c with 20d (22% yield). MS 25 (ESI): m/z 1015.8 (M + Nat Example 20.
Synthesis of Compound 22e 154 WO 2020/219287 Ho " o )--N............,..N.....-0..........,.o............._.o .... NA.._ o o 13d o μ 6a, DMTMM in DMF/H2O PCT /0S2020/027831 [00430] 22e: The solution of compound 18c (15.2 mg, 0.035 mmol) in methanol (2 mL) was added Pd (10% on carbon, 3.7 mg, 0.0035 mmol) and the reaction flask was purged with hydrogen.
It was hydrogenated with a hydrogen balloon at room temperature for 3 hours and s then filtered.
The filtrate was stripped to give compound 19c as a colorless foam.
It was dissolved in anhydrous DMF (0.3 mL) and 13d (15.9 mg, 0.03 mmol) was added.
The obtained colorless clear solution was stirred at room temperature for 15 hours.
It was diluted with DMF (0.2 mL) followed by addition of 6a (15.3 mg, 0.037 mmol) and NMM (4.lμL, 0.037 mmol). DMTMM (20.7 mg, 0.075 mmol) in deionized water (0.1 mL) was then added 10 and the reaction solution was stirred at room temperature for 1.5 hours.
The reaction mixture was stripped under reduced pressure and the residue was purified by silica gel chromatography (CH2Ch/MeOH, 0 to 20% MeOH) to give desired 22e (10 mg, yield 26% ).
MS (ESI): m/z 1049.1 (M + H)+, 1093.2 (M + HCOOH-H)".
Example 21.
Synthesis of Compound 23a DMTMM/NMM Sa [00431] 23a: To the solution of 6a (32 mg, 0.078 mmol) in DMF (0.8 mL) was added NMM (8.6 μL, 0.078 mmol) and the Fmoc protected L-Ala-L-Ala-L-Ala tripeptide linker 21a (53 mg, 0.078 mmol) followed by the addition ofDMTMM (43 mg, 0.156 mmol) in deionized water (0.16 mL).
The reaction mixture was stirred at room temperature for 2 hours.
The 20 reaction solution was stripped under reduced pressure and the residue was purified by silica gel chromatography (4 g column, CH2Ch/MeOH, 0 to 20% MeOH in 15 minutes) to give the desired compound 23a (78 mg, yield 99%). MS (ESI): m/z 1004.5 (M + Ht, 1026.6 (M + Na)+, 1048.4 (M + HCOOH-H)".
Example 22.
Synthesis of Compound 24a 155 WO 2020/219287 morpholine DMF PCT /0S2020/027831 [00432] 24a: To the solution of compound 23a (78 mg, 0.078 mmol) in anhydrous DMF (1 mL) was added morpholine (0.24 mL, 2.7 mmol) and the reaction mixture was stirred at room temperature for 2 hours.
The reaction solution was stripped under reduced pressure and the s residue was purified by silica gel chromatography ( 4 g silica column, eluted with CH2Ch/MeOH, 0 to 20% MeOH in 9 minutes then 20% MeOH for 11 minutes) to give the desired compound 24a (39.6 mg, yield 65%). MS (ESI): m/z 782.4 (M + Ht, 780.0 (M - H)".
Example 23.
Synthesis of Compound 25a }-N~o.NJ( ~o 13b o 0)-J 10 [00433] 25a: To the solution of the compound 24a (20 mg, 0.026 mmol) in anhydrous DMF (0.3 mL) was added 13b (9.6 mg, 0.031 mmol) and the reaction mixture was stirred at room temperature for 4 hours.
The reaction solution was diluted with DMSO and purified by reverse phase semi-prep HPLC (Cl8 column, eluted with CH3CN/H2O, 25% to 55% CH3CN in 23 minutes then 95% CH3CN for 7 minutes).
The fractions containing 25a were combined 1s and lyophilized to give 25a as a white solid.
It was further purified by silica gel chromatography ( 4 g silica column, CH2Ch/MeOH, 0 to 20% MeOH in 15 minutes) to give the desired 25a (7.7 mg, yield 30%). MS (ESI): m/z 975.8 (M + H)+, 997.8 (M + Na)+, 773.7 (M-H)", 1019.7 (M + HCOOH-H)".
Example 24.
Synthesis of Compound 23b o , H o DMTMM/NMM FmocHNJ ,.:...__,.NJ ,,..._ ~o ~ ~ ~ ~ ~ s 6H DMF/H20 (5 1) 21b 156 0 , H 0 FmocHN~N'°"yN~N,,..._S~O : H O : H NH 23b F WO 2020/219287 PCT /0S2020/027831 [00434] 23b: To a solution of 6a (31 mg, 0.076 mmol) in DMF (0.8 mL) was added NMM (8.3 μL, 0.076 mml) and 21b (46.4 mg, 0.076 mmol).
The solution was cooled to O 0c with an ice bath and DMTMM (48 mg, 0.16 mmol)) in deionized water (0.16 mL) was added.
The ice bath was removed and the reaction mixture was stirred at room temperature for 2.5 hours. s The reaction solution was stripped under reduced pressure and the residue was purified by silica gel chromatography (4 g silica column, CH2Ch/MeOH, 0 to 20% MeOH in 15 minutes) to give the desired product compound 23b (31 mg, yield 40%). MS (ESI): m/z 1004.6 (M + H)+, 1048.7 (M + HCOOH-H)".
Example 25.
Synthesis of Compound 24b 0 , H 0 FmocHN-;t-N~N-;t-N-----s~o = H O = H NH 23b morpholine DMF [00435] 24b: To a solution of 23b (31 mg, 0.031 mmol) in anhydrous DMF (0.4 mL) was added morpholine (95 μL, 1.08 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours.
The reaction solution was stripped under reduced pressure and the residue was purified by silica gel chromatography ( 4 g silica column, eluted with 1s CH2Ch/MeOH, 0 to 20% MeOH in 15 minutes then 20% MeOH for 5 minutes) to give product compound 24b (18 mg, yield 75%). MS (ESI): m/z 782.5 (M + H)+, 780.2 (M - H)", 826.4 (M + HCOOH - H)".
Example 26.
Synthesis of Compound 25b o Ho,Ho )-.N~N~N'°'yN~N-----s~O ¼O O = H O = H ~N0H 25b "" "" N I 0 F I,;; N~ 'S-. -· 0 __ , OH 20 [00436] 25b: To a solution of 24b (12.3 mg, 0.016 mmol) in anhydrous DMF (0.3 mL) was added 5-maleimidohexanoic acid N-hydroxysuccinimide ester 13b (7.3 mg, 0.024 mmol) and the reaction mixture was stirred at room temperature for 4 hours.
The reaction solution was 157 WO 2020/219287 PCT /0S2020/027831 stripped under reduced pressure and the residue was purified by silica gel chromatography ( 4 g column, CH2Cl2/MeOH, 0 to 20% MeOH in 15 minutes) to give 3.2 mg 25b and another 6.5 mg impure product.
The impure product was further purified by semi-prep reverse phase HPLC (Cl8 column, eluted with CH3CN/H2O, 25% to 55% CH3CN in 23 minutes then 95% s CH3CN for 7 minutes to give 2.8 mg 25b.
In total 6 mg of 25b was isolated (39% yield).
MS (ESI): m/z 975.6 (M + H)+, 997.6 (M + Na)+, 973.7 (M-H)", 1019.6 (M + HCOOH-H)".
Example 27.
Synthesis of Compound 26a HCI etherate DMF 16a [00437] 26a: To a stirring solution of Sa (58 mg, 0.106 mmol) and compound 16a (55.8 mg, 10 0.106 mmol) in anhydrous DMF (1.5 mL) was added HCl etherate (2 M HCl diethyl ether solution, 64 μL, 0.128 mmol).
After stirred 22 hours at room temperature, the reaction solution was stripped under reduced pressure (35 °cheating bath).
The residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 90% CH3CN in 12 minutes then 90% CH3CN for 3 minutes) to give compound 26a as a 1s white solid (47 mg, yield 48%). MS (ESI): m/z cald. 917.4, found 917.6 (M + H)+, 961.5 (M + HCOOH - H)".
Unreacted Sa was also recovered (12 mg).
Example 28.
Synthesis of Compound 27a morpholine (5 eq) DMF [00438] 27a: To a stirring solution of compound 26a (57 mg, 0.062 mmol) in anhydrous 20 DMF (0.8 mL) was added morpholine (27 μL, 0.31 mmol).
After stirred at room temperature for 6 hours, the reaction solution was stripped under reduced pressure.
The residue was purified by reverse phase HPLC (30 g Cl8 column and eluted with CH3CN/H2O, 20% CH3CN for 3 minutes then to 90% CH3CN in 15 minutes then 90% CH3CN for 3 minutes) to 158 WO 2020/219287 PCT /0S2020/027831 give compound 27a as an off-white solid (35.9 mg, yield 83%). MS (ESI): m/z 695.5 (M + H)+, 739.3 (M + HCOOH - H)".
Example 29.
Synthesis of Compound 28a s [00439] 28a: To a solution of compound 27a (18 mg, 0.026 mmol) in anhydrous DMF (0.3 mL) was added 5-maleimidohexanoic acid N-hydroxysuccinimide ester 13b (12 mg, 0.039 mmol) and NMM (3.1 μL, 0.028 mmol).
After stirred at room temperature for 4 hours the reaction solution was stripped under reduced pressure.
The residue was purified by reverse phase HPLC (30 g Cl8 column, eluted with CH3CN/H2O, 18 minutes run, 20% CH3CN for 3 10 minutes, then 20% to 90% CH3CN in 12 minutes then 90% CH3CN for 3 minutes) to give product 28a as a white solid (11.9 mg, yield 51 % ). MS (ESI): m/z 888.5 (M + H)+, 932.5 (M + HCOOH - H)". 1H NMR (400 MHz, DMSO-d6) 8 8.45 (t, J = 6.7 Hz, lH), 8.11 (d, J = 8.2 Hz, lH), 7.90 (t, J = 7.5 Hz, 2H), 7.78 (dd, J = 15.2, 9.1 Hz, 2H), 7.22 (s, lH), 6.92 (s, 2H), 6.45 (s, lH), 5.36 (s, 2H), 5.17 (s, 2H), 4.54 - 4.38 (m, 2H), 4.15 - 4.09 (m, 2H), 3.38 - 3.33 1s (m, lH), 3.32 - 3.21 (m, lH), 3.15 - 3.06 (m, lH), 2.50 - 2.42 (m, 3H), 1.99 (t, J = 7.4 Hz, 2H), 1.79 (h, J = 7.0 Hz, 2H), 1.67 - 1.55 (m, 6H), 1.38 (p, J = 7.4 Hz, SH), 1.15 - 1.04 (m, 12H), 0.81 (t, J= 7.4 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) 8 174.54, 173.86, 171.34, 171.26, 170.84, 170.79, 170.47, 170.15, 161.42, 158.95, 155.71, 155.16, 150.43, 148.38, 146.97, 146.80, 144.22, 142.23, 129.03, 126.25, 125.69, 125.48, 124.98, 124.50, 122.77, 20 122.48, 117.29, 111.01, 110.78, 95.09, 70.75, 70.67, 67.55, 65.17, 63.64, 48.03, 46.55, 33.20, 28.68, 27.46, 26.96, 25.04, 24.55, 24.05, 23.06, 22.84, 16.39, 16.14, 13.54, 6.13, 5.98; HRMS (M + Ht calcd. 888.3943, found 888.3966. 159 WO 2020/219287 PCT /0S2020/027831 Example 30.
Synthesis of Compound 26b HO ,YH 0 NJ,,..__ FmocHN =: ~ 0 0 - 16b 26b F [00440] 26b: To a stirring solution of Sa (73 mg, 0.14 mmol) and compound 16b (64 mg, 0.14 mmol) in anhydrous DMF (1.2 mL) was added HCl etherate (2 M HCl diethyl ether s solution, 0.14 mL, 0.28 mmol).
After stirring 6 hat room temperature, the reaction solution was stripped under reduced pressure (35 °cheating bath).
The residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 90% CH3CN in 12 min then 90% CH3CN for 3 min) to give compound 26b as an off-white solid (60 mg, yield 50%). MS (ESI): m/z 846.4 (M + H)+, 890.3 (M + HCOOH - H)". 10 Example 31.
Synthesis of Compound 26c HCI etherate (1.8 eq) DMF YH O FmocHN -'-y N -.;i.N.,.._O 0 = H 26c [00441] 26c: To a stirring solution of Sa (36 mg, 0.08 mmol) and 16c (40.2 mg, 0.084 mmol) in anhydrous DMF (0.6 mL) was added HCl etherate (2 M HCl diethyl ether solution, 72 μL, 0.43 mmol).
After stirred 15 hat room temperature, the reaction solution was stripped under 1s reduced pressure (35 °cheating bath).
The residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 25% CH3CN for 3 minutes then to 95% CH3CN in 12 min then 95% CH3CN for 3 min) to give compound 26c as a white solid (41.9 mg, yield 60%). MS (ESI): m/z 874.4 (M + H)+, 918.5 (M + HCOOH- H)".
Unreacted Sa was also recovered (12 mg). 20 Example 32.
Synthesis of Compound 27b 160 WO 2020/219287 morpholine (5 eq) DMF PCT /0S2020/027831 [00442] 27b: To a stirring solution of compound 26b (60 mg, 0.071 mmol) in anhydrous DMF (0.4 mL) was added morpholine (31 μL, 0.36 mmol).
After stirred at room temperature for 3.5 hours, the reaction solution was stripped under reduced pressure.
The residue was 5 purified by reverse phase HPLC (15.5 g Cl8 column and eluted with CH3CN/H2O, 10% CH3CN for 3 minutes then to 90% CH3CN in 9 minutes then 90% CH3CN for 3 minutes) to give compound 27b as an off-white solid (36.7 mg, yield 83%). MS (ESI): m/z 624.5 (M + H)+, 668.3 (M + HCOOH - H)".
Example 33.
Synthesis of Compound 27c morpholine (5 eq) DMF [00443] 27c: To a stirring solution of compound 26c (41.9 mg, 0.048 mmol) in anhydrous DMF (0.4 mL) was added morpholine (21 μL, 0.24 mmol).
After stirring at room temperature for 5 h, the reaction solution was stripped under reduced pressure.
The residue was purified by reverse phase HPLC (30 g Cl8 column and eluted with CH3CN/H2O, 20% CH3CN for 3 15 min then to 90% CH3CN in 12 min then 90% CH3CN for 5 min) to give compound 27c as a white solid (25.5 mg, yield 82%). MS (ESI): m/z 652.5 (M + H)+, 650.2 (M - H)". 696.2 (M + HCOOH-H)".
Example 34.
Synthesis of Compound 28b 14a 27a 161 WO 2020/219287 PCT /0S2020/027831 [00444] 28b: To a stirring solution of the compound 27a (18 mg, 0.026 mmol) and 14a (18.5 mg, 0.039 mmol) in anhydrous DMF (0.2 mL) was added DMTMM (17 mg, 0.052 mmol) and NMM (2.9 μL, 0.026 mmol) at room temperature.
After stirred at room temperature for 19 h, the reaction solution was stripped under reduced pressure (bath temperature 35 °C) and s the residue was purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 20% CH3CN for 3 minutes then to 90% CH3CN in 12 min then 90% CH3CN for 3 min).
The fractions that contained product were combined and lyophilized to give 28b as a white solid (2.3 mg, 7% yield). MS (ESI): m/z 1152.5 (M + H)+, 1150.0 (M - H)", 1196.5 (M + HCOOH -H)". 10 Example 35.
Synthesis of Compound 28c ,YH 0 N..._)l..--.... H2N , N 0 0 = H 27b DMTMMT NMM DMF [00445] 28c: To a stirring solution of 27b (36.7 mg, 0.059 mmol) and14a (42 mg, 0.088 mmol) in anhydrous DMF (0.6 mL) was added DMTMM (39 mg, 0.12 mmol) and NMM (3.2 μL, 0.029 mmol) at room temperature.
After stirring at room temperature for 5 h, the 1s reaction solution was directly loaded on a Cl8 cartridge and purified by reverse phase HPLC (30 g Cl8 column, CH3CN/H2O, 20% CH3CN for 3 minutes then to 90% CH3CN in 12 min then 90% CH3CN for 3 min).
The fractions that contained product were combined and lyophilized to give 28c as a white solid (9.9 mg, yield 15%). MS (ESI): m/z 1081.5 (M + H)+, 1079.2 (M-H)", 1025.5 (M + HCOOH-H)". 20 Example 36.
Synthesis of Compound 28d 27c 0 O 0 {('-•·;~ 0l) ~~~~)-N"o 0 0 O H 0 =H DMF rt, 4 h 162 28d WO 2020/219287 PCT /0S2020/027831 [00446] 28d: To the solution of 27c (10.5 mg, 0.016 mmol) in anhydrous DMF (0.2 mL) was added 5-maleimidohexanoic acid N-hydroxysuccinimide ester 13b (6 mg, 0.019 mmol) and NMM (2.1 μL, 0.019 mmol).
After stirring at room temperature for 4 h the reaction solution was stripped under reduced pressure.
The residue was purified by reverse phase HPLC (30 g s Cl8 column, eluted with CH3CN/H2O, 18 minutes run, 20% CH3CN for 3 minutes, then 20% to 90% CH3CN in 12 minutes then 90% CH3CN for 3 minutes) to give product 28d as a white solid (8.7 mg, yield 63%). MS (ESI): m/z 845.4 (M + Ht, 989.4 (M + HCOOH- H)".
Example 37.
Synthesis of Compound 29a TFA %o}Ho}H O)l~/''i(~~/)'N-./S~ 29a I"" "" F .& N...-:: 10 [00447] 29a: Compound 16a (30 mg, 0. 057mmol) and 8d (50 mg, 0.1 mmol) were suspended in a solution of 20% TFA in dichloromethane (10 mL) and magnetically stirred at room temperature for 30 min.
Solvent was rotary evaporated under vacuum and the residue was taken up in a minimum volume ofDMF then purified on a 100 g Cl8 medium pressure column that was pre-equilibrated with 90: 10 deionized water containing 0.1 % formic acid : 1s acetonitrile.
The column was then eluted at 30 mL/min with 10% acetontrile for 5 min followed by a linear gradient of 10% acetonitrile from 5 min to 95% acetonitrile at 38 min.
Fractions containing desired product were combined, frozen and lyophilized to give 31 mg of white solid 29a (56 % yield). MS (M + Na)+ 987.5.
Example 38.
Synthesis of Compound 30a %0)lN~~')lN~~___,.,Sl--, H o I H o S 29a I"" "" ,-:; N" Morpholine H2N~~)LN~~---.,-,S~ 0 = H O S 30a F [00448] 30a: Compound 29a (28 mg, 0.029 mmol) was dissolved in anhydrous DMF (0.8 mL) and magnetically stirred as morpholine (0.2 mL) was added.
After 1 h the reaction mixture was directly loaded on a 100 g Cl8 cartridge 25:75 CH3CN/H2O, run at 50 mL/min 163 WO 2020/219287 PCT /0S2020/027831 25% CH3CN for 3 minutes then with a linear gradient to 90% CH3CN from 3 - 23 min.
Fractions containing desired product were combined, frozen and lyophilized to give 18 mg (83 % yield) of 30a as a yellow solid. MS (M + H)+ 743.5.
Example 39.
Synthesis of Compound 32a QO H 0 N~Ny1-0H 0 0 = OH OH 'i HO~NAO OH OH 114a DMTMM TEA [00449] 32a: Compound 30a (16 mg, 0.02 mmol) was dissolved in 84:16 DMF:deionized water (0.5 mL) to which DMTMM (15 mg, 0.054 mmol), TEA ( 0.02 mL, 0.14 mmol) and 14a (20 mg, 0.042 mmol) were quickly added and magnetically stirred.
After 35 min the reaction mixture was loaded on a 100 g silica cartridge preequilibrated with dichloromethane 10 then run at 35 mL/min with a linear gradient from 0% to 100% over 30 min of 40:60 methanol:dichloromethane.
Fractions containing desired product were combined and solvent was evaporated under vacuum to give 7 mg (29 % yield) of 32a as a thick oil. MS (M + Na)+ 1223.0.
Example 40.
Synthesis of Compound 33a [00450] 33a: To a solution of 4c (11 mg, 0.021 mmol) in anhydrous DMF (0.2 mL) was added sodium thiomethoxide (3.6 mg, 0.052 mmol) and the reaction mixture was stirred at room temperature for 18 hours.
The reaction solution was directly loaded on a 30g Cl8 cartridge 25:75 CH3CN/H2O, run at 20 mL/min 25% CH3CN for 3 minutes then with a linear 20 gradient to 90% CH3CN from 3 - 12 min.
Fractions containing desired product were 164 WO 2020/219287 PCT /0S2020/027831 combined and evaporated under vacuum to give compound 33a as a white solid (3 .1 mg, yield 30%). MS (ESI): m/z 483.4 (M + H)+, 481.3 (M- H)".
Example 41.
Synthesis of Compound 34a and Compound 34b VO(acac) tBuOOH + s [00451] 34a and 34b: Compound Sc (30 mg, 0.064 mmol) was magnetically stirred in DMF (1 mL) to which vanadium acetylacetonate (3 mg, 0.008 mmol) and a solution of 5 M tertbutyl hydroperoxide in decane (0.05 mL, 0.25 mmol) were added.
After 5 min the solution was directly loaded on a 30 g Cl8 cartridge 25:75 CH3CN/H2O, run at 20 mL/min 25% CH3CN for 3 minutes then with a linear gradient to 90% CH3CN from 3 - 12 min.
Fractions 10 containing pure 34a were combined separately from fractions containing pure 34b and both were separately frozen and lyophilized to give 6 mg 34a (19% yield) and 15 mg 34b (47% yield) both as yellow solids. 34a MS (M + H)+ 487.4, 34b MS (M + H)+ 503.6.
Example 42.
Synthesis of Compound 35a Br~ O NH O MeSNa Mes~ O NH O DMF F 0 _, OH 4e F __, OH 0 35a 1s [00452] 35a: To a solution of compound 4e (17 mg, 0.025 mmol) in anhydrous DMF (0.3 mL) was added sodium thiomethoxide (7 mg, 0.1 mmol) and the reaction mixture was stirred at room temperature for 24 hours.
The reaction solution was diluted with DMSO and injected on the semi-prep HPLC for purification (Cl8 column, CH3CN/H2O, 25% to 65% CH3CN in 23 minutes) to give the desire product 35a (2.7 mg, yield 19%). MS (ESI): m/z 554.4 (M + 20 H)+, 552.5 (M - H)".
Example 43.
Synthesis of Compound 29b 165 WO 2020/219287 PCT /0S2020/027831 [00453] 29b: Compound 16a (30 mg, 0. 057mmol) and Se (50 mg, 0.1 mmol) were suspended in a solution of 20% TFA in dichloromethane (10 mL) and magnetically stirred at room temperature for 30 min.
Solvent was rotary evaporated under vacuum and the residue s was taken up in a minimum volume ofDMF then purified on a 100 g Cl8 medium pressure column that was pre-equilibrated with 90: 10 deionized water containing 0.1 % formic acid : acetonitrile.
The column was then eluted at 30 mL/min with 10% acetonitrile for 5 min followed by a linear gradient of 10% acetonitrile from 5 min to 95% acetonitrile at 38 min.
Fractions containing desired product were combined, frozen and lyophilized to give 31 mg of 10 white solid 29b (56 % yield). MS (ESI): MS (M + Nat calcd. 973.3, found 973.7.
Example 44.
Synthesis of Compound 30b Morpholine [00454] 30b: Compound 29b (28 mg, 0.029 mmol) was dissolved in anhydrous DMF (0.8 mL) and magnetically stirred as morpholine (0.2 mL, 2.32 mmol) was added.
After 1 h the 1s reaction mixture was directly loaded on a 100 g Cl8 cartridge 25:75 CH3CN/H2O, run at 50 mL/min 25% CH3CN for 3 min then with a linear gradient to 90% CH3CN from 3 - 23 min.
Fractions containing desired product were combined, frozen and lyophilized to give 18 mg (83 % yield) of30b as a yellow solid. 1HNMR (400 MHz, DMSO-d6) 8 8.52 (t, J= 6.3 Hz, lH), 8.31 (d, J = 8.3 Hz, lH), 8.11 (d, J = 7.4 Hz, 2H), 7.87 (t, J = 9. l Hz, 2H), 7.69 (d, J = 20 7.5 Hz, lH), 7.37 (t, J = 7.4 Hz, lH), 7.31 (t, J = 3.7 Hz, 2H), 5.43 (s, 2H), 5.31 (s, 2H), 4.47 (d, J = 2.6 Hz, 2H), 4.32 - 4.09 (m, 4H), 3.69 (t, J = 4.6 Hz, 2H), 3.36 (q, J = 6.9 Hz, lH), 2.84 (s, 4H), 2.61 - 2.54 (m, 3H), 2.46 - 2.42 (m, 4H), 1.94 - 1.75 (m, 2H), 1.17 (dd, J = 7.2, 3.4 Hz, 6H), 1.12 (d, J= 6.8 Hz, 3H), 0.87 (t, J= 7.3 Hz, 3H). MS (ESI): MS (M + Ht calcd. 729.3, found 729.4. 166 WO 2020/219287 PCT /0S2020/027831 Example 45.
Synthesis of Compound 32b [00455] 32b: Compound 30b (16 mg, 0.02 mmol) was dissolved in 84: 16 DMF:deionized water (0.5 mL) to which DMTMM (15 mg, 0.054 mmol), TEA ( 0.02 mL, 0.14 mmol) and s 14a (20 mg, 0.042 mmol) were quickly added and magnetically stirred.
After 35 min the reaction mixture was loaded on a 100 g silica cartridge preequilibrated with dichloromethane then run at 35 mL/min with a linear gradient over 30 min from 0% to 100% of 40:60 methanol:dichloromethane.
Fractions containing desired product were combined and solvent was evaporated under vacuum to give 7 mg of 32b (29 % yield) as a thick oil. 1H NMR ( 400 10 MHz, DMSO-d6) 8 7.86 - 7.83 (m, lH), 7.71 (s, lH), 7.69 (d, J = I. 1 Hz, lH), 7.66 (d, J = 8.2 Hz, lH), 7.51 - 7.47 (m, 2H), 7.28 (t, J = 1.0 Hz, lH), 6.61 (s, 2H), 5.59-5.53 (m, lH), 5.40 (dd, J = 3.3, 1. 1 Hz, 2H), 5.29-5.26 (m, 2H), 4.72 (s, 2H), 4.52-4.46 (m, lH), 4.38 (s, lH), 4.35 (dd, J = 3.5, 1.8 Hz, 2H), 4.28-4.22 (m, 2H), 4.21 - 4.13 (m, 2H), 3.74 (t, J = 6.5 Hz, 2H), 3.70 (ddd, J = 11.9, 5.7, 4.8 Hz, lH), 3.60 - 3.51 (m, 2H), 3.44 (dd, J = 11.9, 4.9 1s Hz, lH), 3.3 (broads, 8H), 3.20 (dd, J = 4.7, 3.7 Hz, 2H), 2.91 (s, 3H), 2.89 (s, 3H), 2.56 (td, J = 6.4, 1.7 Hz, 2H), 2.31 (s, 3), 2.37 - 2.21 (m, 2H), 2.07 - 1.82 (m, 3H), 1.72 (dq, J = 13.7, 8.1 Hz, lH), 1.53 (d, J= 5.5 Hz, 6H), 1.45 (d, J= 5.9 Hz, 3H), 0.86 (t, J= 8.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) 8174.75, 174.58, 172.85, 172.75, 172.45, 171.62, 171.37, 169.30, 163.44, 160.52, 157.18, 149.96, 148.73, 147.39, 147.32, 142.26, 132.98, 131.74, 20 127.54, 127.38, 127.24. 126.88, 124.90, 124.84, 124.34, 122.88, 118.32, 116.83, 116.67, 97.97, 74.87, 73.80, 72.41, 72.34, 69.44, 65.10, 62.94, 53.02, 50.02, 49.92, 49.62, 48.46, 45.53, 42.38, 40.85, 35.32, 35.13, 34.00, 32.31, 32.24, 30.20, 26.63, 20.49, 17.81, 17.71, 17.61, 7.68. HRMS (M + Ht calcd. 1186.4237, found 1186.4220. 167 WO 2020/219287 PCT /0S2020/027831 Example 46.
General method for the preparation of conjugates 0 H O l H 0 q~N0N'r(N0N-o"f'o O ' H O ' H NH 0 0 TCEP Ab -------- Ab'SH ------------------ 0 H O l H 0 Ab s~~N0N'r(N0N-o"f'o O • H O • H NH O 0 DAR ML-66-22a Ab = huML66
[00456] Humanized IgG 1 antibodies such as anti-epidermal growth factor (ML66), anti-folate receptor a (FRa) and the chimeric antibody that binds to Kunitz soybean trypsin inhibitor s (KTI) were generated.
Conjugation of antibodies to maleimide-bearing payloads were performed as described for the preparation of ML66-22a.
The resulting conjugates will be designated herein as target binder-payload, for example ML66 conjugated to 22a is ML66- 22a Example 47.
Synthesis of ML66-22a 10
[00457] ML66-22a: ML66 at 5 mg/ml was treated with 7.0 equivalents of TCEP in 50mM EPPS pH7.4, 5 mM EDTA at 37°C for 1-1.5 hrs.
The mixture was then cooled to room temperature.
The conjugation reaction between antibody and the payload was performed at 2 mg/ml by adding 15-20 equivalents of 22a dissolved in DMSO in buffer (50mM EPPS, pH7.4) containing 20% DMSO, and spinning on a tube rotator for 1.5-2.5 hrs at room 1s temperature.
The reaction mixture was immediately purified into formulation buffer (10 mM acetate, 9% sucrose, 0.01 % Tween-20, pH 5.0) using NAP desalting columns (Illustra Sephadex G-25, GE Healthcare).
The resulting conjugate had a drug to antibody ratio (DAR) of 7.5, and was 99 % monomeric measured by size exclusion chromatography.
[00458] Biophysical evaluations for inter-chain high DAR conjugate, including determination 20 of conjugate concentration, yield, DAR ( drug to antibody ratio), free drug, percent monomer 168 WO 2020/219287 PCT /0S2020/027831 and DAR distribution, were carried out.
The conjugate concentration was determined to have a final protein concentration of 4.5 mg/ml (via UV-Vis using extinction coefficient E2so= 205520 M"1cm·1 ), DAR 7.5 (via UV-Vis using extinction coefficients E2so= 10764 M"1cm·1, £370= 20982 M"1cm·1 for 22a), 99 % monomer (via size exclusion UPLC protein BEH SEC 5 column), <l % free drug (via Hi SEP HPLC column), and mostly homogenous 8 drug linked per antibody (via Q-ToF Mass Spectrometry, and Butyl-NPR HIC chromatography).
The yield for this specific inter-chain conjugation ML66-22a was 75%.
[00459] UPLC protein BEH SEC Method: The monomer percentage analysis was carried out on a Waters Acquity UPLC H-class system equipped with an Acquity UPLC protein BEH 10 SEC column (200A, l.7um, 4.6mm x 150 mm, part# 186005225).
The mobile phase was 400 mM sodium perchloride, 50mM sodium phosphate, 5% IPA, pH7.0, flow rate 0.30 mL/min, run time 20 min.
[00460] HiSep HPLC Method: The free drug percentage analysis was performed on Agilent HPLC system equipped with a Supelco analytical HiSep column (25cm x 4.6mm, Sum, Cat# 15 58919).
The mobile phase consisted of0.l M ammonium, pH 7.0 (solvent A) and acetonitrile (solvent B).
The method was run at 0.70 mL/min with solvent A, using a linear gradient starting from 25% solvent B to 40% solvent B from 0 - 25 min.
Example 48.
In vitro cytotoxicity assay
[00461] Cytotoxic potencies were assessed in flat-bottomed 96 well plates (Costar) using a 20 water-soluble tetrazonium salt (WST-8) based cell viability assay (Dojindo, Molecular Technologies, Inc.) as previously described (Kovtun YV, et al.
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Cancer Res 2010;70(6):2528-37).
Briefly, human tumor cells (1,000-5,000 cells/well, depending on the cell line), in the appropriate culture medium were incubated, with conjugates in the presence or absence of an 25 excess of the corresponding unconjugated antibodies, or with the metabolites for 5 days, at 37 °C, 6% CO2.
Cell viability was determined from background-corrected WST-8 absorbance.
[00462] The results of this study are summarized in the following tables. FIG. 12 depicts the cytotoxicity of the sulfide-bearing compound Sc and its sulfoxide 34a and sulfone 34b. 169 WO 2020/219287 PCT /0S2020/027831 Table 7 A.
In vitro cytotoxicities (ICso values) of non-conjugated compounds Cell Lines (Compound concentrations Molar) Compound Namalwa KB N-Luc SUDHL-1 HSC-2 MDA-MB-468 998 3.E-10 4.E-10 2.E-10 l.E-09 9.E-10 4a 3.E-09 4.E-09 4b l.E-09 3.E-09 7a 9.E-10 l.E-09 5.E-10 4.E-09 3.E-09 7b 2.E-09 7.E-09 7c 7.E-10 2.E-10 l.E-09 l.E-09 8a 2.E-10 6.E-10 9.E-10 6.E-10 2.E-09 33a 7.E-10 2.E-09 34a 7.E-09 9.E-09 7.E-09 34b 2.E-09 3.E-09 3.E-09 35a 6.E-10 7.E-09 Table 7B.
In vitro cytotoxicities (ICso values) of non-conjugated compounds Cell Lines (Compound concentrations Molar) Compound N-Luc HSC-2 998 6E-10 IE-09 7a 9E-10 2E-9 8a 2E-10 SE-10 8c 2E-10 4E-10 8p 2E-10 6E-10 N-Luc indicates Namalwa cells that were stably transfected with the Luciferase gene Example 49.
Bystander cell killing assay s
[00463] Cell Titer Glo and One Glo reagents were purchased from Promega.
The ability of ADCs to induce bystander killing was determined by one of two assays.
Both assays were performed in U-bottomed 96-well plates (Costar) to keep mixed antigen negative (Ag-) and antigen positive (Ag+) cells in close proximity to each other. 170 WO 2020/219287 PCT /0S2020/027831
[00464] Namalwa-Luciferase (N-Luc) Ag- cells (1000 cells per well) in the appropriate culture media were incubated in wells of a U-bottomed 96 well plate with the designated number ofMDA-MB-468 Ag+ cells and ADC (1.1 nM) for 5 days, at 37 °C, 6% CO2.
The concentration of conjugate used in the assay was high enough to kill all Ag+ cells but not s able to kill Ag- cells unless Ag+ cells were also present.
On day 5, cell viability was determined by Cell Titer Glo assay according to the manufacturer's protocol; luminescence signals were read using a Victor3 plate reader.
The table below shows the in vitro cytotoxicities as obtained in the previous Example and the bystander killing of the compounds described herein. 1 o Table 8.
In vitro cytotoxicities and bystander killing of ADCs ADC DAR Cell Lines (ADC Concentrations) Bystander HSC-2 N-Luc MDA-MB-468 MDA+N-Luc ML66-999 7.5 7.0E-11 IE-7 7E-10 2E-9 ML66-22a 7.5 7.0E-11 IE-7 4E-10 4E-9 ML66-22c 7.8 1.0E-7 2.0E-9 6.0E-8 ML66-22d 7.1 2.0E-7 4.0E-8 9.0E-9 ML66-22e 6.9 3.0E-7 4.0E-10 2.0E-9 ML66-25a 6.9 1.0E-8 ML66-25b 7.3 >4E-7 ML66-28a 6.6 5E-7 7E-10 5E-10 ML66-28c 5.9 7.0E-8 ML66-28b 6.9 2.0E-8 7.0E-10 5.0E-10 ML66-28d 6.6 >2E-7 7.0E-10 4.0E-10 ML66-32a 6.5 3.0E-8 3E-9 2.0E-9 ML66-32b 6E-7 IE-9 6E-10 N-Luc indicates Namalwa cells that were stably transfected with the Luciferase gene Example 50.
Method for determining in vivo efficacy in xenograft models
[00465] Female CB.17 SCID mice at 6 weeks of age were received from Charles River Laboratories.
All in vivo procedures were performed in strict accordance with the NIH Guide 171 WO 2020/219287 PCT /0S2020/027831 for the Care and Use of Laboratory Animals.
The in vivo efficacy of ADCs were evaluated in the given tumor xenograft models.
Female SCID mice were inoculated subcutaneously in the right flank with the desired cell type in I: I ratio of serum-free medium.
The animals were then randomly distributed into groups of 6 or 8 mice per group.
Control mice were 5 treated with phosphate-buffered saline, vehicle.
The required concentrations of ADCs were made by diluting stock samples with vehicle.
Xenografts were grown to approximately 100 mm 3, then mice were administered ADC or vehicle by tail vein intravenous (i.v.) injection (200 μL/mouse ).
All dosing was based on the weight of the antibody component of the conjugate.
Tumor sizes were measured twice weekly in three dimensions using a caliper with 10 tumor volumes expressed in mm3 calculated using the formula V = l/2(1ength x width x height).
Body weight was also measured twice per week.
Data from these studies was interpreted using standardized methods as previously described (Bissery MC et al.
Experimental anti tumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Cancer Res 1991;51(18):4845-52). 15 Example 51.
Mouse tolerability to ML66-999, ML66-22a and ML-28a ADCs
[00466] The tolerability of ADCs was evaluated in female CD-I mice by performing daily body weight measurements and clinical observations for 2 weeks following injection of the ADCs. A IO mg/kg pre-dose of naked ML66 antibody was intravenously administered to thirty-two 7-week-old female CD-I mice because this was shown to alleviate the acute 20 infusion reaction caused by ML66 alone at doses of greater than 20 mg/kg.
One mouse died following this injection of naked antibody.
Two hours later, three groups of seven to eight mice each were dosed with an intravenous bolus injection of 1500 μg/kg payload ofML66- 999 (58 mg/kg antibody), ML66-22a (59 mg/kg antibody), or ML66-28a (69 mg/kg antibody).
The maximum tolerated dose (MTD) was defined as the highest dose at which no 25 animals died or were required to be euthanized due to >20% body weight loss or signs of distress or morbidity (hunching, lack of movement, inability to eat or drink, or signs of pain/distress).
Based on these criteria, all three ADCs were well tolerated at a 1500 μg/kg payload dose. FIG. 19 depicts the mouse tolerability to ML66-999, ML66-22a and ML66- 28a ADCs. 172 WO 2020/219287 PCT /0S2020/027831 Example 52.
Method for determination of ADC pharmacokinetic (PK) parameters in mice
[00467] Three groups of eleven 7-week-old female CD-I mice were each dosed with a single intravenous bolus injection of 10 mg/kg naked antibody or ADC.
Terminal blood samples s were collected from 3 mice at 2 minutes, 3 mice at 24 hours, and 5 mice at 72 hours after injections for each ADC.
The blood was processed to serum and the ADCs were purified using affinity capture with anti-human Fe beads.
The samples were analyzed by anti-human Fe ELISA to determine the concentration of the antibody component (irrespective of payload loading).
Samples were also analyzed by size exclusion chromatography (SEC) and mass 10 spectrometry (MS).
Partial loss of linker-payload from the captured ADC at all time points were measured by intact MS method.
The ADC concentration was calculated based on the total antibody concentration and the drug-to-antibody ratio (DAR).
[00468] FIG. 13 and Table 9 show the pharmacokinetics ofML66-999 in mice. FIG. 14 and Table 10 show the pharmacokinetics ofML66-999 in mice.
Table 11 summarizes the 1s binding of ADCs or naked antibody to the corresponding antigen expressing cell lines. FIG. 15 and 16 show the in vitro cytotoxicities ofML66-999 and ML66-22a against Ag+ and Agcells.
Fractional retained bioactivity of the ADC in the plasma samples over time was determined in cytotoxicity assays with Ag+ or Ag- cells.
The ADCs retained most of their activity against Ag+ cells at each of the time points, while remaining over 200-fold less 20 active against Ag- cells, indicating that the cytotoxicities, were due to intact ADC, with little or no contribution from any released payload.
Table 9.
ML-66-999 Total Ab Cone. ADC Cone. (μg/mL) DAR (μg/mL) by Mass Spec by Mass Spec by ELISA ADC standard NA NA 7.68 0.033 h (2 min) 240 238 7.62 24 h 85 84 7.62 72 h 57 50 6.72 173 WO 2020/219287 PCT /0S2020/027831 Table 10.
ML-66-22a Total Ab Cone. ADC Cone. (μg/mL) DAR (μg/mL) by Mass Spec by Mass Spec by ELISA ADC standard NA NA 6.98 0.033 h (2 min) 169 168 6.92 24 h 80 74 6.50 72 h 54 43 5.60 Table 11.
Binding of ADCs or naked antibody to the corresponding antigen expressing cell lines Cell Line (Binding EC50, M) Designation DAR NCI-H2110 PC-9 NakedML66 2E-9 ML66-999 7.4 3E-9 ML66-22a 7.5 3E-9 ML66-22c 7.8 7E-10 ML66-22d 7.1 2E-9 ML66-22e 6.9 2E-9 ML66-25a 6.9 5E-9 ML66-25b 7.2 3E-9 ML66-28a 6.6 lE-9 ML66-28b 6.9 lE-9 ML66-28c 5.9 2E-9 ML66-28d 6.6 lE-9 ML66-32a 7.5 lE-09 s Example 53.
Anti-tumor Activity of anti-EGFR Antibody Drug Conjugates in Nude Mice Bearing HSC-2 Human Head and Neck Squamous Cell Carcinoma Xenografts 174 ™
[00469] The anti-tumor activity of 1, 3, and 10 mg/kg ofML66-999 and ML66-22a were evaluated in female Nude mice bearing HSC-2 cells, a human head and neck squamous cell carcinoma xenograft model.
[00470] Mice were inoculated with 1 x 107 HSC-2 cells in 0.1ml 50% Matrigel/ 50% serum 5 free medium by subcutaneous injection in the area on the right hind flank.
Female athymic Foxn I 1111 mice (6 weeks of age) were obtained.
Upon receipt, the animals were observed for 9 days prior to study initiation.
Animals showed no sign of disease or illness upon arrival, or prior to treatment.
[00471] Forty-eight mice were randomized into 8 groups (6 mice per group) by tumor 10 volume.
The tumor volumes ranged from 68.48 to 118.26 (93.42 ± 11.25, Mean± SD) mm3.
The mice were measured, randomized, and dosed based on the tumor volume on day 4 post implantation (11/12/18).
Body weights of the mice ranged from 19.46 to 25.77 (22.98 ± 1.50, Mean± SD) grams.
Mice in each group were identified by punch method.
Administration of the test agents and vehicle were carried out intravenously by using a 1.0 ml syringe fitted 15 with a 27 gauge, ½ inch needle.
Antibody drug conjugate test agents were dosed qdxl at 1, 3, or 10 mg/kg, where 75 μg/kg or 250 μg/kg based on payload correlates to approximately 3 or 10 mg/kg based on antibody concentration.
The groups included: a control group dosed with vehicle (PBS, 200 μL), a control group dosed with the non-targeting KTI-999 at 10 mg/kg, ML66-999 dosed at 1, 3, and 10 mg/kg based on antibody concentration, and ML66-22a 20 dosed at l, 3, and l 0 mg/kg based on antibody concentration.
[00472] Tumor size was measured two times per week in three dimensions using a caliper.
The tumor volume was expressed in mm1 using the formula Volume= Length x Width x Height x ½. A mouse was considered to have a partial regression (PR) when tumor volume was reduced by 50% or greater and a complete tumor regression (CR) was when no palpable 25 tumor could be detected.
Tumor volume was determined by Study Log software.
[00473] Tumor growth inhibition (%TIC) is the ratio of the median tumor volume (TV) of the treatment group (T) to the median TV of the control group (C) at a predetermined time (e.g. the time when the median TV for control tumors reach a maximum tumor volume ~1000mm3, which is when the mice are euthanized). %TIC was calculated on day 22 post 175 WO 2020/219287 PCT /0S2020/027831 inoculation, when the median TV of the control group reached 1038 mm 3.
According to NCI standards, a T/C :S 42% is the minimum level of anti-tumor activity and a T/C <10% is considered a high anti-tumor activity level.
[00474] Body weight (BW) of all the mice was measured two times per week as a rough 5 index of drug toxicity and was determined by Study Log software.
Body weights of mice were expressed as percent change in body weight from the pre-treatment body weight as follows: % BW change= [(BWpost / BWpre)- l] x 100, where BWpost is weight after treatment and BWpre is the starting body weight prior to treatment.
Percent body weight loss (BWL) was expressed as the mean change in body weight post treatment.
Animals were euthanized if the 10 tumor volume became larger than 1000 mm3, the tumors became necrotic, the mice lost >20% of their initial body weight, or the mice become moribund at any time during the study.
[00475] FIG. 17 and Table 12 depict the efficacy of ADCs in a HSC-2 xenograft models.
The ML66-999 and ML66-22a conjugates had similar anti-tumor activity. ML66-KTI dosed at 10 mg/kg had a T/C value of 70% (inactive), with no tumor regressions.
This demonstrated 15 that the activity of the ML66 conjugates is EGFR-targeted since the control ADC was inactive. ML66-999 dosed at 1 mg/kg had a T/C value of 49% (inactive), with no tumor regressions. ML66-999 dosed at 3 mg/kg had a T/C value of 7% (highly active), with 4 partial tumor regressions out of 6 mice and 1 complete regression. ML66-999 dosed at 10 mg/kg had a T /C value of 3% (highly active), with 6 partial tumor regressions out of 6 mice 20 and 2 complete regressions. ML66-22a dosed at 1 mg/kg had a T/C value of 39% (active), with 1 partial tumor regressions out of 6 mice and no complete regressions. ML66-22a dosed at 3 mg/kg had a T/C value of 5% (highly active), with 3 partial tumor regressions out of 6 mice and 1 complete regression. ML66-22a dosed at 10 mg/kg had a T/C value of 2% (highly active), with 6 partial tumor regressions out of 6 mice and 5 complete regressions.
No 25 significant body weight loss was observed at any of the indicated doses for any of the conjugates indicating that the conjugates were well tolerated.
The results from this study suggest that both the ML66-999 and ML66-22a conjugates demonstrated dose dependent anti-tumor activity and were efficacious in the HSC-2 head and neck squamous cell carcinoma tumor xenograft model. 176 WO 2020/219287 PCT /0S2020/027831 Table 12.
ADC Dose HSC-2 ADC (DAR) μg/kg payload mg/kg Ab TIC (Day 22) PR CR KTI-999 (7.6) 259 10 70% 0/6 0/6 ML66-999 (7. 5) 254 10 3% 6/6 2/6 ML66-999 (7. 5) 76 3 7% 4/6 1/6 ML66-999(7. 5) I 49% 0/6 0/6 ML66-22a (7.5) 258 10 2% 6/6 5/6 ML-66-22a (7.5) 77 3 5% 3/6 1/6 ML66-22a (7.5) I 39% 1/6 0/6 Example 54.
Anti-tumor Activity of Conjugates in Nude Mice Bearing Non-Small Cell Lung Cancer (NSCLC) Xenografts
[00476] The anti-tumor activity of the conjugates in Nude Mice Bearing Non-Small Cell s Lung Cancer (NSCLC) Xenografts was determined in a manner similar to that for HSC-2 cells as described in Example 53.
[00477] Female athymic Nude mice (Foxnl nu) at 6 weeks of age were received from Charles River Laboratories.
All in vivo procedures were performed in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals.
The anti-tumor activity of the ADCs was 10 evaluated in non-small cell lung cancer (NSCLC) squamous HI 703 tumor xenograft models.
Female Nude mice were inoculated subcutaneously in the right flank with the desired cell type in I: I ratio of serum-free medium:Matrigel (5 x 106 cells/mouse).
Tumor volumes (TV) were measured twice weekly in three dimensions using a caliper with tumor volumes expressed in mm3 calculated using the formula TV= l/2(1ength x width x height). 1s Xenografts were grown to-100 mm3 and mice were randomly distributed into groups of 6 mice per group based on their TV on day 16 (with a 116.0 +/- 18.5 mm3 [mean+/- SD] TV) post cell inoculation.
Stock ADCs were diluted with conjugate dilution buffer and mice were dosed by individual body weights.
Mice received a single intravenous (IV) bolus injection of vehicle (phosphate-buffered saline (PBS) at 200 μL/mouse) or ADC at 75 μg/kg or 250 20 μg/kg based on payload (approximately 3 or 10 mg/kg based on antibody concentration) at a 177 WO 2020/219287 PCT /0S2020/027831 dose volume of 5 mL/kg.
Tumor growth inhibition (T /C) is the ratio of the median tumor volume (TV) of the treatment group (T) to the median TV of the control group (C) at a predetermined time ( e.g. the time when the median TV for control tumors reach a maximum tumor volume -1000mm3 , which is when the mice are euthanized).
According to NCI s standards, a T/C :S 42% is the minimum level of anti-tumor activity and a T/C <10% is considered a high anti-tumor activity level. A mouse was considered to have a partial regression (PR) when TV was reduced by 50% or greater and a complete regression (CR) when no palpable tumor could be detected. TIC, PR, and CR for both efficacy studies are listed in the table below.
Body weights were also measured twice per week as a rough index 10 of drug toxicity.
[00478] FIG. 20 and Table 14 depict the efficacy of ADCs in HI 703 xenografts models.
The results suggest that both the ML66-999 and ML66-22a conjugates demonstrated dose dependent anti-tumor activity and were efficacious in the HI 703 tumor xenograft model.
Table 14.
Hl 703 efficacy study results ADC Dose H1703 ADC (DAR) μg/kg payload mg/kg Ab TIC (Day 43) PR CR KTI-999 (7.6) 250 9.9 58 0/6 0/6 ML66-999 (7. 6) 250 9.7 13 3/6 1/6 ML66-999 (7. 6) 75 2.9 86 0/6 0/6 ML66-22a (7.5) 250 9.8 9 3/6 0/6 ML66-22a (7.5) 75 2.9 69 0/6 0/6 ML66-22b (6.4) 250 11.4 3 6/6 0/6 ML66-22b (6.4) 75 3.4 7 4/6 2/6 1s Example 55.
Anti-tumor Activity of anti-EGFR Antibody Drug Conjugates in Nude Mice Bearing FaDu Human Head and Neck Squamous Cell Carcinoma Xenografts
[00479] The anti-tumor activity of 1, 3, and 10 mg/kg ofML66-999 and ML66-22a were evaluated in female Nude mice bearing FaDu cells, a human head and neck squamous cell carcinoma xenograft model. 178 WO 2020/219287 PCT /0S2020/027831
[00480] Mice were inoculated with 1 x 107 FaDu cells in 0.1ml 50% Matrigel/ 50% serum free medium by subcutaneous injection in the area on the right hind flank.
Female athymic Foxnl nu mice (6 weeks of age) were obtained.
Upon receipt, the animals were observed for 7 days prior to study initiation.
Animals showed no sign of disease or illness upon arrival, or 5 prior to treatment.
[00481] Sixty-four mice were randomized into 8 groups (8 mice per group) by tumor volume.
The tumor volumes ranged from 74.07 to 128.73 (104.66 ± 15.70, Mean± SD) mm3 .
The mice were measured, randomized, and dosed based on the tumor volume on day 6 post implantation (11/19/18).
Body weights of the mice ranged from 20.48 to 25.77 (23.55 ± 1.25, 10 Mean± SD) grams.
Mice in each group were identified by punch method.
Administration of the test agents and vehicle were carried out intravenously by using a 1.0 ml syringe fitted with a 27 gauge, ½ inch needle.
Antibody drug conjugate test agents were dosed qdxl at 1, 3, or 10 mg/kg.
The groups included: a control group dosed with vehicle (PBS, 200 μL), a control group dosed with the non-targeting KTI-999 at 10 mg/kg, ML66-999 dosed at 1, 3, 15 and 10 mg/kg, and ML66-22a dosed at 1, 3, and 10 mg/kg.
[00482] Tumor size was measured two times per week in three dimensions using a caliper.
The tumor volume was expressed in mm3 using the formula Volume= Length x Width x Height x ½. A mouse was considered to have a partial regression (PR) when tumor volume was reduced by 50% or greater and a complete tumor regression (CR) was when no palpable 20 tumor could be detected.
Tumor volume was determined by Study Log software.
[00483] Tumor growth inhibition (¾T/C) is the ratio of the median tumor volume (TV) of the treatment group (T) to the median TV of the control group (C) at a predetermined time (e.g. the time when the median TV for control tumors reach a maximum tumor volume -1000mm3 , which is when the mice are euthanized). %TIC was calculated on day 21 post 25 inoculation, when the median TV of the control group reached 749 mm 3.
According to NCI standards, a T/C :S 42% is the minimum level of anti-tumor activity and a T/C <10% is considered a high anti-tumor activity level.
[00484] Body weight (BW) of all the mice was measured two times per week as a rough index of drug toxicity and was determined by Study Log software.
Body weights of mice were 179 WO 2020/219287 PCT /0S2020/027831 expressed as percent change in body weight from the pre-treatment body weight as follows: % BW change= [(BWpost / BWpre)- l] x 100, where BWpost is weight after treatment and BWpre is the starting body weight prior to treatment.
Percent body weight loss (BWL) was expressed as the mean change in body weight post treatment.
Animals were euthanized if the 5 tumor volume became larger than 1000 mm3 , the tumors became necrotic, the mice lost >20% of their initial body weight, or the mice become moribund at any time during the study.
[00485] FIG. 18 and Table 13 depict the efficacy of ADCs in a FaDu xenograft models.
The ML66-999 and ML66-22a conjugates had similar anti-tumor activity. ML66-KTI dosed at 10 mg/kg had a T/C value of20% (active), with 2 partial tumor regressions out of 8 mice and 2 10 complete regressions.
This demonstrated that some of the anti-tumor activity in this model is non-targeted. ML66-999 dosed at 1 mg/kg had a T/C value of 12% (active), with 4 partial tumor regressions out of 8 mice and 2 complete regressions. ML66-999 dosed at 3 mg/kg had a T/C value of 2% (highly active), with 8 partial tumor regressions out of 8 mice and 4 complete regressions. ML66-999 dosed at 10 mg/kg had a T/C value of 0% (highly active), 15 with 8 partial tumor regressions out of 8 mice and 8 complete regressions. ML66-22a dosed at 1 mg/kg had a T/C value of 13% (active), with 4 partial tumor regressions out of 8 mice and 3 complete regressions. ML66-22a dosed at 3 mg/kg had a T/C value of 0% (highly active), with 8 partial tumor regressions out of 8 mice and 8 complete regressions. ML66-22a dosed at 10 mg/kg had a T/C value of 0% (highly active), with 8 partial tumor regressions out 20 of 8 mice and 8 complete regressions.
No significant body weight loss was observed at any of the indicated doses for any of the conjugates indicating that the conjugates were well tolerated.
The results from this study suggest that both the ML66-999 and ML66-22a conjugates demonstrated dose dependent anti-tumor activity and were efficacious in the FaDu head and neck squamous cell carcinoma tumor xenograft model. 25 Table 13.
ADC, dose TIC Day 21 PR CR (mg/kg) KTI-999 (10) 20% 2/8 2/8 180 WO 2020/219287 PCT /0S2020/027831 ML66-999 (10) 0% 8/8 8/8 ML66-999 (3) 2% 8/8 4/8 ML66-999 (1) 12% 4/8 2/8 ML66-22a (10) 0% 8/8 8/8 ML66-22a (3) 0% 8/8 8/8 ML66-22a (1) 13% 4/8 3/8 Example 56.
Mouse tolerability of AbF-999 and AbF-22a ADCs:
[00486] The tolerability of non-cross-reactive ADCs was evaluated in female CD-I mice by performing daily body weight measurements and clinical observations for 2 weeks following injection of the ADCs.
Three groups of three mice each were dosed with an IV bolus s injection of 5000 μg/kg based on payload of AbF-22a (184 mg/kg based on antibody) or AbF- 999 (198 mg/kg antibody).
The maximum tolerated dose (MTD) was defined as the highest dose at which no animals died or were required to be euthanized due to >20% body weight loss or signs of distress or morbidity (hunching, lack of movement, inability to eat or drink, or signs of pain/distress).
GraphPad was used for statistical analyses of the body weights in 10 each group (two-way ANOVA with a Tukey's multiple comparisons test showed that the AbF-999 group was significantly different from both the vehicle and AbF-22a groups, p<0.05). FIG. 21 depicts these results.
[00487] While certain embodiments have been illustrated and described, it should be understood that changes and modifications can be made therein in accordance with ordinary 1s skill in the art without departing from the technology in its broader aspects as defined in the following claims.
[00488] The embodiments, illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. 181
[00489] The present disclosure is not to be limited in terms of the particular embodiments described in this application.
Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art.
Functionally equivalent methods and compositions within the scope of the disclosure, in addition to those 5 enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions.
Such modifications and variations are intended to fall within the scope of the appended claims.
The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.
It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, or 10 compositions, which can of course vary.
It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[00490] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby 15 described in terms of any individual member or subgroup of members of the Markush group.
[00491] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof.
Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down 20 into at least equal halves, thirds, quarters, fifths, tenths, etc.
As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.
As will also be understood by one skilled in the art all language such as "up to," "at least," "greater than," "less than," and the like, include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above.
Finally, as will 25 be understood by one skilled in the art, a range includes each individual member. [00492], 182
[00493] EMBODIMENTS OF THE DISCLOSURE: 1. A compound of Formula I, or a pharmaceutically acceptable salt, thereof: 5 Z-L 1-D (Formula I) wherein: Dis represented by the following structural formula: JV\A 0 R1 is -F, -CH3, or -CF 3; 10 R2 is -H, -F, -OR3, -SR3, -S(O)R4, -S(O)2R4, C1-C6 alkyl, or C1-C6 fluoroalkyl; or R1 and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; R3 is Hor C1-C6 alkyl; R4 is C1-C6 alkyl; L1 is absent, -(C1-C6 alkylene)-, -(C1-C6 alkylene)-X1-(C1-C6 alkylene)-, -X1'-(C1-C6 alkylene)-*, or -(C1-C6 alkylene)-X1-L2-*; where* is the site covalently attached to Z; X1 is -0-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5 C(=O)-, or -C(=O)NR5 -; \'. X ts -0-, -S-, -S(O)-, or -S(O)2-; L2 is phenylene; 20 each R5 is independently -H, C1-Cc, alkyl, C1-Cc, fluoroalkyl, C1-Cc, cycloalkyl, aryl, heteroaryl, or benzyl; Z is -Hor -X2 • ' X2 is -OR6, -SR6, -S(O)R6, -S(O)2R6, -SSR6, or -N(R6)2; each R6 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 25 heteroaryl, or benzyl; 183 WO 2020/219287 PCT /0S2020/027831 Li and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -0R7 , -SR7 , -N(R7)2, Ci-C6 alkyl, Ci-C6 fluoroalkyl, Ci-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, 5 heteroaryl, or benzyl; with the proviso that ifRi is F, then Li is -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi( Ci-C6 alkylene)-, -Xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z; and Z is -X2 ; and with the proviso that if Riis F and R2 is -0Me, then -L i_z cannot be -NH2. 10 2. A compound of Formula I, or a pharmaceutically acceptable salt, thereof: Z-Li-D (Formula I) wherein: D is represented by the following structural formula: ,NV\ 0 Riis -F, -CH3, or -CF 3; R2 is -H, -F, -0R3 , -SR3 , -S(0)R4, -S(0)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; R3 is Hor Ci-C6 alkyl; 20 R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, -xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z; xi is -0-, -S-, -S(0)-, -S(0)2-, -C(=0)-, -NR5 -, -NR5 C(=0)-, or -C(=0)NR5 -; xi' is -0-, -S-, -S(0)-, or -S(0)2-; L 2 is phenylene; each R5 is independently -H, Ci-C6 alkyl, Ci-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z is -Hor -X2• ' 184 WO 2020/219287 PCT /0S2020/027831 X2 is -OR6, -SR6, -S(O)R6, -S(O)2R6, -SSR6, or -N(R6)2; each R6 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected 5 from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; with the proviso that ifR1 is F, then L1 is -(C1-C6 alkylene)-, -(C1-C6 alkylene)-X1- (C1-C6 alkylene)-, -X1'-(C1-C6 alkylene)-*, or -(C1-C6 alkylene)-X1-L2-*; where* is the site covalently attached to Z; and Z is -X2 ; with the proviso that if R1 is F and R2 is -OMe, then -L 1-Z cannot be -NH2; and with the proviso that if R1 is F and R2 is -Me, then -L 1-Z cannot be -CH2OH. 3.
The compound of embodiment 1 or embodiment 2, wherein R1 is-Hor -F. 15 4.
The compound of any one of embodiments 1-3, wherein R1 is -F. 5.
The compound of any one of embodiments 1-4, R2 is -H, -F, -OCF3, -CF3, -OMe, -OEt, - SMe, -S(O)Me, -S(O)2Me, -SEt, -S(O)Et, -S(O2)Et, methyl, or ethyl. 6.
The compound of any one of embodiments 1-5, wherein R2 is -F. 7.
The compound of any one of embodiments 1-5, wherein R2 is -OMe, -SMe, -S(O)Me, or 20 methyl. 8.
The compound of any one of embodiments 1-5, wherein R2 is methyl. 9.
The compound of embodiment 1 or embodiment 2, wherein R1 is -F and R2 is -F. 10.
The compound of embodiment 1 or embodiment 2, wherein R1 is methyl and R2 is -F. 11.
The compound of embodiment 1 or embodiment 2, wherein R 1 is -F and R2 is -methyl. 25 12.
The compound of any one of embodiments 1-11, wherein -L 1-Z is -H. 185 WO 2020/219287 PCT /0S2020/027831 13.
The compound of any one of embodiments 1-11, wherein -L1-Z is -(C1-C6 alkylene)-H, or -(C1-C6 alkylene)-X2. 14.
The compound of embodiment 13, wherein -L 1-Z is methyl, ethyl, propyl, or butyl. 15.
The compound of any one of embodiments 1-11, wherein -L1-Z is -(C1-C4 alkylene)-OR6, 5 -(C1-C4 alkylene)-SR6, or-(C1-C4 alkylene)-N(R6)2. 16.
The compound of embodiment 15, wherein -L 1-Z is -CH20H, -(CH2)20H, -(CH2)3QH, - (CH2)4QH, -CH20Me, -(CH2)20Me, -(CH2)3QMe, -(CH2)4QMe, -CH2SH, -(CH2)2SH, - (CH2)3SH, -(CH2)4SH, -CH2SMe, -(CH2)2SMe, -(CH2)3SMe, -(CH2)4SMe, -CH2NH2, - (CH2)2NH2, -(CH2)3NH2, -(CH2)4NH2, 10 17.
The compound of embodiments any one of 1-11, wherein -L 1-Z is -(C1-Cs alkylene)- NR5C(=O)-(C1-Cs alkylene)-OR6, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-SR6, - (C1-Cs alkylene)-S-(C1-Cs alkylene)-SR6, or -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SSR6. 18.
The compound of embodiment 17, wherein-L1-Z is -CH2NHC(=O)CH20H, - CH2NHC(=O)(CH2)20H, -CH2NHC(=O)(CH2)3QH, -CH2NHC(=O)(CH2)4QH, - 15 CH2NHC(=O)(CH2)sOH, -CH2NHC(=O)CH20Me, -CH2NHC(=O)(CH2)20Me, - CH2NHC(=O)(CH2)3QMe, -CH2NHC(=O)(CH2)4QMe, -CH2NHC(=O)(CH2)sOMe, - CH2NHC(=O)CH2SH, -CH2NHC(=O)(CH2)2SH, -CH2NHC(=O)(CH2)3SH, - CH2NHC(=O)(CH2)4SH, -CH2NHC(=O)(CH2)sSH, -CH2NHC(=O)CH2SMe, - CH2NHC(=O)(CH2)2SMe, -CH2NHC(=O)(CH2)3SMe, -CH2NHC(=O)(CH2)4SMe, - 20 CH2NHC(=O)(CH2)sSMe, -CH2SCH20H, -CH2S(CH2)20H, -CH2S(CH2)3QH, - CH2S(CH2)4QH, -CH2S(CH2)sOH, -CH2SCH20Me, -CH2S(CH2)20Me, - CH2 S( CH2)3 OMe, -CH2S( CH2)4QMe, -CH2 S( CH2)sOMe,-CH2SCH2SH, -CH2S( CH2)2SH, -CH2S(CH2)3SH, -CH2S(CH2)4SH, -CH2S(CH2)sSH, -CH2SCH2SMe, -CH2S(CH2)2SMe, -CH2S(CH2)3SMe, -CH2S(CH2)4SMe, or -CH2S(CH2)sSMe. 25 19.
The compound of embodiment 17 or embodiment 18, wherein each R5 is independently - H, methyl, or benzyl. 186 WO 2020/219287 PCT /0S2020/027831 20.
The compound of any one of embodiments 15-18, wherein each R6 is independently -H, methyl, or benzyl. 21.
The compound of any one of embodiments 1-11, wherein -L1-Z is -X1'-(C1-C4 alkylene)x2_ s 22.
The compound of embodiment 21, wherein -L 1-Z is -OCH2OH, -O(CH2)2OH, - O(CH2)3QH, -O(CH2)4QH, -SCH2OH, -S(CH2)2OH, -S(CH2)3QH, -S(CH2)4QH, - S(O)CH2OH, -S(O)(CH2)2OH, -S(O)(CH2)3QH, -S(O)(CH2)4QH, -S(O)2CH2OH, - S(O)2(CH2)2OH, -S(O)2(CH2)3QH, -S(O)2(CH2)4QH, -OCH2SMe, - O(CH2)2SMe, - O(CH2)3SMe, -O(CH2)4SMe, -SCH2SMe, - S(CH2)2SMe, -S(CH2)3SMe, -S(CH2)4SMe, - 10 S(O)CH2SMe, -S(O)(CH2)2SMe, -S(O)(CH2)3SMe, -S(O)(CH2)4SMe, -S(O)2CH2SMe, - S(O)2(CH2)2SMe, -S(O)2(CH2)3SMe, or -S(O)2(CH2)4SMe. 23.
The compound of any one of embodiments 1-11, wherein -L1-Z is -(C1-C6 alkylene)-X1- L2-x2_ 24.
The compound of embodiment 23, wherein -L 1-Z is 25.
The compound of embodiment 1, wherein the compound is any one of the compounds selected from the following: 187 WO 2020/219287 PCT /0S2020/027831 ,....s F OH 0 26.
The compound of embodiment 1, wherein the compound is any one of the compounds selected from Table lB. s 27. A compound of Formula II, or a pharmaceutically acceptable salt thereof: E-A-Z'-L i_D (Formula II) wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -0R3, -SR3, -S(0)R4, -S(0)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-* or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(0)-, -S(0)2-, -C(=0)-, -NR5 -, -NR5 C(=0)-, or -C(=0)NR5 -; xi· is -0-, -S-, -S(0)-, or -S(0)2-; 188 WO 2020/219287 PCT /0S2020/027831 L 2 is phenylene; each R5 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 10 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more polyol; and Eis -C(=O)-L3-X3; L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to X3 ; Y1 is absent, -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)- or -C(=O)NR9 -; Y2 is absent, -(CRcRdO)o-, or -(CR~dcRc'Rd'O)p-; n, m, o, and p are each independently 1-1 O; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, 25 -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 189 WO 2020/219287 or -SR10• ' 11 ~-s~ 11 PCT /0S2020/027831 each W' is independently -H, -N(Rgg)2, C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, s C3-C6 cycloalkyl, aryl, heteroaryl, or -(CH2CH2O)q-Rff; q is I to 24; each Raa, Rb\ Rec, Ree, and Rff are independently-Hor optionally substituted C1-C6 alkyl; each RYY and Rxx are independently-Hor C1-C6 alkyl; Rgg are each independently-Hor C1-C6 alkyl; and R9 and R10 are each independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 28.
The compound of embodiment 27, wherein R1 is-Hor -F. 29.
The compound of embodiment 27 or embodiment 28, wherein R1 is -F. 1s 30.
The compound of any one of embodiments 27-29, R2 is -H, -F, -OCF3, -Cf 3, -OMe, - OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, -S(O)Et, -S(O2)Et, methyl, or ethyl. 31.
The compound of any one of embodiments 27-30, wherein R2 is -F. 32.
The compound of any one of embodiments 27-30, wherein R2 is -OMe, -SMe, -S(O)Me, or methyl. 20 33.
The compound of any one of embodiments 27-30, wherein R2 is methyl. 34.
The compound of embodiment 27, wherein R1 is -F and R2 is -F. 190 WO 2020/219287 PCT /0S2020/027831 35.
The compound of embodiment 27, wherein R1 is methyl and R2 is -F. 36.
The compound of embodiment 27, wherein R1 is -F and R2 is -methyl. 37.
The compound of any one of embodiments 27-36, wherein -L1-Z'-* is -(C1-C4 alkylene)O- CH2-NR8-*, -(C1-C4 alkylene)-S-CH2-NR8-*, or -(C1-C4 alkylene)-NR8-*, where* is 5 the site covalently attached to A 38.
The compound of embodiment 37, wherein -L 1-Z'-* is -CH2O-CH2NH-*, -(CH2)2OCH2NH-*, -(CH2)3Q-CH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2SCH2NH-*, -(CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, - (CH2)3NH-*, or-(CH2)4NH-. 10 39.
The compound of any one of embodiments 27-36, wherein -L1-Z'-* is -(C1-Cs alkylene)- NR5C(=O)-(C1-Cs alkylene)-O-CH2-NR8-*, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2-NR8-*, or -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*, where* is the site covalently attached to A 40.
The compound of embodiment 39, wherein -L 1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, 15 -CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, - CH2NHC(=O)(CH2)3S-CH2-NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, - CH2NHC(=O)(CH2)sS-CH2-NH-*, -CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, - 20 CH2S(CH2)3Q-CH2-NH-*, -CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, - CH2SCH2S-CH2-NH-*, -CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, - CH2S(CH2)4S-CH2-NH-*, or -CH2S(CH2)sS-CH2-NH-*. 41.
The compound of embodiment 39 or embodiment 40, wherein each R5 is independently - H, methyl, or benzyl. 25 42.
The compound of any one of embodiments 37-41, wherein each R8 is independently -H, methyl, or benzyl. 191 WO 2020/219287 PCT /0S2020/027831 43.
The compound of any one of embodiments 27-36, wherein -L1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or -X1'-(C1-C4 alkylene)NR8-*, where* is the site covalently attached to A 44.
The compound of embodiment 43, wherein -L 1-Z' -* is -OCH20-CH2-NH-*, - O(CH2)20- s CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH20-CH2-NH-*, - S(CH2)20-CH2-NH-*, -S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH20-CH2- NH-*, -S(O)(CH2)20-CH2-NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, - S(0)2CH20-CH2-NH-*, -S(0)2(CH2)20-CH2-NH-*, -S(0)2(CH2)3Q-CH2-NH-*, - S(0)2(CH2)4Q-CH2-NH-*, -OCH2S-CH2-NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2- 10 NH-*, -O(CH2)4S-CH2-NH-*, -SCH2S-CH2-NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3SCH2- NH-*, -S(CH2)4S-CH2-NH-*, -S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, - S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4S-CH2-NH-*, -S(0)2CH2S-CH2-NH-*, - S(0)2(CH2)2S-CH2-NH-*, -S(0)2(CH2)3S-CH2-NH-*, -S(0)2(CH2)4S-CH2-NH-*, -OCH2- NH-*, -O(CH2)2-NH-*, - O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, - S(CH2)2-NH- 1s *, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, -S(O)(CH2)2-NH-*, -S(O)(CH2)3- NH-*, -S(O)(CH2)4-NH-*, -S(0)2CH2-NH-*, -S(0)2(CH2)2-NH-*, -S(0)2(CH2)3-NH-*, or -S(0)2(CH2)4-NH-*. 45.
The compound of any one of embodiments 27-36, wherein -L 1-Z'-* is -(C1-C6 alkylene)X1- L2-Z'-*, where* is the site covalently attached to A 20 46.
The compound of embodiment 45, wherein -L 1-Z' -* is H .f'~Su HPI N ... * I ./. * .rf'-...........,..N ~ ,,,_,,, N,,, H or O , where* is the site covalently attached to A 47.
The compound of any one of embodiments 27-46, wherein A is a peptide comprising 2 to 8 amino acids. 192 WO 2020/219287 PCT /0S2020/027831 48.
The compound of any one of embodiments 27-47, wherein A is a peptide comprising 2 to 4 amino acids. 49.
The compound of any one of embodiments 27-48, wherein at least one amino acid in said peptide is a L amino acid. s 50.
The compound of any one of embodiments 27-49, wherein each amino acid in said peptide is a L amino acid. 51.
The compound of any one of embodiments 27-48, wherein at least one amino acid in said peptide is a D amino acid. 52.
The compound of any one of embodiments 27-46, wherein A is -(AA1)-(AA2)a1-*, where 10 * is the site covalently attached to E; AA1 and AA2 are each independently an amino acid residue; and al is an integer from 1-9. 53.
The compound of embodiment 52, wherein -AA1-(AA2)al-* is -Gly-Gly-Gly-*, -AlaVal-*, -Val-Ala-*, -Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -LysLys-*, -Ala-Lys-*, -Lys-Ala-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-*, 1s -Phe-Ala-*,-Ala-Phe-*, -Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg*, -N9-nitro-Arg-Phe *, -Phe-Phe-Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly*, -Leu-Ala-Leu-*, -Ile-Ala-Leu-*, -Leu-Ala-Ile-*, -Val-Ala-Val-*, -Ala-Leu-Ala-Leu-*,Leu- Ala-Leu-Ala-*, -~-Ala-Leu-Ala-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, - Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, -Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, - 20 Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -Ala-Leu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, - Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, -Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -GlnLeu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -Arg-Tyr-*, -Phe-Gln-*, -Gln-Phe-*, -ValThr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*. 54.
The compound of embodiment 52, wherein -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-D- 2s Arg-*, -L-Val-Cit-*, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -LVal- D-Lys-*, -L-Val-D-Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-DAla-*, -Val-D-Cit-*, -L-Ala-L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*. 193 WO 2020/219287 55.
The compound of embodiment 52, wherein -AA1-(AA2)a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-* 5 -Gln-Leu-*, -Leu-Gln-* -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, 10 -Gly-Gly-Ala-Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly-*. 15 56.
The compound of embodiment 52, wherein -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-Ala-L-Val-*, -L-Ala-D-Val-*, 20 -L-Val-L-Ala-*, -L-Val-D-Ala-* -L-Gln-L-Leu-*, -L-Gln-D-Leu-*, -L-Leu-L-Gln-*, 25 -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, 30 -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-L-Ala-*, 194 PCT /0S2020/027831 WO 2020/219287 -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly-*, -Gly-D-Ala-Gly-Gly-*, 5 -Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, -Gly-Gly-L-Val-Gly-*, -Gly-D-Val-Gly-Gly-*, -Gly-Gly-D-Val-Gly-*, 10 -Gly-L-Phe-Gly-Gly-*, or -Gly-Gly-L-Phe-Gly-*. 57.
The compound of embodiment 52, wherein -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-LAla-*, 15 -L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*.
PCT /0S2020/027831 58.
The compound of any one of embodiments 27-57, wherein A is substituted with one or more polyol. 59.
The compound of any one of embodiments 27-58, wherein Eis substituted with one or 20 more polyol. 60.
The compound of any one of embodiments 27-59, wherein polyol is -(C1-C6 alkylene)xs_ y3. ' wherein: X5 is -NR12C(=O)- or -C(=O)NR12 -; 25 Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 195 WO 2020/219287 PCT /0S2020/027831 0 OH OH \~~~OH 61.
The compound of embodiment 60, wherein polyol is R12 OH OH wherein R12 is Hor methyl. 62.
The compound of any one of embodiments 27-61, wherein Eis -C(=O)-(C1-C10 alkylene)-X3 . s 63.
The compound of embodiment 62, wherein E is 196 WO 2020/219287 PCT /0S2020/027831 64.
The compound of any one of embodiments 27-61, wherein Eis -C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X3 ; Y1 is -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)-; and 0 0 )-N~ \-N~Br X 3 is O 0 or -SR10. 11 ~-s~ 11 10 65.
The compound of any one of embodiments 27-61, wherein Eis -C(=O)-Y1-(CH2)2-X4- (CH2)2-X3 ; Y1 is -(CH2O)n- or -(CH2CH2O)m-; X4 is -NHC(=O)-; n is 2; m is 2 to 6; 197 WO 2020/219287 or -SR10 . 11 ~-s~ 11 PCT /0S2020/027831 66.
The compound of embodiment 27, wherein the compound is any one of the compounds s selected from Table 2. 67. A compound of Formula III, or a pharmaceutically acceptable salt thereof: CBA-E'-A-Z'-L i_D (Formula III) wherein: D is represented by the following structural formula: ,NV\ 0 Riis -H -F -CH3 or -CF3· ' ' ' ' R2 is -H, -F, -0R3, -SR3, -S(0)R4, -S(0)2R4, Ci-C6 alkyl, or Ci-C6 fluoroalkyl; or Ri and R2 taken together with the carbon atoms to which they are attached form a methylenedioxy or a difluoromethylenedioxy ring; with the proviso that both Ri and R2 1s cannot be -H; R3 is Hor Ci-C6 alkyl; R4 is Ci-C6 alkyl; Li is absent, -(Ci-C6 alkylene)-, -(Ci-C6 alkylene)-Xi-(Ci-C6 alkylene)-, xi'-(Ci-C6 alkylene)-*, or -(Ci-C6 alkylene)-Xi-L2-*; where* is the site covalently attached to Z'; xi is -0-, -S-, -S(0)-, -S(0)2-, -C(=0)-, -NR5 -, -NR5 C(=0)-, or -C(=0)NR5 -; xi· is -0-, -S-, -S(0)-, or -S(0)2-; L 2 is phenylene; 198 WO 2020/219287 PCT /0S2020/027831 each R5 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; Z' is -O-CH2-NR8-*, -S-CH2-NR8-*, -NR8-*; where* is the site covalently attached to A ' each R8 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; L 1 and L 2 are each independently optionally substituted with 1-4 substituents selected from halogen, -CN, -OR7 , -SR7 , -N(R7)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; and 10 each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more polyol; E' is -C(=O)-L3-X6-*; where* is the site covalently linked to CBA; 15 L3 is -(C1-C10 alkylene)- or -Y1-(C1-C10 alkylene)-X4-Y2-(C1-C10 alkylene)-*; where* is the site covalently attached to x6; Y1 is absent, -(CRaRbO)n- or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)- or -C(=O)NR9 -; Y2 is absent, -(CRcRdO)o-, or -(CR~dcRc'Rd'O)p-; n, m, o, and p are each independently 1-1 O; each Ra, Rh, Ra', Rb', RC, Rd, Re', and Rd' are independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; wherein L3 is optionally substituted with 0-4 substituents selected from halogen, -CN, -OR11 , -SR11 , -N(R11)2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 25 cycloalkyl, C2-C10 heterocycloalkyl, aryl, heteroaryl, and polyol; each R 11 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 199 WO 2020/219287 o oy* o o~~:xN ~ ~_11 I \ ~ S~* ~~ O \_..:z h * II 'z. 0 N 0 d CN * -0' ~ PCT /0S2020/027831 11 ~-NRaa_~~* CRbbRcc_*; where* is the site covalently attached to CBA; each Raa, Rb\ Rec, and Ree are independently-Hor optionally substituted C1-C6 alkyl; each RYY and Rxx are independently-Hor C1-C6 alkyl; R9 is independently -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; and CBA is a cell binding agent. 10 68.
The compound of embodiment 67, wherein R1 is-Hor -F. 69.
The compound of embodiment 67 or embodiment 68, wherein R1 is -F. 70.
The compound of any one of embodiments 67-69, R2 is -H, -F, -OCF3, -Cf 3, -OMe, - OEt, -SMe, -S(O)Me, -S(O)2Me, -SEt, -S(O)Et, -S(O2)Et, methyl, or ethyl. 71.
The compound of any one of embodiments 67-70, wherein R2 is -F. 1s 72.
The compound of any one of embodiments 67-70, wherein R2 is -OMe, -SMe, -S(O)Me, or methyl. 73.
The compound of any one of embodiments 67-70, wherein R2 is methyl. 74.
The compound of embodiment 67, wherein R1 is -F and R2 is -F. 200 WO 2020/219287 PCT /0S2020/027831 75.
The compound of embodiment 67, wherein R1 is methyl and R2 is -F. 76.
The compound of embodiment 67, wherein R1 is -F and R2 is -methyl. 77.
The compound of any one of embodiments 67-76, wherein -L1-Z'-* is -(C1-C4 alkylene)O- CH2-NR8-*, -(C1-C4 alkylene)-S-CH2-NR8-*, or -(C1-C4 alkylene)-NR8-*, where* is 5 the site covalently attached to A 78.
The compound of embodiment 77, wherein -L 1-Z'-* is -CH2O-CH2NH-*, -(CH2)2OCH2NH-*, -(CH2)3Q-CH2NH-*, -(CH2)4Q-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2SCH2NH-*, -(CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, - (CH2)3NH-*, or -(CH2)4NH-. 10 79.
The compound of any one of embodiments 67-76, wherein -L1-Z'-* is -(C1-Cs alkylene)- NR5C(=O)-(C1-Cs alkylene)-O-CH2-NR8-*, -(C1-Cs alkylene)-NR5C(=O)-(C1-Cs alkylene)-S-CH2-NR8-*, -(C1-Cs alkylene)-S-(C1-Cs alkylene)-S-CH2-NR8-*, or -(C1-Cs alkylene)-S-(C1-Cs alkylene)-SS-CH2-NR8-*, where* is the site covalently attached to A 80.
The compound of embodiment 79, wherein -L 1-Z'-* is -CH2NHC(=O)CH2O-CH2-NH-*, 15 -CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3Q-CH2-NH-*, - CH2NHC(=O)(CH2)4Q-CH2-NH-*, -CH2NHC(=O)(CH2)sO-CH2-NH-*, - CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, - CH2NHC(=O)(CH2)3S-CH2-NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, - CH2NHC(=O)(CH2)sS-CH2-NH-*, -CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, - 20 CH2S(CH2)3Q-CH2-NH-*, -CH2S(CH2)4Q-CH2-NH-*, -CH2S(CH2)sO-CH2-NH-*, - CH2SCH2S-CH2-NH-*, -CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, - CH2S(CH2)4S-CH2-NH-*, or -CH2S(CH2)sS-CH2-NH-*. 81.
The compound of embodiment 79 or embodiment 80, wherein each R5 is independently - H, methyl, or benzyl. 25 82.
The compound of any one of embodiments 77-81, wherein each R8 is independently -H, methyl, or benzyl. 201 WO 2020/219287 PCT /0S2020/027831 83.
The compound of any one of embodiments 67-76, wherein -L1-Z'-* is -X1'-(C1-C4 alkylene)-O-CH2-NR8-*, -X1'-(C1-C4 alkylene)-S-CH2-NR8-*, or -X1'-(C1-C4 alkylene)NRs-* ' 84.
The compound of embodiment 83, wherein -L 1-Z' -* is -OCH2O-CH2-NH-*, - O(CH2)2Os CH2-NH-*, - O(CH2)3Q-CH2-NH-*, -O(CH2)4Q-CH2-NH-*, -SCH2O-CH2-NH-*, - S(CH2)2O-CH2-NH-*, -S(CH2)3Q-CH2-NH-*, -S(CH2)4Q-CH2-NH-*, -S(O)CH2O-CH2- NH-*, -S(O)(CH2)2O-CH2-NH-*, -S(O)(CH2)3Q-CH2-NH-*, -S(O)(CH2)4Q-CH2-NH-*, - S(O)2CH2O-CH2-NH-*, -S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3Q-CH2-NH-*, - S(O)2(CH2)4Q-CH2-NH-*, -OCH2S-CH2-NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2- 10 NH-*, -O(CH2)4S-CH2-NH-*, -SCH2S-CH2-NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3SCH2- NH-*, -S(CH2)4S-CH2-NH-*, -S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, - S(O)(CH2)3S-CH2-NH-*, -S(O)(CH2)4S-CH2-NH-*, -S(O)2CH2S-CH2-NH-*, - S(O)2(CH2)2S-CH2-NH-*, -S(O)2(CH2)3S-CH2-NH-*, -S(O)2(CH2)4S-CH2-NH-*, -OCH2- NH-*, -O(CH2)2-NH-*, -O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, -S(CH2)2-NH- 1s *, -S(CH2)3-NH-*, -S(CH2)4-NH-*, -S(O)CH2-NH-*, -S(O)(CH2)2-NH-*, -S(O)(CH2)3- NH-*, -S(O)(CH2)4-NH-*, -S(O)2CH2-NH-*, -S(O)2(CH2)2-NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*. 85.
The compound of any one of embodiments 67-76, wherein -L1-Z'-* is -(C1-C6 alkylene)X1- L 2-Z' -*. 20 86.
The compound of embodiment 85, wherein -L 1-Z' -* is 87.
The compound of any one of embodiments 67-86, wherein A is a peptide comprising 2 to 8 amino acids. 88.
The compound of any one of embodiments 67-87, wherein A is a peptide comprising 2 to 2s 4 amino acids. 202 WO 2020/219287 PCT /0S2020/027831 89.
The compound of any one of embodiments 67-88, wherein at least one amino acid in said peptide is a L amino acid. 90.
The compound of any one of embodiments 67-89, wherein each amino acid in said peptide is a L amino acid. s 91.
The compound of any one of embodiments 67-88, wherein at least one amino acid in said peptide is a D amino acid. 92.
The compound of any one of embodiments 67-86, wherein A is -(AA1)-(AA2)a1-*, where * is the point of attachment to E', AA 1 and AA2 are each independently an amino acid residue; and al is an integer from 1-9. 10 93.
The compound of embodiment 92, -AA1-(AA2)al-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val- Ala-*, -Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -AlaLys-*, -Lys-Ala-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-*, -Phe-Ala*,- Ala-Phe-*, -Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9- nitro-Arg-Phe *, -Phe-Phe-Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu- 1s Ala-Leu-*, -Ile-Ala-Leu-*, -Leu-Ala-Ile-*, -Val-Ala-Val-*, -Ala-Leu-Ala-Leu-*,-LeuAla- Leu-Ala-*, -~-Ala-Leu-Ala-Leu-*, -Gly-Phe-Leu-Gly-* ,-Gly-Leu-Phe-Gly-*, -ValArg-*, -Arg-Val-*, -Arg-Arg-*, -Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -ThrMet-*, -Met-Thr-*, -Leu-Ala-*, -Ala-Leu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -SerVal-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, -Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu- 20 *, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -Arg-Tyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*. 94.
The compound of embodiment 92, wherein -AA1-(AA2)a1-* is -Val-D-Lys-*, -Val-DArg-*, -L-Val-Cit-*, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -LVal- D-Lys-*, -L-Val-D-Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D- 2s Ala-*, -Val-D-Cit-*, -L-Ala-L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-Ser-L-Val-*. 95.
The compound of embodiment 92, wherein -AA1-(AA2)a1-* is: -Ala-Ala-*, 203 WO 2020/219287 -Ala-Val-*, -Val-Ala-* -Gln-Leu-*, -Leu-Gln-* 5 -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala-Gly-*, -Gly-Val-Gly-Gly-*, 10 -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly-*. 96.
The compound of embodiment 92, wherein -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, 15 -L-Ala-D-Ala-*, -L-Ala-L-Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-* 20 -L-Gln-L-Leu-*, -L-Gln-D-Leu-*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, 25 -L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-L-Ala-*, 30 -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, 204 PCT /0S2020/027831 WO 2020/219287 PCT /0S2020/027831 -Gly-Gly-L-Ala-Gly-*, -Gly-D-Ala-Gly-Gly-*, -Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, 5 -Gly-Gly-L-Val-Gly-*, -Gly-D-Val-Gly-Gly-*, -Gly-Gly-L-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or -Gly-Gly-L-Phe-Gly-*. 10 97.
The compound of embodiment 92, wherein -AA1-(AA2)a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*. 15 98.
The compound of any one of embodiments 67-97, wherein A is substituted with one or more polyol. 99.
The compound of any one of embodiments 67-98, wherein E' is substituted with one or more polyol. 100.
The compound of any one of embodiments 67-99, wherein polyol is -(C1-C6 20 alkylene)-X5-Y3; wherein: X5 is -NR12C(=O)- or -C(=O)NR12 -; Y3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 25 101.
The compound of embodiment 100, wherein polyol is 0 OH OH \~~~OH R12 OH OH ; wherein R12 is Hor methyl. 205 WO 2020/219287 PCT /0S2020/027831 102.
The compound of embodiments 63-93, wherein E' is -C(=O)-(C1-C10 alkylene)-X6-*. 103.
The compound of embodiment 102, wherein E' is ,.... N, N a-!( * l_;y 0 , -C(=O)CH2CH2-C(=O)-CRbbRcc_*, or -C(=O)CH2CH2-NRee_C(=O)- CRbbRcc_*; where* is the site covalently attached to CBA. 104.
The compound of embodiments any one of embodiments 63-93, wherein E' is - 10 C(=O)-Y1-(C1-C10 alkylene)-X4-(C1-C10 alkylene)-X6-*; Y1 is -(CRaRbO)n-, or -(CRaRbCRa'Rb'O)m-; X4 is -NR9C(=O)-; and 206 WO 2020/219287 PCT /0S2020/027831 11 ~-N R aa - ~ ~ * d CN 0 * j-Nu* 0 H \: ' s is the site covalently attached to CBA. 105.
The compound of any one of embodiments 63-93, wherein E' is -C(=O)-Y1-(CH2)2- X4-(CH2)2-X6-*; Y1 is -(CH2O)n-, or -(CH2CH2O)m-; X4 is -NHC(=O)-; 10 nis2;mis2to6; 207 11 ~-NRaa_~~* WO 2020/219287 PCT /0S2020/027831 CN/½ d * :,., 'N HOJ :::::,-..1 N o--!( I ~ ,0 ' *' ~ '-C(=O)-CRbbRcc_*, or -NRee_c(=O)- CRbbRcc_*; where* is the site covalently attached to the CBA. 106.
The compound of any one of embodiments 63-105, wherein the CBA comprises a - ~ ~O S-CBA ? O~ i/-N ~-N I SH group that covalently links with E' to provide O 0 "/ 0 N~ >lyS-CBA '(® '---Ny HO S-CBA ✓ 11 ~-NR88-S~ II S-CBA /'() N, ~N o--!(_ S-CBA ' S-CBA 107.
The compound of any one of embodiments 67-106, wherein CBA is an antibody and 1 o -E'-A-Z'-L 1 - D is a drug-linker structure, the average number of drug-linker structures conjugated per antibody is in the range of from 2 to 10. 208 WO 2020/219287 PCT /0S2020/027831 108.
The compound of embodiment 107, wherein the average number of drug-linker structures conjugated per antibody is in the range of from 2 to 10. 109.
The compound of embodiment 107, wherein the average number of drug-linker structures conjugated per antibody is in the range of from 6 to 8. 5 110.
The compound of embodiment 107, wherein the average number of drug-linker structures conjugated per antibody is 8. 111.
The compound of any one of embodiments 67-110, wherein the CBA is an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal antibody, a single chain monoclonal antibody, or a monoclonal antibody 10 fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, a domain antibody fragment that specifically binds to the target cell, a probody, a nanobody, a hexabody, a lymphokine, a hormone, a vitamin, a growth factor, a colony stimulating factor, or a nutrient-transport molecule. 15 112.
The compound of any one of embodiments 67-111, wherein the CBA binds to target cells selected from tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing any one or more of 5T4, ADAM-9, ALK, AMHRII, ASCT2, Axl, B7-H3, BCMA, C4.4a, CA6, CA9, CanAg, CD123, CD138, CD142, 20 CD166, CD184, CD19, CD20, CD205, CD22, CD248, CD25, CD3, CD30, CD33, CD352, CD37, CD38, CD40L, CD44v6, CD45, CD46, CD48, CD51, CD56, CD7, CD70, CD71, CD74, CD79b, CDH6, CEACAM5, CEACAM6, cKIT, CLDN18.2, CLDN6, CLL-1, c-MET, Cripto, CSP-I, CXCR5, DLK-1, DLL3, DPEP3, Dysadherin, EFNA4, EGFR, EGFRviii, ENPP3, EpCAM, EphA2, EphA3, ETBR, FGFR2, FGFR3, FLT3, 25 FOLR-alpha, FSH, GCC, GD2, GD3, Globo H, GPC-1, GPC3, gpNMB, HER-2, HER-3, HLA-DR, HSP90, IGF-IR, IL-13R, ILIRAP, IL7R, Interleukin-4 Receptor (IL4R), KAAG-1, LAMP-I, Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, LIV-I, LRP-1, LRRC15, Ly6E, MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MTI-MMP, MTX3, MTX5, MUCI, MUC16, 209 WO 2020/219287 PCT /0S2020/027831 NaPi2b, Nectin-4, NOTCH3, OAcGD2, OX00IL, p-Cadherin, PD-LI, Phosphatidylserine (PS), Polymorphic epithelial mucin (PEM), Prolactin Receptor (PRLR), PSMA, PTK7, RNF43, RORI, ROR2, SAIL, SLAMF7, SLC44A4, SLITRK6, SSTR2, STEAP-1, STING, STn, TIM-I, TM4SF1, TNF- alpha, TRA, TROP-2, Tumors associated glycoprotein 72 (TAG-72), tumor-specific epitope ofmucin-1 (TA-MUCI), CDS, TIM-3, UPK2, or UPKlb antigen. 113.
The compound of any one of embodiments 67-110, wherein the cell-binding agent is an anti-folate receptor antibody or an antibody fragment thereof, an anti-EGFR antibody or an antibody fragment thereof, an anti-CD33 antibody or an antibody fragment thereof, 10 an anti-CD19 antibody or an antibody fragment thereof, an anti-Mucl antibody or an antibody fragment thereof, an anti-CD37 antibody or an antibody fragment thereof, or an anti-EpCAM antibody or an antibody fragment thereof. 114. A pharmaceutical composition comprising a compound according to any one of embodiments 1-113, or the pharmaceutically acceptable salt thereof, and a 1s pharmaceutically acceptable carrier. 115. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of embodiment 114. 116.
The method of embodiment 115, wherein the cancer is a lymphoma or a leukemia. 20 117.
The method of embodiment 116, wherein the cancer is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), acute B lymphoblastic leukemia or B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), acute promyelocytic leukemia (APL), B-cell chronic 2s lymphoproliferative disease (B-CLPD), atypical chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL ), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), mantel cell leukemia (MCL), small 210 WO 2020/219287 PCT /0S2020/027831 lymphocytic lymphoma (SLL), Hodgkin's lymphoma, systemic mastocytosis, and Burkitt's lymphoma. 118.
The method of embodiment 115, wherein the cancer is endometrial cancer, lung cancer, colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell s carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular cancer, myeloid cancer, melanoma, and lymphoid cancer. 119.
The method of embodiment 115, wherein the lung cancer is non-small cell lung cancer or small-cell lung cancer. 10
[00494] Other embodiments are set forth in the following claims. 211

Claims (2)

  1. 212 WHAT IS CLAIMED IS: 1. A compound of Formula I, or a pharmaceutically acceptable salt, thereof: Z—L1—D (Formula I) wherein: D is represented by the following structural formula: ; R 1 is -F; R 2 is methyl; -L1 -Z is (i) -(C1-C4 alkylene)-OR6 , -(C1-C4 alkylene)-SR6 , or -(C1-C4 alkylene)- N(R6 )2; (ii) -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-OR6 , -(C1-C5 alkylene)- NR5C(=O)-(C1-C5 alkylene)-SR6 ,-(C1-C5 alkylene)-S-(C1-C5 alkylene)-SR6 , or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SSR6 ; (iii) -X1’-(C1-C4 alkylene)-X2 ; or (iv) -L1 -Z is -(C1-C6 alkylene)-X1 -L2 -X2 ; each R5 is independently -H, methyl, or benzyl; each R6 is independently -H, methyl, or benzyl; X 1 is -O-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5C(=O)-, or -C(=O)NR5 -; X 1’ is -O-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene optionally substituted with 1-4 substituents of halogen, -CN, -OR7 , - SR7 , -N(R7 )2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; X 2 is -OR6 , -SR6 , -S(O)R6 , -S(O)2R 6 , -SSR6 , or -N(R6 )2; and each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; with the proviso that –L1 -Z cannot be –CH2OH. 2. The compound of claim 1, wherein -L1 -Z is -(C1-C4 alkylene)-OR6 , -(C1-C4 alkylene)- SR6 , or -(C1-C4 alkylene)-N(R6 )2. 213 3. The compound of claim 2, wherein -L1 -Z is -(CH2)2OH, -(CH2)3OH, -(CH2)4OH, - CH2OMe, -(CH2)2OMe, -(CH2)3OMe, -(CH2)4OMe, -CH2SH, -(CH2)2SH, -(CH2)3SH, - (CH2)4SH, -CH2SMe, -(CH2)2SMe, -(CH2)3SMe, -(CH2)4SMe, -CH2NH2, -(CH2)2NH2, - (CH2)3NH2, -(CH2)4NH2. 4. The compound of claim 1, wherein -L1 -Z is -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-OR6 , -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-SR6 , -(C1-C5 alkylene)-S-(C1- C5 alkylene)-SR6 , or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SSR6 . 5. The compound of claim 4, wherein -L1 -Z is -CH2NHC(=O)CH2OH, - CH2NHC(=O)(CH2)2OH, -CH2NHC(=O)(CH2)3OH, -CH2NHC(=O)(CH2)4OH, - CH2NHC(=O)(CH2)5OH, -CH2NHC(=O)CH2OMe, -CH2NHC(=O)(CH2)2OMe, - CH2NHC(=O)(CH2)3OMe, -CH2NHC(=O)(CH2)4OMe, -CH2NHC(=O)(CH2)5OMe, - CH2NHC(=O)CH2SH, -CH2NHC(=O)(CH2)2SH, -CH2NHC(=O)(CH2)3SH, - CH2NHC(=O)(CH2)4SH, -CH2NHC(=O)(CH2)5SH, -CH2NHC(=O)CH2SMe, - CH2NHC(=O)(CH2)2SMe, -CH2NHC(=O)(CH2)3SMe, -CH2NHC(=O)(CH2)4SMe, - CH2NHC(=O)(CH2)5SMe, -CH2SCH2OH, -CH2S(CH2)2OH, -CH2S(CH2)3OH, - CH2S(CH2)4OH, -CH2S(CH2)5OH, -CH2SCH2OMe, -CH2S(CH2)2OMe, -CH2S(CH2)3OMe, - CH2S(CH2)4OMe, -CH2S(CH2)5OMe,-CH2SCH2SH, -CH2S(CH2)2SH, -CH2S(CH2)3SH, - CH2S(CH2)4SH, -CH2S(CH2)5SH, -CH2SCH2SMe, -CH2S(CH2)2SMe, -CH2S(CH2)3SMe, - CH2S(CH2)4SMe, or -CH2S(CH2)5SMe. 6. The compound of claim 1, wherein -L1 -Z is -X1’-(C1-C4 alkylene)-X2 . 7. The compound of claim 6, wherein -L1 -Z is -OCH2OH, -O(CH2)2OH, -O(CH2)3OH, - O(CH2)4OH, -SCH2OH, -S(CH2)2OH, -S(CH2)3OH, -S(CH2)4OH, -S(O)CH2OH, - S(O)(CH2)2OH, -S(O)(CH2)3OH, -S(O)(CH2)4OH, -S(O)2CH2OH, -S(O)2(CH2)2OH, - S(O)2(CH2)3OH, -S(O)2(CH2)4OH, -OCH2SMe, - O(CH2)2SMe, - O(CH2)3SMe, - O(CH2)4SMe, -SCH2SMe, - S(CH2)2SMe, -S(CH2)3SMe, -S(CH2)4SMe, -S(O)CH2SMe, - S(O)(CH2)2SMe, -S(O)(CH2)3SMe, -S(O)(CH2)4SMe, -S(O)2CH2SMe, -S(O)2(CH2)2SMe, - S(O)2(CH2)3SMe, or -S(O)2(CH2)4SMe. 8. The compound of claim 1, wherein -L1 -Z is -(C1-C6 alkylene)-X1 -L2 -X2 . 214 9. The compound of claim 8, wherein -L1 -Z is or . 10. The compound of claim 1, wherein the compound is one of the following: , , , , or . 11. The compound of claim 1, wherein the compound is represented by the following formula: , , , 215 , , , , , , , , , , or . 216 12. A compound of Formula II, or a pharmaceutically acceptable salt thereof: E—A—Z’—L1—D (Formula II) wherein: D is represented by the following structural formula: ; R 1 is -F; R 2 is methyl; -L1 -Z’-* is (i) -(C1-C4 alkylene)-O-CH2-NR8 -*, -(C1-C4 alkylene)-S-CH2-NR8 -*, or - (C1-C4 alkylene)-NR8 -*; (ii) -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-O-CH2-NR8 - *, -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-S-CH2-NR8 -*, -(C1-C5 alkylene)-S-(C1- C5 alkylene)-S-CH2-NR8 -*, or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SS-CH2-NR8 -*; (iii) X 1’-(C1-C4 alkylene)-O-CH2-NR8 -*, -X1’-(C1-C4 alkylene)-S-CH2-NR8 -*, or -X1’-(C1-C4 alkylene)-NR8 -* or (iv) -(C1-C6 alkylene)-X1 -L2 -Z’-*, where Z’ is -O-CH2-NR8 -*, -SCH2-NR8 -*, -NR8 -*; where * is the site covalently attached to A; each R5 is independently -H, methyl, or benzyl; each R8 is independently -H, methyl, or benzyl; X 1 is -O-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5C(=O)-, or -C(=O)NR5 -; X 1’ is -O-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene optionally substituted with 1-4 substituents of halogen, -CN, -OR7 , - SR7 , -N(R7 )2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more group that is -(C1-C6 alkylene)-X5 -Y3 wherein: X is -NR12C(=O)- or -C(=O)NR12-; Y 3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and 217 R 12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; E is -C(=O)-(C1-C10 alkylene)-X3 ; and X 3 is . 13. The compound of claim 12, wherein -L1 -Z’-* is -(C1-C4 alkylene)-O-CH2-NR8 -*, - (C1-C4 alkylene)-S-CH2-NR8 -*, or -(C1-C4 alkylene)-NR8 -*, where * is the site covalently attached to A. 14. The compound of claim 13, wherein -L1 -Z’-* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH- *, -(CH2)3O-CH2NH-*, -(CH2)4O-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, - (CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or - (CH2)4NH-. 15. The compound of claim 12, wherein -L1 -Z’-* is -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-O-CH2-NR8 -*, -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-S-CH2-NR8 -*,-(C1- C5 alkylene)-S-(C1-C5 alkylene)-S-CH2-NR8 -*, or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SSCH2-NR8 -*, where * is the site covalently attached to A. 16. The compound of claim 15, wherein -L1 -Z’-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3O-CH2-NH-*, - CH2NHC(=O)(CH2)4O-CH2-NH-*, -CH2NHC(=O)(CH2)5O-CH2-NH-*, - CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3SCA 3137125 218 CH2-NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)5S-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3O-CH2-NH-*, - CH2S(CH2)4O-CH2-NH-*, -CH2S(CH2)5O-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - CH2S(CH2)5S-CH2-NH-*, where * is the site covalently attached to A. 17. The compound of claim 12, wherein -L1 -Z’-* is -X1’-(C1-C4 alkylene)-O-CH2-NR8 -*, -X1’-(C1-C4 alkylene)-S-CH2-NR8 -*, or -X1’-(C1-C4 alkylene)-NR8 -*, where * is the site covalently attached to A. 18. The compound of claim 17, wherein -L1 -Z’-* is -OCH2O-CH2-NH-*, - O(CH2)2OCH2-NH-*, - O(CH2)3O-CH2-NH-*, -O(CH2)4O-CH2-NH-*, -SCH2O-CH2-NH-*, - S(CH2)2O-CH2-NH-*, -S(CH2)3O-CH2-NH-*, -S(CH2)4O-CH2-NH-*, -S(O)CH2O-CH2-NH- *, -S(O)(CH2)2O-CH2-NH-*, -S(O)(CH2)3O-CH2-NH-*, -S(O)(CH2)4O-CH2-NH-*, - S(O)2CH2O-CH2-NH-*, -S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3O-CH2-NH-*, - S(O)2(CH2)4O-CH2-NH-*, -OCH2S-CH2-NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH- *, -O(CH2)4S-CH2-NH-*, -SCH2S-CH2-NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, -S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3SCH2-NH-*, -S(O)(CH2)4S-CH2-NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, - S(O)2(CH2)3S-CH2-NH-*, -S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, - O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, - S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4- NH-*, -S(O)CH2-NH-*, -S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, - S(O)2CH2-NH-*, -S(O)2(CH2)2-NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*. 19. The compound of claim 12, wherein -L1 -Z’-* is -(C1-C6 alkylene)-X1 -L2 -Z’-*, where * is the site covalently attached to A. 20. The compound of claim 19, wherein -L1 -Z’-* is or , where * is the site covalently attached to A. 219 21. The compound of any one of claims 12-20, wherein A is a peptide comprising 2 to 8 amino acids. 22. The compound of any one of claims 12-21, wherein A is a peptide comprising 2 to 4 amino acids. 23. The compound of any one of claims 12-22, wherein at least one amino acid in said peptide is a L amino acid. 24. The compound of any one of claims 12-23, wherein each amino acid in said peptide is a L amino acid. 25. The compound of any one of claims 12-22, wherein at least one amino acid in said peptide is a D amino acid. 26. The compound of any one of claims 12-20, wherein A is -(AA1 )-(AA2 )a1-*, where * is the site covalently attached to E; AA1 and AA2 are each independently an amino acid residue; and a1 is an integer from 1-9. 27. The compound of claim 26, wherein -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -Val-Ala-*, -Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -AlaLys-*, -Lys-Ala-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-* , -Phe-Ala-*,- Ala-Phe-*, -Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-ArgPhe *, -Phe-Phe-Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, - Ile-Ala-Leu-*, -Leu-Ala-Ile-*, -Val-Ala-Val-*, -Ala-Leu-Ala-Leu-*,-Leu-Ala-Leu-Ala-*, -βAla-Leu-Ala-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, - Arg-Arg-*, -Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -LeuAla-*, -Ala-Leu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, - Ser-Gly-*, -Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -TyrArg-*, -Arg-Tyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -TyrMet-*. 28. The compound of claim 26, wherein -AA1 -(AA2 )a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cit-*, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-DCA 3137125 220 Lys-*, -L-Val-D-Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, - Val-D-Cit-*, -L-Ala-L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-SerL-Val-*. 29. The compound of claim 26, wherein -AA1 -(AA2 )a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-* -Gln-Leu-*, -Leu-Gln-* -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala-Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly-*. 30. The compound of claim 26, wherein -AA1 -(AA2 )a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-Ala-L-Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-* -L-Gln-L-Leu-*, -L-Gln-D-Leu-*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, 221 -L-Ala-L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly-*, -Gly-D-Ala-Gly-Gly-*, -Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, -Gly-Gly-L-Val-Gly-*, -Gly-D-Val-Gly-Gly-*, -Gly-Gly-D-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or -Gly-Gly-L-Phe-Gly-*. 31. The compound of claim 26, wherein -AA1 -(AA2 )a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-LAla-*, -L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*. 32. The compound of any one of claims 12-31, wherein A is substituted with one or more group that is -(C1-C6 alkylene)-X5 -Y3 wherein: X is -NR12C(=O)- or -C(=O)NR12-; Y 3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R 12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 222 33. The compound of any one of claims 12-32, wherein -(C1-C6 alkylene)-X5 -Y3 is ; wherein R12 is H or methyl. 34. The compound of any one of claims 12-33, wherein E is or . 35. The compound of claim 12, wherein the compound is represented by the following formula: , , 223 , , , ,. , 224 ,. , , , , 225 , , , , 226 , , , , 227 , , or . 36. The compound of claim 12, wherein the compound is represented by the following formula: , or a pharmaceutically acceptable salt thereof. 37. The compound of claim 12, wherein the compound is represented by the following formula: 228 , or a pharmaceutically acceptable salt thereof. 38. The compound of claim 12, wherein the compound is represented by the following formula: ; ; or , or a pharmaceutically acceptable salt thereof . 39. A compound of Formula III, or a pharmaceutically acceptable salt thereof: CBA—E’—A—Z’—L1—D (Formula III) 229 wherein: D is represented by the following structural formula: ; R 1 is -F; R 2 is methyl; -L1 -Z’-* is (i) -(C1-C4 alkylene)-O-CH2-NR8 -*, -(C1-C4 alkylene)-S-CH2-NR8 -*, or - (C1-C4 alkylene)-NR8 -*; (ii) -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-O-CH2-NR8 - *, -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-S-CH2-NR8 -*, -(C1-C5 alkylene)-S-(C1- C5 alkylene)-S-CH2-NR8 -*, or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SS-CH2-NR8 -*; (iii) -L1 -Z’-* is -X1’-(C1-C4 alkylene)-O-CH2-NR8 -*, -X1’-(C1-C4 alkylene)-S-CH2-NR8 -*, or - X 1’-(C1-C4 alkylene)-NR8 -*; or (iv) -(C1-C6 alkylene)-X1 -L2 -Z’-*, where Z’ is -O-CH2- NR8 -*, -S-CH2-NR8 -*, -NR8 -*; where * is the site covalently attached to A; each R5 is independently -H, methyl, or benzyl; each R8 is independently -H, methyl, or benzyl; X 1 is -O-, -S-, -S(O)-, -S(O)2-, -C(=O)-, -NR5 -, -NR5C(=O)-, or -C(=O)NR5 -; X 1’ is -O-, -S-, -S(O)-, or -S(O)2-; L 2 is phenylene optionally substituted with 1-4 substituents of halogen, -CN, -OR7 , - SR7 , -N(R7 )2, C1-C6 alkyl, C1-C6 fluoroalkyl, C1-C6 heteroalkyl, C3-C6 cycloalkyl, C2-C10 heterocycloalkyl, aryl, or heteroaryl; each R7 is independently H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; A is a peptide comprising 2 to 10 amino acids; wherein A is optionally substituted with one or more group that is -(C1-C6 alkylene)-X5 -Y3 wherein: X is -NR12C(=O)- or -C(=O)NR12-; Y 3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and R 12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl; 230 E’ is -C(=O)-(C1-C10 alkylene)-X6 -*; where * is the site covalently linked to CBA; X 6 is ; and CBA is a cell binding agent, wherein the cell binding agent is an antibody or an antigen-binding fragment thereof. 40. The compound of claim 39, wherein -L1 -Z’-* is -(C1-C4 alkylene)-O-CH2-NR8 -*, - (C1-C4 alkylene)-S-CH2-NR8 -*, or -(C1-C4 alkylene)-NR8 -*, where * is the site covalently attached to A. 41. The compound of claim 40, wherein -L1 -Z’-* is -CH2O-CH2NH-*, -(CH2)2O-CH2NH- *, -(CH2)3O-CH2NH-*, -(CH2)4O-CH2NH-*, -CH2S-CH2NH-*, -(CH2)2S-CH2NH-*, - (CH2)3S-CH2NH-*, -(CH2)4S-CH2NH-*, -CH2NH-*, -(CH2)2NH-*, -(CH2)3NH-*, or - (CH2)4NH-. 42. The compound of claim 39, wherein -L1 -Z’-* is -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-O-CH2-NR8 -*, -(C1-C5 alkylene)-NR5C(=O)-(C1-C5 alkylene)-S-CH2-NR8 -*,-(C1- C5 alkylene)-S-(C1-C5 alkylene)-S-CH2-NR8 -*, or -(C1-C5 alkylene)-S-(C1-C5 alkylene)-SSCH2-NR8 -*, where * is the site covalently attached to A. 43. The compound of claim 42, wherein -L1 -Z’-* is -CH2NHC(=O)CH2O-CH2-NH-*, - CH2NHC(=O)(CH2)2O-CH2-NH-*, -CH2NHC(=O)(CH2)3O-CH2-NH-*, - CH2NHC(=O)(CH2)4O-CH2-NH-*, -CH2NHC(=O)(CH2)5O-CH2-NH-*, - 231 CH2NHC(=O)CH2S-CH2-NH-*, -CH2NHC(=O)(CH2)2S-CH2-NH-*, -CH2NHC(=O)(CH2)3SCH2-NH-*, -CH2NHC(=O)(CH2)4S-CH2-NH-*, -CH2NHC(=O)(CH2)5S-CH2-NH-*, - CH2SCH2O-CH2-NH-*, -CH2S(CH2)2O-CH2-NH-*, -CH2S(CH2)3O-CH2-NH-*, - CH2S(CH2)4O-CH2-NH-*, -CH2S(CH2)5O-CH2-NH-*, -CH2SCH2S-CH2-NH-*, - CH2S(CH2)2S-CH2-NH-*, -CH2S(CH2)3S-CH2-NH-*, -CH2S(CH2)4S-CH2-NH-*, or - CH2S(CH2)5S-CH2-NH-*. 44. The compound of claim 39, wherein -L1 -Z’-* is -X1’-(C1-C4 alkylene)-O-CH2-NR8 -*, -X1’-(C1-C4 alkylene)-S-CH2-NR8 -*, or -X1’-(C1-C4 alkylene)-NR8 -*, where * is the site covalently attached to A. 45. The compound of claim 44, wherein -L1 -Z’-* is -OCH2O-CH2-NH-*, - O(CH2)2OCH2-NH-*, - O(CH2)3O-CH2-NH-*, -O(CH2)4O-CH2-NH-*, -SCH2O-CH2-NH-*, -S(CH2)2OCH2-NH-*, -S(CH2)3O-CH2-NH-*, -S(CH2)4O-CH2-NH-*, -S(O)CH2O-CH2-NH-*, - S(O)(CH2)2O-CH2-NH-*, -S(O)(CH2)3O-CH2-NH-*, -S(O)(CH2)4O-CH2-NH-*, - S(O)2CH2O-CH2-NH-*, -S(O)2(CH2)2O-CH2-NH-*, -S(O)2(CH2)3O-CH2-NH-*, - S(O)2(CH2)4O-CH2-NH-*, -OCH2S-CH2-NH-*, -O(CH2)2S-CH2-NH-*, -O(CH2)3S-CH2-NH- *, -O(CH2)4S-CH2-NH-*, -SCH2S-CH2-NH-*, - S(CH2)2S-CH2-NH-*, -S(CH2)3S-CH2-NH-*, -S(CH2)4S-CH2-NH-*, -S(O)CH2S-CH2-NH-*, -S(O)(CH2)2S-CH2-NH-*, -S(O)(CH2)3SCH2-NH-*, -S(O)(CH2)4S-CH2-NH-*, -S(O)2CH2S-CH2-NH-*, -S(O)2(CH2)2S-CH2-NH-*, - S(O)2(CH2)3S-CH2-NH-*, -S(O)2(CH2)4S-CH2-NH-*, -OCH2-NH-*, -O(CH2)2-NH-*, - O(CH2)3-NH-*, -O(CH2)4S-NH-*, -SCH2-NH-*, -S(CH2)2-NH-*, -S(CH2)3-NH-*, -S(CH2)4- NH-*, -S(O)CH2-NH-*, -S(O)(CH2)2-NH-*, -S(O)(CH2)3-NH-*, -S(O)(CH2)4-NH-*, - S(O)2CH2-NH-*, -S(O)2(CH2)2-NH-*, -S(O)2(CH2)3-NH-*, or -S(O)2(CH2)4-NH-*. 46. The compound of claim 39, wherein -L1 -Z’-* is -(C1-C6 alkylene)-X1 -L2 -Z’-*, where * is the site covalently attached to A. 47. The compound of claim 46, wherein -L1 -Z’-* is 232 or , where * is the site covalently attached to A. 48. The compound of any one of claims 39-47, wherein A is a peptide comprising 2 to 8 amino acids. 49. The compound of any one of claims 39-48, wherein A is a peptide comprising 2 to 4 amino acids. 50. The compound of any one of claims 39-49, wherein at least one amino acid in said peptide is a L amino acid. 51. The compound of any one of claims 39-50, wherein each amino acid in said peptide is a L amino acid. 52. The compound of any one of claims 39-49, wherein at least one amino acid in said peptide is a D amino acid. 53. The compound of any one of claims 39-47, wherein A is -(AA1 )-(AA2 )a1-*, where * is the point of attachment to E’, AA1 and AA2 are each independently an amino acid residue; and a1 is an integer from 1-9. 54. The compound of claim 53, -AA1-(AA2)a1-* is -Gly-Gly-Gly-*, -Ala-Val-*, -ValAla-*, -Val-Cit-*, -Val-Lys-*, -Lys-Val-*, -Phe-Lys-*,-Lys-Phe-*, -Lys-Lys-*, -Ala-Lys-*, - Lys-Ala-*, -Phe-Cit-*,-Cit-Phe-*, -Leu-Cit-*,- Cit-Leu-* - Ile -Cit-* , -Phe-Ala-*,-Ala-Phe-*, -Phe-N9-tosyl-Arg-*, -N9-tosyl-Arg-Phe-*, -Phe-N9-nitro-Arg-*, -N9-nitro-Arg-Phe *, -PhePhe-Lys-*, -Lys-Phe-Phe-*, -Gly-Phe-Lys-*, Lys-Phe-Gly-*, -Leu-Ala-Leu-*, -Ile-Ala-Leu- *, -Leu-Ala-Ile-*, -Val-Ala-Val-*, -Ala-Leu-Ala-Leu-*,-Leu-Ala-Leu-Ala-*, -β-Ala-LeuAla-Leu-*, -Gly-Phe-Leu-Gly-*,-Gly-Leu-Phe-Gly-*, -Val-Arg-*, -Arg-Val-*, -Arg-Arg-*, - Ala-Ala-*, -Ala-Met-*, -Met-Ala-*, -Thr-Thr-*, -Thr-Met-*, -Met-Thr-*, -Leu-Ala-*, -AlaLeu-*, -Cit-Val-*, -Gln-Val-*, -Val-Gln-*, -Ser-Val-*, -Val-Ser-*, -Ser-Ala-*, -Ser-Gly-*, - 233 Ala-Ser-*, -Gly-Ser-*, -Leu-Gln-*, -Gln-Leu-*, -Phe-Arg-*, -Arg-Phe-*, -Tyr-Arg-*, -ArgTyr-*, -Phe-Gln-*, -Gln-Phe-*, -Val-Thr-*, -Thr-Val-*, -Met-Tyr-*, and -Tyr-Met-*. 55. The compound of claim 53, wherein -AA1 -(AA2 )a1-* is -Val-D-Lys-*, -Val-D-Arg-*, -L-Val-Cit-*, -L-Val-Lys-*, -L-Val-Arg-*, -L-Val-D-Cit-*, -L-Phe-Phe-Lys-*, -L-Val-DLys-*, -L-Val-D-Arg-*, -L-Arg-D-Arg-*, -L-Ala-Ala-*, -L-Ala-D-Ala-*, -Ala-D-Ala-*, - Val-D-Cit-*, -L-Ala-L-Ala-*, -L-Ala-L-Val-*, -L-Gln-L-Val-*, -L-Gln-L-Leu-*, or -L-SerL-Val-*. 56. The compound of claim 53, wherein -AA1 -(AA2 )a1-* is: -Ala-Ala-*, -Ala-Val-*, -Val-Ala-* -Gln-Leu-*, -Leu-Gln-* -Ala-Ala-Ala-*, -Ala-Ala-Ala-Ala-*, -Gly-Ala-Gly-Gly-*, -Gly-Gly-Ala-Gly-*, -Gly-Val-Gly-Gly-*, -Gly-Gly-Val-Gly-*, -Gly-Phe-Gly-Gly-*, or -Gly-Gly-Phe-Gly-*. 57. The compound of claim 53, wherein -AA1 -(AA2 )a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-*, -L-Ala-L-Val-*, -L-Ala-D-Val-*, -L-Val-L-Ala-*, -L-Val-D-Ala-* -L-Gln-L-Leu-*, 234 -L-Gln-D-Leu-*, -L-Leu-L-Gln-*, -L-Leu-D-Gln-*, -L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-*, -L-Ala-L-Ala-L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-L-Ala-*, -L-Ala-L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-D-Ala-*, -Gly-L-Ala-Gly-Gly-*, -Gly-Gly-L-Ala-Gly-*, -Gly-D-Ala-Gly-Gly-*, -Gly-Gly-D-Ala-Gly-*, -Gly-L-Val-Gly-Gly-*, -Gly-Gly-L-Val-Gly-*, -Gly-D-Val-Gly-Gly-*, -Gly-Gly-L-Val-Gly-*, -Gly-L-Phe-Gly-Gly-*, or -Gly-Gly-L-Phe-Gly-*. 58. The compound of claim 53, wherein -AA1 -(AA2 )a1-* is: -L-Ala-L-Ala-*, -L-Ala-D-Ala-L-Ala-*, -L-Ala-L-Ala-L-Ala-*, or -L-Ala-L-Ala-L-Ala-L-Ala-*. 59. The compound of any one of claims 39-58, wherein A is substituted with one or more group that is -(C1-C6 alkylene)-X5 -Y3 wherein: X is -NR12C(=O)- or -C(=O)NR12-; Y 3 is -C1-C10 alkyl, where Y3 is substituted with 0-10 OH groups; and 235 R 12 is -H, C1-C6 alkyl, C1-C6 fluoroalkyl, C3-C6 cycloalkyl, aryl, heteroaryl, or benzyl. 60. The compound of any one of claims 39-59, wherein -(C1-C6 alkylene)-X5 -Y3 is ; wherein R12 is H or methyl. 61. The compound of any one of claims 39-54, wherein E’ is or . 62. The compound of any one of claims 39-61, wherein the CBA comprises a -SH group that covalently links with E’ to provide . 63. The compound of any one of claims 39-62, wherein CBA is an antibody and —E’— A—Z’—L1— D is a drug-linker structure, the average number of drug-linker structures conjugated per antibody is in the range of from 2 to 10. 64. The compound of claim 63, wherein the average number of drug-linker structures conjugated per antibody is in the range of from 2 to 10. 65. The compound of claim 63, wherein the average number of drug-linker structures conjugated per antibody is in the range of from 6 to 8. 66. The compound of claim 63, wherein the average number of drug-linker structures conjugated per antibody is 8. 67. The compound of any one of claims 39-66, wherein the CBA is an antibody, a single chain antibody, an antibody fragment that specifically binds to the target cell, a monoclonal 236 antibody, a single chain monoclonal antibody, or a monoclonal antibody fragment that specifically binds to a target cell, a chimeric antibody, a chimeric antibody fragment that specifically binds to the target cell, a domain antibody, or a domain antibody fragment that specifically binds to the target cell. 68. The compound of any one of claims 39-67, wherein the CBA binds to target cells of tumor cells, virus infected cells, microorganism infected cells, parasite infected cells, autoimmune cells, activated cells, myeloid cells, activated T-cells, B cells, or melanocytes; cells expressing any one or more of 5T4, ADAM-9, ALK, AMHRII, ASCT2, Axl, B7-H3, BCMA, C4.4a, CA6, CA9, CanAg, CD123, CD138, CD142, CD166, CD184, CD19, CD20, CD205, CD22, CD248, CD25, CD3, CD30, CD33, CD352, CD37, CD38, CD40L, CD44v6, CD45, CD46, CD48, CD51, CD56, CD7, CD70, CD71, CD74, CD79b, CDH6, CEACAM5, CEACAM6, cKIT, CLDN18.
  2. 2, CLDN6, CLL-1, c-MET, Cripto, CSP-1, CXCR5, DLK-1, DLL3, DPEP3, Dysadherin, EFNA4 , EGFR, EGFRviii, ENPP3, EpCAM, EphA2, EphA3, ETBR, FGFR2, FGFR3, FLT3, FOLR-alpha, FSH, GCC, GD2, GD3, Globo H, GPC-1, GPC3, gpNMB, HER-2, HER-3, HLA-DR, HSP90, IGF-1R, IL-13R, IL1RAP, IL7R, Interleukin-4 Receptor (IL4R), KAAG-1, LAMP-1, Lewis Y antigen, LGALS3BP, LGR5, LH/hCG, LHRH, LIV-1, LRP-1, LRRC15, Ly6E, MAGE, Mesothelin (MSLN), MET, MHC class I chain-related protein A and B (MICA and MICB), MT1-MMP, MTX3, MTX5, MUC1, MUC16, NaPi2b, Nectin-4, NOTCH3, OAcGD2, OX001L, p-Cadherin, PD-L1, Phosphatidylserine (PS), Polymorphic epithelial mucin (PEM), Prolactin Receptor (PRLR), PSMA, PTK7, RNF43, ROR1, ROR2, SAIL, SLAMF7, SLC44A4, SLITRK6, SSTR2, STEAP-1, STING, STn, TIM-1, TM4SF1, TNF- alpha, TRA, TROP-2, Tumor-associated glycoprotein 72 (TAG-72), tumor-specific epitope of mucin-1 (TA-MUC1), CD5, TIM-3, UPK2, or UPK1b antigen. 69. The compound of any one of claims 39-66, wherein the cell-binding agent is an antifolate receptor antibody or an antibody fragment thereof, an anti-EGFR antibody or an antibody fragment thereof, an anti-CD33 antibody or an antibody fragment thereof, an antiCD19 antibody or an antibody fragment thereof, an anti-Muc1 antibody or an antibody fragment thereof, an anti-CD37 antibody or an antibody fragment thereof, or an anti-EpCAM antibody or an antibody fragment thereof. 237 70. A pharmaceutical composition comprising a compound according to any one of claims 1-69, or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 71. Use of a therapeutically effective amount of the pharmaceutical composition of claim 70 for the treatment of cancer in a subject in need thereof, wherein the pharmaceutical composition is for administration to the subject. 72. Use of a therapeutically effective amount of the pharmaceutical composition of claim 70 in the manufacture of a medicament for treatment of cancer in a subject in need thereof, wherein the pharmaceutical composition is for administration to the subject. 73. The use of claim 71 or 72, wherein the cancer is a lymphoma or a leukemia. 74. The use of claim 73, wherein the cancer is acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), acute B lymphoblastic leukemia or B-cell acute lymphoblastic leukemia (BALL), chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), acute promyelocytic leukemia (APL), B-cell chronic lymphoproliferative disease (B-CLPD), atypical chronic lymphocytic leukemia, diffuse large B-cell lymphoma (DLBCL), blastic plasmacytoid dendritic cell neoplasm (BPDCN), non-Hodgkin lymphomas (NHL), mantel cell leukemia (MCL), small lymphocytic lymphoma (SLL), Hodgkin’s lymphoma, systemic mastocytosis, or Burkitt’s lymphoma. 75. The use of claim 71 or 72, wherein the cancer is endometrial cancer, lung cancer, colorectal cancer, bladder cancer, gastric cancer, pancreatic cancer, renal cell carcinoma, prostate cancer, esophageal cancer, breast cancer, head and neck cancer, uterine cancer, ovarian cancer, liver cancer, cervical cancer, thyroid cancer, testicular cancer, myeloid cancer, melanoma, or lymphoid cancer. 76. The use of claim 71 or 72, wherein the lung cancer is non-small cell lung cancer or small-cell lung cancer.
CA3137125A 2019-04-26 2020-04-10 Camptothecin derivatives Active CA3137125C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962839440P 2019-04-26 2019-04-26
US62/839,440 2019-04-26
US201962875169P 2019-07-17 2019-07-17
US62/875,169 2019-07-17
US202062978159P 2020-02-18 2020-02-18
US62/978,159 2020-02-18
PCT/US2020/027831 WO2020219287A1 (en) 2019-04-26 2020-04-10 Camptothecin derivatives

Publications (2)

Publication Number Publication Date
CA3137125A1 CA3137125A1 (en) 2020-10-29
CA3137125C true CA3137125C (en) 2026-03-10

Family

ID=

Similar Documents

Publication Publication Date Title
AU2020263231B2 (en) Camptothecin derivatives
KR102638901B1 (en) Conjugates comprising cell-binding agents and cytotoxic agents
KR102891599B1 (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
CA3137125C (en) Camptothecin derivatives
RU2844846C2 (en) Camptothecin derivatives
HK40104845A (en) Camptothecin derivatives
HK40069519A (en) Camptothecin derivatives
HK40069519B (en) Camptothecin derivatives